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Summary 
The HIV/AIDS pandemic has dramatically concentrated in sub-Saharan Africa. There are 36.7 
million people living with HIV (PLWHIV) worldwide and over 50% of them reside in Eastern and 
Southern Africa. Sub-Saharan Africa is also home of 85% of pregnant women living with HIV 
and 90% of HIV-infected children. During the last decade prevention of mother-to-child 
transmission (PMTCT) programs have been implemented in most countries with an increasing 
coverage and an estimated reduction of new paediatric HIV infections by 60% since the year 
2000. 
Although HIV/AIDS appears to have stabilized worldwide, many challenges persist. Despite the 
progressive roll-out of PMTCT, in 2015, nearly a quarter of pregnant women living with HIV did 
not access antiretrovirals drugs and an estimated 150,000 new paediatric infections occurred. 
There are 1.8 million children living with HIV and they represent an underprivileged 
population. Importantly, the scale-up of paediatric ART has encountered substantial barriers 
and in 2015, only 49% of children in need accessed treatment. 
Since the early 2000’s different PMTCT recommendations have been developed for resource-
limited countries. These recommendations have been periodically revised and updated based 
on the latest evidence and the implementation experiences. Currently, the WHO recommends 
what is known as PMTCT “Option B+”: lifelong ART for all pregnant and breastfeeding women 
regardless of their CD4 counts and clinical stage. The main challenges that drove to these 
latest PMTCT guidelines were the unresolved health system barriers to CD4 testing for ART 
eligibility, the high fertility rates in countries most affected by HIV and the perceived need of 
simplification of recommendations. The supposed benefits of Option B+ were: a) streamlined 
implementation given its simplicity; b) high potential to reach maximum coverage and 
promote the virtual elimination of paediatric HIV; c) reduced HIV transmission to partners; and 
d) protection from conception of the subsequent pregnancies. While Option B+ has truly 
resulted in better ART coverage among pregnant women and in a decrease in the number of 
new paediatric HIV infections, some barriers to its optimal potential still exist. The efficiency of 
the guidelines simplification will only be fully palpable if the inadequate human resources, 
infrastructure and supply chain are addressed. Moreover, strategies to ameliorate the high 
early defaulter rate have to be prioritised. Adequate counselling and preparation of patients 
before initiating ART and patient education need to be put at the frontline along with other 
program areas to ensure adherence among mostly asymptomatic pregnant women and 
mothers. 
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Children infected with HIV present more rapid diseases progression than adults. Timely 
diagnosis and ART initiation is therefore vital for this population. Testing and diagnosing 
children for HIV must be enhanced within PMTCT programs, ensuring that all HIV-exposed 
infants are tested within the first two months of life and that results reach their caregivers. 
Also, approaches to identify HIV-infected children outside PMTCT programs must be expanded 
to places where children congregate, especially to places where children at high risk of HIV 
may seek for services. Yet, after being diagnosed with HIV, children encounter barriers to 
access life-saving treatment. These barriers are mainly related to the service delivery models, 
the health workers’ capacity to provide quality paediatric HIV/AIDS care and treatment, and 
the availability of paediatric antiretroviral formulations.  
Due to several factors, long-term treatment success and virological suppression is harder to 
achieve in children living with HIV compared to adults. The high rates of virological failure and 
development of acquired drug resistance-associated mutations, coupled with the limited 
paediatric antiretroviral drugs available, represent a threat to paediatric ART programs in 
Africa that needs attention.   
Novel strategies to increase the uptake of PMTCT services are needed in sub-Saharan Africa to 
reach the goal of elimination of paediatric HIV. In this same region, HIV diagnosis, linkage into 
care, ART coverage and treatment outcomes of children need to be improved. Family-centred 
approaches may facilitate access to HIV and improve the clinical care provided to pregnant 
women, mothers and children living with HIV and their families. 
This thesis was developed mainly as an operational and implementation science research. 
Through the work presented here we designed and tested a family-centred HIV service 
delivery model in a rural Tanzanian setting, Ifakara. The basis was the identification of gaps for 
delivering PMTCT in this rural setting. First, we conducted a cross-sectional study to assess the 
PMTCT services uptake in Ifakara. Second, we designed and implemented a package of 
measures as a strategy to improve paediatric and maternal HIV care. Third, we evaluated the 
impact of the strategy on the clinical outcomes of pregnant women and children by comparing 
prospectively collected data from before and after the implementation. Forth, we did a 
prospective study evaluating the PMTCT cascade after the implementation of the package of 
measures and the roll-out of Option B+ in the country and we compared the results with the 
initial cross-sectional assessment. Last, we assessed the outcomes of children and adolescents 
on ART and investigated the prevalence and determinants of virological failure and acquired 
antiretroviral drug resistances. 
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The first study assessed the PMTCT care pathway in Ifakara during the period 2010 – 2011. It 
described the departments and health workers involved and the circuit pregnant women, 
mothers and infants were supposed to follow, identified the existing gaps, and proposed 
solutions to bridge them and improve the outcomes of HIV-infected mothers and their 
offspring. Although all services and most resources were in place for a well-functioning PMTCT 
program, major gaps were identified, such as the very poor linkage to HIV care and the lack of 
a standardised follow-up for HIV-exposed infants. The study emphasised the need for much 
simpler and effective PMTCT recommendations, as Option B+, a new model of care integrating 
maternal and HIV services, and an update of the training that health workers attending HIV-
infected pregnant women received. This first study set the basis for the development of the 
One Stop Clinic, the maternal and paediatric unit of the HIV clinic of Ifakara, a unit designed to 
be integrated within the reproductive and child health clinic.    
The second and third studies assessed the impact of the One Stop Clinic on the care provided 
to HIV-infected mothers, children and their families. Study 2 described the baseline 
characteristics, clinical outcomes and retention in care of pregnant women and children 
enrolled in HIV care before (2008 – 2012) and after (2013 – 2014) the implementation of the 
One Stop Clinic in combination with the evolution to a paperless clinic and the expansion of 
provider-initiated HIV testing and counselling in the hospital wards. The strategy resulted in an 
increased number of mothers and children diagnosed and linked into care, a higher detection 
of children with AIDS, universal treatment coverage, lower loss to follow-up, and an early 
mother-to-child transmission (MTCT) rate below the threshold of elimination. Hence, this 
study documents a feasible and scalable model for family-centred HIV care in sub-Saharan 
Africa. 
The third study re-assessed the PMTCT cascade in Ifakara during the period 2014 - 2015. It 
evaluated the impact of the measures taken after the first assessment presented in Study 1 
combined with the adoption of Option B+ guidelines by the Government of Tanzania. PMTCT 
was assessed at the antenatal clinic, HIV care and labour ward, and compared with the pre-B+ 
period. The implementation of Option B+ through the One Stop Clinic model resulted in 
universal HIV testing in the antenatal clinic, high rates of linkage to care and ART provision, 
and a MTCT rate of 2.2%. However, HIV testing in late pregnancy and labour were poor, and 
retention during early ART was not optimal. This study reports the improvements reached with 
Option B+ implemented through a comprehensive service delivery model and drives attention 
to the barriers limiting the full efficacy of Option B+ recommendations. 
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The forth study presented a well-characterised series of HIV-infected children from rural 
Tanzania with virological failure and acquired drug resistance-associated mutations. The 
acquisition of resistance mutations among African children living with HIV has been scarcely 
reported and this study contributes to the better understanding of this emerging public health 
concern. 
The results of Study 4 drove the attention to an emerging concern that needed a more 
comprehensive characterization. This is the rationale for the fifth study. All children and 
adolescents attending the One Stop Clinic in Ifakara and on ART for at least twelve months 
were included in this study. Among 213 children and adolescents, 25.4% presented virological 
failure. ART-associated resistance mutations were indentified in 90% of them, with multiclass 
resistances in 79%. Suboptimal adherence, female gender, and current non-nucleoside reverse 
transcriptase inhibitor (NNRTI)-based ART independently increased the odds of virological 
failure. Higher CD4 cell percentage and older age at ART initiation were protective. The 
findings of this study provide relevant information for clinicians and health policy makers and 
raise concerns about the effectiveness of current paediatric ART programmes in sub-Saharan 
Africa. The results of the study advocate for the strengthening of adherence strategies, the 
development of new paediatric drug formulations, and the universal roll-out of routine viral 
load monitoring. 
In conclusion, the studies included in this thesis show that with an operational approach, real 
changes can be implemented in a rural Tanzanian setting. The One Stop Clinic model resulted 
in more pregnant women living with HIV diagnosed and linked into care, over 90% of them 
receiving drugs for PMTCT, and one of the lowest attrition rates reported from rural Africa. 
The outcome of such PMTCT service provision improvements is a MTCT rate of HIV of only 
2.2%. The new paediatric HIV case finding approaches that came along the One Stop Clinic 
allowed diagnosing and treating HIV-infected children that were previously not identified. 
Moreover, the child-friendly approach of our strategy helped to better understand and analyse 
treatment failure among children, one of the major barriers for paediatric ART programs 
success. The work in Ifakara documents a feasible and scalable model for maternal and 
paediatric HIV care that if extended to other sub-Saharan African settings can contribute to the 
goals of zero new infections among children, keep mothers in good health and close the 
paediatric treatment gap. 
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Muhtasari 
Janga la UKIMWI limeathiri zaidi nchi za kusini mwa jangwa la Sahara. Duniani kote, watu 
milioni 36.7 wanaishi na maambukizi ya VVU, Zaidi ya 50% kati yao wanaishi katika nchi za 
Afrika mashariki na kusini.  Asilimia 85% ya wanawake wajawazito wanaoishi na maambukizi ya 
vvu, na asilimia 90% ya watoto wenye maambukizi ya VVU wanaishi katika chi za kusini mwa 
jangwa la Sahara. Kwa muongo uliopita, programu nyingi za kuzuia maambukizi ya VVU kutoka 
kwa mama kwenda kwa mtoto zimefanyika katika nchi hizi, na zimepelekea kupungua kwa 
maambukizi mapya ya VVU kwa watoto kwa takriban asilimia 60% tangu mwaka 2000. 
Japokuwa janga la UKIMWI linaonekana kupungua duniani kote, bado kuna changamoto 
nyingi. Pamoja na kuenea kwa programu ya  kuzuia maambukizi ya VVU kutoka kwa mama 
kwenda kwa mtoto (PMTCT), kwa mwaka 2015 karibu robo ya wanawake wajawazito waishio 
na maambukizi ya VVU hawakupata dawa za kupunguza makali ya virusi  (ARV) na  kulikuwa na 
maambukizi mapya ya VVU kwa watoto 150,000. Watoto milioni 1.8 wanaishi na maambukizi 
ya VVU na wanawakilisha jamii zinazoishi katika mazingira magumu. Zaidi ya yote, usambazaji 
wa dawa za ARV za watoto unakumbwa na changamoto nyingi, na kwa mwaka 2015, ni asilimia 
49% tu ya watoto wenye maambukizi walipata dawa za hizo za kupunguza makali ya 
maambukizi. 
Tangu mwanzoni mwa miaka ya 2000, kumekuwa na mapendekezo tofauti ya kuzuia 
maambukizi ya VVU kutoka kwa mama kwenda kwa mtoto kwa ajili ya kutumika katika nchi 
zinazoendelea. Mapendekezo haya yamekuwa yakipitiwa na kurekebishwa kulingana na 
ushahidi wa kisayansi na matokeo ya utekelezaji. Kwa sasa shirika la afya duniani 
linapendekeza njia inayotambulika kama “OPTION B +”: Mwanamke mjamzito na 
anayenyonyesha atatumia dawa za ARV kwa maisha yake yote bila kujali kiasi cha seli zake za 
kinga (CD4) au hatua ya ugonjwa wa UKIMWI. Changamoto kubwa zilizopelekea mapendekezo 
haya ya sasa ni vikwazo katika upimaji wa seli za kinga (CD4) ili kutambua uhitaji wa matibabu 
ya ARV, kasi ya kuzaliana kuwa juu katika nchi hizi zilizoathirika Zaidi na UKIMWI, na 
kuonekana kwa uhitaji wa kurahisisha utekelezaji wa mapendekezo hayo. Faida zilizotarajiwa 
kutokana na matumizi ya “option B+” ni a) utekelezaji sawia kutokana na urahisi wake b) 
uwezekano wa kufikia watu wengi na kuondoa maambukizi kutoka kwa mama kwenda kwa 
mtoto c) Kupunguza maambukizi ya VVU kati ya watu walio katika mahusiano ya kimapenzi d) 
kuzuia maambukizi kwa watoto katika mimba zitakazofuata. 
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Japokuwa Option B+ imepelekea ongezeko la wanawake wajawazito walio katika matibabu ya 
ARV na kupungua maambukizi mapya ya VVU kwa watoto bado kumekuwa na changamoto 
zinazozuia utimilifu wake.  Urahisi wa muongozo huu utathibitika zaidi iwapo changamoto za 
rasilimali watu, upatikanaji na usambazaji vitendea kazi na zitatatuliwa. Zaidi ya yote, hatua za 
kupunguza ongezeko la watu wanaokatisha matibabu zanatakiwa kupewa kipaumbele.  
Ushauri nasaha na maandalizi ya wagonjwa kabla ya kuanzisha dawa za ARV, na elimu ya 
UKIMWI kwa wagonjwa vinatakiwa kupewa kipaumbele sambamba na huduma nyingine ili 
kuongeza uzingatiaji wa matibabu kwa wanawake wajawazito na wanaonyonyesha wasio na 
dalili zozote za ugonjwa wa UKIMWI. 
Watoto walio na maambukizi ya VVU wanapata dalili za ugonjwa wa UKIMWI mapema zaidi 
kuliko watu wazima. Kutambua maambukizi na kuanza dawa kwa wakati ni muhimu sana kwa 
watoto. Kupima na kutambua maambukizi ya VVU kwa watoto kunatakiwa kuwa kipengele 
katika programu za kuzuia maambukizi ya VVU kutoka kwa mama kwenda kwa mtoto, 
kuhakikisha kwamba watoto wote waliozaliwa na wanawake wenye maambukizi wanapimwa 
katika miezi miwili ya kwanza ya maisha na majibu ya vipimo yanawafikia wazazi/walezi wao. 
Njia za kutambua watoto walio na maambukizi ya VVU nje ya programu za kuzuia maambukizi 
kutoka kwa mama kwenda kwa mtoto zinatakiwa kuimarishwa pia na kuongezwa katika 
maeneo wanapokusanyika watoto, hususan maeneo ambapo watoto wenye uwezekano 
mkubwa wa kuwa na mambukizi wanapatiwa huduma za afya.  Hata baada ya kugundulika na 
maambukizi ya VVU, kuna changamoto nyingi katika kuwapatia watoto hawa matibabu 
yanayoweza kuokoa maisha yao. Changamoto hizi zinahusiana zaidi na mifumo ya utoaji wa 
huduma za afya, uwezo wa wahudumu wa afya kutoa huduma na matibabu stahiki kwa watoto 
waishio na maambukizi ya VVU na upatikanaji wa dawa za ARV zilizo katika mfumo na kiwango 
stahiki kwa watoto. 
Kutokana na sababu mbalimbali, matokeo mazuri ya matibabu na kunyima virusi uwezo wa 
kuzaliana ni ngumu zaidi kufikiwa kwa watoto waishio na maambukizi ukilinganisha na watu 
wazima. Uwezekano mkubwa wa virusi kuendelea kuzaliana kwa kasi na kupata usugu wa 
dawa ukichanganywa na changamoto za upatikanaji wa dawa za VVU za watoto vinapelekea 
tishio kwa programu za huduma za ARV kwa watoto katika bara la Afrika, na vinahitaji 
kuangaliwa kwa ukaribu. 
Hatua madhubuti za kuongeza upatikanaji wa huduma za kuzuia maambukizi ya VVU kutoka 
kwa mama kwenda kwa mtoto zinahitajika katika nchi za kusini mwa jangwa la Sahara ili 
kufikia lengo la kutokomeza kabisa tatizo la Ukimwi kwa mtoto.  Katika nchi hizi, Upimaji wa 
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VVU, kuanza huduma za matibabu, upatikanaji wa dawa za ARV na matokeo ya matibabu kwa 
watoto vinahitaji kuimarishwa. Programu zinazolenga familia nzima zinaweza kuongeza 
upatikanaji wa huduma na kuimarisha matibabu yanayotolewa kwa wanawake wajawazito, 
wamama na watoto waishio na maambukizi ya VVU pamoja na familia zao.  
Utafiti huu ulijikita Zaidi katika utekelezaji wa huduma za kuzuia maambukizi ya VVU kutoka 
kwa mama kwenda kwa mtoto.   Kupitia mrejesho huu wa kazi, tulibuni na kujaribu utoaji wa 
huduma uanolenga familia kwa ujumla katika maeneo ya Tanzania vijijini, Ifakara. Lengo hasa 
lilikuwa kutambua changamoto katika utoaji wa huduma za kuzuia maambukizi ya VVU kutoka 
kwa mama kwenda kwa mtoto katika maeneo ya vijijini.  
Kwanza tulifanya utafiti kutambua mapokeo ya huduma za kuzuia maambukizi ya VVU kutoka 
kwa mama kwenda kwa mtoto katika eneo la Ifakara. Pili tukabuni na kutekeleza mfumo wa 
huduma zinazolenga kuboresha huduma za afya kwa wanawake na watoto walio na 
maambukizi ya VVU. Tatu, tukafanya tathmini ya matokeo ya mfumo huu wa huduma katika 
afya za wanawake wajawazito na watoto kwa kulinganisha takwimu zilizokusanywa kabla na 
baada ya utekelezaji wa mfumo huu. Nne, Tulifanya tathmini ya huduma za kuzuia maambukizi 
ya VVU kutoka kwa mama kwenda kwa mtoto baada ya utekelezaji wa mfumo huu uliobuniwa 
sambamba na kuenea kwa huduma za Option B+ nchini, na kulinganisha takwimu za tathmini 
hii na zile za utafiti wa kwanza.  Na mwisho tulifanya tathmini kwa watoto na vijana 
wanaotumia dawa za ARV ili kutambua ukubwa wa tatizo la kupata usugu wa dawa na virusi 
kuendelea kuzaliana mwilini na visababishi vyake. 
Utafiti wa kwanza ulichunguza utekelezaji wa huduma za  kuzuia maambukizi kutoka kwa 
mama kwenda kwa mtoto katika eneo la Ifakara kwa kipindi cha mwaka 2010 hadi 2011.  
Ulichunguza na kupambanua kwa undani kuhusu idara na wafanyakazi wanaohusika na 
utaratibu ambao mama wajawazito na watoto walitakiwa kupitia ili kupata huduma, ilitambua 
mapungufu yaliyopo na kupendekeza hatua za kuchukua ili kuboresha huduma za afya kwa 
wanawake wajawazito wenye maambukizi ya VVU na watoto wao. Japo kuwa huduma na 
miundo mbinu ya kuwezesha kutekelezaji wa programu za kuzuia maambukizi kutoka kwa 
mama kwenda kwa mtoto ilikuwepo, baadhi ya vikwazo viliibuliwa ikiwemo utaratibu hafifu 
wa kuwaunganisha wagonjwa katika huduma za tiba na kutokuwa na ufuatiliaji stahiki wa 
watoto walio zaliwa na wazazi wenye VVU. Utafiti ulisisitiza uwepo wa taratibu rahisi na 
madhubuti za kuzuia maambukizi kutoka kwa mama kwenda kwa matoto kama Option B+, 
mbinu mpya ya kuunganisha huduma za afya ya uzazi na huduma za tiba ya VVU, na mrejesho 
wa mafunzo ya mara kwa mara yaliyotolewa kwa wafanyakazi wanaotoa huduma kwa 
 xii 
 
wajawazito wanaoishi na maambukizi ya VVU. Utafiti huu wa kwanza uliweka msingi wa 
uanzishwaji wa kliniki ijulikanayo kwa jina la One Stop Clinic, kitengo cha VVU cha Ifakara 
kinacho husika na  mama na mtoto, kitengo kilichoundwa na kujumuishwa ndani ya huduma za 
afya ya uzazi na mtoto.   
Utafiti wa pili na watatu ulichunguza matokeo ya huduma iliyo tolewa na One Stop Clinic kwa 
mama wajawazito wenye VVU, watoto na familia zao. Utafiti wa pili ulichunguza tabia/asili ya 
washiriki na matokeo ya matibabu na kudumu katika huduma kwa wanawake na watoto walio 
jiunga katika huduma ya VVU kabla(2008-2012) na baada (2013-2014), utekelezwaji wa One 
Stop Clinic ikiunganishwa na mabadiliko ya kuachana na matumizi ya makaratasi na kutumia 
elekitroniki na kutanuka wa huduma ya huduma ya upimaji na ushauri nasaha katika wodi za 
hospitali. Mbinu hii ilipelekea kuongezeko ya akina mama na watoto walio gundulika na VVU 
na kujiunga na huduma, ongezeko la watoto waliogundulika na UKIMWI, ongezeko la walio 
pata matibabu ya ARV, kupungua kwa wagonjwa wanaisitisha huduma na kupungua kwa 
maambukizi kutoka kwa mama kwenda kwa mtoto mpaka kufikia chini ya kiwango cha 
kutokomeza maambukizi ya VVU kutoka kwa mama kwenda kwa mtoto. Hatimaye utafiti huu 
unatoa mrejesho wa mfumo wa matibabu ya VVU unaolenga familia nzima ambao 
unatekelezeka na unaweza kuenezwa kwa nchi zilizo kusini mwa jangwa la sahara. 
Utafiti wa tatu ulichunguza tena kwa mara nyingine utekelezaji wa huduma za kuzuia 
maambukizi ya VVU katika eneo la Ifakara kwa mwaka 2014-2015. Ulitathmini matokeo ya 
maboresho yaliyotokana na utafiti wa kwanza sambamba na utekelezaji wa Option B+ 
ulioafikiwa na serikali ya Tanzania. Huduma ya kuzuia maambukizi ya VVU kutoka kwa mama 
kwenda kwa mtoto ulichunguzwa katika kliniki ya afya ya mama na mtoto, katika sehemu za 
kutolea huduma za VVU na wodi za wazazi na kulinganishwa na kabla ya kipindi cha utekelezaji 
wa Option B+. Utekelezwaji wa Option B+ katika kitengo cha One Stop Clinic umepelekea 
upimaji wa VVU kwa takribani watu wote wanao hudhuria katika kliniki ya mama na mtoto, 
kiasi kikubwa cha watu wenye VVU kujiunga na huduma na kuanza matibabu ya ARV, na 
maambukizi kutoka kwa mama kwenda kwa mtoto kupungua hadi asilimia 2.2%. Hatahivyo, 
upimaji wa VVU Kipindi cha mwishoni mwa ujauzito na katika wodi ya wazazi ilikua hafifu, na 
kubaki katika huduma za matibabu wakati wa kuanza ARV haukua wa kuridhisha. Utafiti huu 
hutoa taarifa juu ya mafanikio yaliyofikiwa kutokana na utekelezwaji wa  Option B+ na 
kuainisha vikwazo vinavyo kabili utekelezaji wa mpango wa Option B+. 
Utafiti wa nne ulionesha sifa za watoto wanaoishi na VVU Tanzania vijijini na usugu wa virusi 
vya Ukimwi kwa dawa za kupunguza makali ya UKIMWI. Usugu wa dawa hizi miongoni mwa 
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watoto wa Afrika umekuwa ukiripotiwa kwa uchache sana na hivyo utafiti huu umesaidia 
kutambua uwepo wa tatizo hili.  
Matokeo ya utafiti huu wa nne ume vuta mawazo ya watu kuhusu uwepo wa tatizo unaohitaji 
mbinu madhubuti za utatuzi na ndilo lengo la utafiti wa tano. Watoto wote na vijana 
waliohudhuria One Stop Clinic Ifakara angalau kwa kipindi cha miezi kumi na mbili walishiriki 
katika utafiti huu. Kati ya watoto na vijana wakubwa 213, Asilimia 25.4% waligundulika kuwa 
kuzaliana kwa virusi vya Ukimwi katika miili yao haukusitishwa, 90% VVU walikua na usugu  
kwa dawa za kupunguza makali ya VVU, na 79% walikuwa na usugu kwa dawa zaidi ya moja. 
Kutokuwa na uzingataji mzuri wa dawa, jinsia ya kike na kutumia dawa yenye mchanganyiko 
wa NNRTI uliongeza uwezekano wa kuwa na usugu wa VVU. Kiasi kikubwa cha CD4 na umri 
mkubwa wakati wa kuanza ARV ilionekana kuwa ni kinga dhidi ya kupata usugu wa daw. 
Matokeo ya huu utafiti yanatoa taarifa muhimu kwa wataalamu wa afya na kwa watengeneza 
sera na kuibua maswali juu ya ubora wa programu matibabu ya ARV kwa watoto katika nchi za 
kusini mwa jangwa la Sahara. Matokeo ya utafiti huu hutangaza hitaji la kuimarisha mbinu za 
kuongeza uzingatiaji wa tiba, kutengenezwa kwa michanganyiko mipya ya dawa za watoto na 
uwepo wa vipimo vya idadi ya virusi mwilini. 
Kwa kuhitimisha, utafiti huu umeonyesha kuwa mabadiliko ya kweli yanaweza kutekelezeka 
katika maeneo ya Tanzania vijijini. Programu ya One stop Clinic imepelekea ongezeko la 
upimaji wa VVU kwa wajawazito na kujiunga katika huduma za matibabu, Zaidi ya 90% ya 
hawa wajawazito walipata dawa kwa ajili ya kuzuia maambukizi ya VVU kutoka kwa mama 
kwenda kwa mtoto, ambapo ni moja ya viwango vya juu vilivyowahi kuripotiwa kutoka sehemu 
za Afrika vijijini.   Utekelezaji wa huduma hizi umepelekea maambukizi ya VVU kutoka kwa 
mama kwenda kwa mtoto kupungua hadi asilimia 2.2% tu. Mbinu za kutafuta watoto wenye 
VVU iliyotumiwa na One Stop Clinic ilifanikisha kugundua na kutibu watoto wenye maambukizi 
ya VVU ambao hapo mwanzo hawakugundulika. Zaidi ya yote, mbinu rafiki kwa watoto 
zimesaidia kutambua na kutathmini usugu wa VVU kwa dawa miongoni mwao, ambacho ni 
kikwazo kikubwa kwa matokeo mazuri ya matibabu kwa watoto. Kazi iliyofanyika ifakara 
imepelekea mrejesho huu wa mfumo unaotekelezeka na unaoweza kuenezwa ambao 
ukipelekwa pia katika nchi zingine za kusini mwa jangwa la Sahara  unaweza kupelekea 
kutokomezwa kabisa kwa maambukizi mapya kwa watoto, kuwaweka wamama katika afya 
njema na kuziba nyufa katika  matibabu ya VVU kwa watoto. 
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Acronyms and abbreviations 
3TC Lamivudine 
ABC Abacavir 
AIDS Acquired Immune Deficiency 
Syndrome 
ANC Antenatal Care Clinic 
ART Antiretroviral Treatment 
ARV Antiretroviral 
ATV/r Ritonavir-boosted Atazanavir 
AZT Zidovudine 
BMI Body Mass Index 
CDC Centers for Disease Control and 
Prevention 
CDCI Chronic Diseases Clinic of Ifakara 
CI Confidence Interval 
CME Continuous Medical Education 
D4T Stavudine 
DRM Drug Resistance-associated 
Mutation 
EFV Efavirenz 
EID Early Infant Diagnosis of HIV 
FTC Emtricitabine 
HIV Human Immunodeficiency Virus 
IQR Interquartile Range 
KIULARCO  Kilombero and Ulanga 
Antiretroviral Cohort 
LPV/r Ritonavir-boosted Lopinavir 
MTCT Mother-To-Child Transmission of 
HIV 
NNRTI Non-Nucleoside Reverse 
Transcriptase Inhibitor 
NRTI Nucleoside/nucleotide Reverse 
Transcriptase Inhibitor 
NVP Nevirapine 
OR Odds ratio 
PI Protease Inhibitor 
PITC Provider-Initiated HIV Testing and 
Counselling 
PLWHIV  People Living With HIV 
PMTCT Prevention of Mother-To-Child 
Transmission of HIV 
RCHC Reproductive and Child Health Clinic 
sdNVP single dose Nevirapine 
SFRH St Francis Referral Hospital of 
Ifakara 
SOP Standard Operating Procedure 
SSA Sub-Saharan Africa 
UNAIDS  Joint United Nations Programme 
on HIV/AIDS 
VCT Voluntary Counselling and Testing 
VF Virological Failure 
VL Viral Load 
WHO World Health Organization
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1. General Introduction 
1.1. The Global burden of HIV/AIDS 
HIV/AIDS is one of the worst pandemics in history. Since the first AIDS cases were reported in 
the United States in 1981 (Centers for Disease Control (CDC), 1981), all regions in the world 
have been affected, but sub-Saharan African countries bear a disproportionate share of the 
global burden.  
Currently there are 36.7 million people living with HIV (PLWHIV) in the world. The most 
affected regions are Eastern and Southern Africa, where over 50% of PLWHIV reside.  Much 
progress was made during the first decade of the 21st century, when the rate of new HIV 
infections in sub-Saharan Africa decreased by 50% between 2001 and 2011.  During recent 
years this progress has slowed alarmingly, the number of new HIV infection in 2016 was 1.8 
million, virtually the same that in 2010 (2.2 million) (UNAIDS, 2017). 
 
Source: UNAIDS estimates 2017 
Before ART became available in sub-Saharan Africa, HIV infection resulted in premature death 
for most infected people (Morgan and Whitworth, 2001). Increased international funding, 
coupled with a dramatic reduction in antiretroviral prices about a decade ago (Badri et al., 
2006) has resulted in previously unimaginable access to ART (Reynolds and Quinn, 2010). ART 
roll-out in resource-limited settings constitutes one of the great achievements of global health 
in the last decade. Today, HIV-infected people on ART in sub-Saharan Africa can expect to have 
an overall life expectancy similar to that of HIV-negative individuals, and population-level 
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benefits include declining mortality rates in adults and children and increasing life expectancy 
(Bor et al., 2012, 2013; Tanser et al., 2013). 
Through the years, evidence that earlier initiation of ART further delayed HIV disease 
progression emerged (When To Start Consortium et al., 2009; Severe et al., 2010; De Cock and 
El-Sadr, 2013; Le et al., 2013). As a result, the WHO launched several revisions of its guidelines, 
and the recommended CD4 threshold for ART initiation progressively increased. Based on the 
latest evidence (INSIGHT START Study Group et al., 2015; TEMPRANO ANRS 12136 Study 
Group et al., 2015) the current WHO guidelines, published in September 2015, recommend 
initiating ART in all PLWHIV with any CD4 cell count. However, acknowledging the feasibility 
limitations of implementing these guidelines, a stepwise approach to implementation was 
recommended, determined by each country’s capabilities. At the end of 2015, 17 million 
people were receiving HIV treatment worldwide, representing a global ART coverage of 46%. 
ART expansion has resulted in an annual AIDS-related deaths decrease since 2010 of 26% 
globally, and 38% in Southern and Eastern Africa (UNAIDS, 2016a).  
 
Source: UNAIDS estimates 2016 
Although the success in scaling up ART and stabilization of the epidemic must be 
acknowledged, challenges remain in Africa. Logistical factors prevent the full success of ART 
scale-up, key populations are sometimes neglected by country-specific guidelines, and the long 
survival and aging of the HIV-infected population complicates the management of HIV and its 
associated co-morbidities. Enhancement of local health systems is key to overcome these 
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challenges and be able to provide ongoing, sustainable, and comprehensive HIV care to the 
millions of people in need (Barker et al., 2007; Mutevedzi and Newell, 2014). 
1.2. Prevention of Mother-To-Child Transmission of HIV 
The majority of paediatric HIV infections are acquired through mother-to-child transmission 
(MTCT), which can occur during pregnancy (in utero), during labour and delivery, or through 
the breast milk. Over 90% of paediatric HIV infections occur in sub-Saharan Africa, where 85% 
of pregnant women living with HIV reside (UNAIDS, 2014b). Without any preventive 
intervention, the MTCT rate among infants who breastfeed ranges from 25 to 40% (De Cock et 
al., 2000). 
During the nineties, PMTCT was shown to be effective in well-resourced settings through the 
administration of antiretroviral prophylaxis to the mother during pregnancy, labour and 
delivery, and to the infant for the first six weeks of life (Connor et al., 1994). Further evidence 
demonstrated that combined antiretroviral therapy given to the mother together with 
Reproduced with permission from 
Challenges in the Elimination of 
Pediatric HIV-1 Infection. Luzuriaga 
K, Mofenson LM. N Engl J Med. 2016 
Feb 25; 374(8):761-70. Copyright 
Massachusetts Medical Society. 
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elective caesarean section and avoidance of breastfeeding reduced MTCT to less than 1% 
(European Collaborative Study, 2005). 
In most low income countries elective caesarean section and avoidance of breastfeeding are 
not safe or sustainable practices. The WHO issued the firsts PMTCT recommendations for 
resource limited settings in 2000. These guidelines have been revised, updated and simplified 
over the years to incorporate new evidence and to be aligned with the global commitment to 
universal treatment access and zero new infections among children.   
In 2011, the UNAIDS presented “The Global Plan Towards the Elimination of New HIV 
Infections Among Children by 2015 and Keeping their Mothers Alive” (known as “Global 
Plan”) (UNAIDS, 2011). The Global Plan recommends a four-pronged approach for PMTCT: 1) 
Prong 1 is prevention of HIV infections among women of childbearing age, 2) Prong 2 targets 
prevention of unintended pregnancies among HIV-infected women, 3) Prong 3 emphasizes 
the prevention of HIV transmission from infected women to their infants, and 4) Prong 4 
includes provision of comprehensive treatment, care and support to mothers living with HIV 
and their families. To deliver this Prong 4 comprehensive PMTCT package the integration of 
HIV services for pregnant women, mothers, and children into the existing maternal and child 
health services is recommended.  
Since 2012, the WHO recommends what is known as PMTCT “Option B+”, meaning: lifelong 
ART for all pregnant and breastfeeding  women regardless of their CD4 counts and clinical 
stage (WHO, 2012a, 2016). This option was first implemented in Malawi in 2011 (Schouten et 
al., 2011), and given its ease of implementation and chances to increase PMTCT service 
coverage, improve maternal health and reduce transmission to serodiscordant sexual 
partners, was rapidly endorsed by the WHO. As of 2016, most sub-Saharan African countries 
had rolled out Option B+ (UNAIDS, 2015a).   
According to UNAIDS, in 2014, in the Global Plan priority countries in Africa, 77% of HIV-
infected pregnant women received antiretroviral drugs for PMTCT and the MTCT decreased 
from 28% in 2009 to 14% (UNAIDS, 2015a). This represents a 70% decline in the number of 
new HIV infections among children between 2000 and 2015 (UNAIDS, 2016b). 
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New HIV infections among children (aged 0–14 years) and percentage of pregnant 
women living with HIV receiving antiretroviral medicines (either prophylaxis or 
lifelong therapy) to prevent mother-to-child transmission 
 
Source: UNAIDS estimates 2016 
A crucial step of all PMTCT programs is Early Infant Diagnosis of HIV (EID), the HIV testing of 
infants to determine if they have acquired HIV. Given the rapid progression of HIV disease in 
untreated perinatally infected infants, timely diagnosis is critical. Maternal HIV antibodies are 
passively transferred to the baby across the placenta, and thus, assays that detect viral 
material (virological tests) are needed to diagnose HIV infection in infants. There are 
theoretical concerns about the use of HIV RNA virological testing in infants who have taken 
or are taking antiretroviral prophylaxis for PMTCT or in those who are breastfeeding from 
mothers on ART. While the performance of HIV RNA assays in specimens from infants is 
being assessed, the WHO recommends pro-viral HIV DNA PCR from whole blood or dried 
blood spots as the preferred method to detect HIV infection (WHO, 2010d). Despite the 
important progress on the numbers of pregnant women receiving antiretrovirals for PMTCT, 
testing of HIV-exposed infants is lagging behind. In 2014, only 49% of the estimated 1.2 
million HIV-exposed infants received a virological HIV test within the firsts 2 months of life 
(UNAIDS, 2015a). This represents an important improvement from the reported 10% in 2009, 
but it is still alarmingly low, and undermines the opportunity to provide timely care and 
treatment to HIV-infected infants. 
One of the main challenges of PMTCT programs derives from the length of the process. 
Prevention of vertical HIV infection starts with the first antenatal care visit and must be 
continued until the end of the breastfeeding period. In 2014, in the sub-Saharan Africa 
priority countries, the MTCT rate at 6 weeks of life was 5%, but rose to 14% at the end of the 
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breastfeeding period. Transmission during breastfeeding occurred mostly due to inadequate 
adherence and retention in care of HIV-infected mothers (van Lettow et al., 2014; Kim et al., 
2015; Chan et al., 2016; Haas et al., 2016). PMTCT programs have been mostly focused on 
the antepartum component of prevention, and now emphasis on the follow-up and retention 
in care during the long breastfeeding period is needed. The integration of PMTCT and 
paediatric HIV care within the maternal and child health services is strongly recommended by 
WHO to improve the retention of HIV-affected mother-infants pairs (UNAIDS, 2011; WHO, 
2014b). However, integration alone may not be sufficient. There is not a single risk factor 
that drives to the observed challenges in retention in care and adherence to ART during 
pregnancy and breastfeeding periods. In a recently published review, Myer and Philips 
propose a framework that recognizes the fundamental drivers of disengagement from HIV 
care of pregnant and postpartum women (Myer and Phillips, 2017).  
Conceptual model for considering determinants of engagement in ART services in 
pregnant and postpartum women 
 
Source: Beyond “Option B+”: Understanding Antiretroviral Therapy (ART) Adherence, retention in Care and 
Engagement in ART Services among Pregnant and Postpartum Women Initiating Therapy in Sub-Saharan 
Africa. J Acquir Immune Defic Syndr. 2017 Jun 1; 75 Suppl 2: S115-S122  
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Intervention packages targeting this wide range of factors from different levels including 
health systems, individual psychological and social factors and biological aspects, need to be 
developed, implemented and tested.  
1.2.1. HIV and Prevention of Mother-to-Child Transmission in Tanzania 
Tanzania, in Eastern Africa, is one of the countries most affected by the HIV pandemic. In 
2015, there were an estimated 1.4 million PLWHIV in the country, 91,000 being children (< 15 
years). The HIV prevalence among adults (15-49 years) is 4.7% and there were 54,000 new 
HIV infections and 36,000 AIDS-related deaths during 2015 (UNAIDS, 2015b). 
HIV care and treatment services are offered free of cost to all people in need through a 
network of clinics coordinated by the National AIDS Control Programme. The firsts clinics 
become operational in 2004 and currently there are more than 1,200 treatment centres 
located at referral, regional and district hospitals as well as primary health facilities 
(Tanzanian MoHSW, 2015).   
The PMTCT program in Tanzania started also in 2004, when the first guidelines were 
developed. The current guidelines were published in September 2013 and recommend 
Option B+ (Tanzanian MoHSW, 2013b). This option was progressively rolled out during 2013 
and 2014 to all health facilities providing PMTCT care.  
The Ministry of Health and Social Welfare recommends the provision of comprehensive 
treatment, care and support to mothers living with HIV and their families. To deliver this 
comprehensive PMTCT package is critical to link and integrate HIV health services within the 
reproductive and child health clinics. Such integration needs to be accompanied by a 
continuous training on HIV of the attending health workers in the antenatal and child health 
clinics, a strong supply chain of HIV tests, antiretroviral drugs and drugs for opportunistic 
infections, and a strategy to overcome shortages of staff. These requisites are frequently 
unmet and prevent an optimal implementation of Option B+. 
In 2015, after Option B+ was already deployed to the whole country, 86% of pregnant 
women living with HIV received antiretrovirals for PMTCT (UNAIDS, 2015b). The reported 
MTCT rate in 2014 was 3% at 6 weeks of life and 9% at the end of breastfeeding, 
representing a 72% decline in the number of new paediatric HIV infections since 2009 
(UNAIDS, 2015a). Similarly to other countries in sub-Saharan Africa, in 2015, only 43% of HIV-
exposed infants received an EID test by the age of 2 months. 
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1.3. Children living with HIV 
There are an estimated 2.1 million of children living with HIV in the world (UNAIDS, 2017). 
Over 90% of them reside in sub-Saharan Africa and MTCT accounts for over 90% of the 
infections (UNAIDS, 2013). Despite the laudable progress of PMTCT interventions 
implementation, 150,000 new infections occurred in 2015 (411 children infected every day), 
highlighting the number of women who do not access antenatal care or the necessary 
measures to prevent HIV transmission to their infants.  
  
 
Source: UNAIDS estimates 2017 
Progression of HIV diseases in children is more rapid than in adults. In sub-Saharan Africa, 
without treatment, 53% of infected children die before their second birthday and 75% before 
the age of three years (Newell et al., 2004). This rapid disease progression and poor clinical 
outcomes make of vital importance the provision of EID for all HIV-exposed infants and early 
ART initiation for those who become infected. By the end of 2015, an estimated 5 million 
 9 
 
children had died of AIDS-related causes since the start of the HIV epidemic. Only in 2016, 
120,000 children died due to AIDS (over 320 children per day). Most of these deaths could 
have been avoided if HIV transmission had been averted in first place, but in cases in which 
infants were perinatally infected, early diagnosis and treatment would have reduced early 
infant mortality by 76% (Violari et al., 2008). 
 
Source: UNAIDS estimates 2017 
Since 2010, earlier treatment for HIV-infected children has been progressively promoted. The 
WHO recommended, in 2010, to treat all children under the age of two years, irrespective of 
their clinical or immunological stage. In 2013, the age threshold was raised to five years (WHO, 
2013) and, in 2015, treatment for all HIV-infected children was recommended (WHO, 2015). 
Implementation of such recommendations and the scale-up of paediatric ART have 
encountered substantial challenges that have resulted in a slow progress and a concerning gap 
in treatment coverage. Of the 1.8 million children under 15 years of age living with HIV, only 
49% accessed ART in 2015 (UNAIDS, 2016b). This is an improvement compared to 27% in 2013 
and 10% in 2009, but still too many children are not accessing health-restoring treatment. 
Reasons for the slow progress of paediatric ART scale-up can be divided into: i) gaps identifying 
HIV-infected children, and ii) barriers to access ART.  
Gaps identifying HIV-infected infants and children  
Despite the remarkable progress of PMTCT programs in delivering antiretrovirals to HIV-
infected pregnant women, the progress made with EID is less robust. As already mentioned in 
the previous section, in 2015, less than half of HIV-exposed infants got a virological test done 
within the firsts two months of life.  A main reason for this low coverage is the low post-
partum retention in care of mothers and the weak systems to track mothers and infants who 
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do not return for testing or results (Chatterjee et al., 2011; Essajee et al., 2017). Also, EID 
circuits are often affected by stock outs of testing kits or laboratory reagents, delays in sample 
collection, and long turn-around times of results (Nuwagaba-Biribonwoha et al., 2010; Hsiao, 
Stinson and Myer, 2013).   
Since PMTCT interventions include lifelong maternal ART the number of infections expected 
among infants born from mothers enrolled and retained in a PMTCT program is low. Thus, 
most HIV-infected infants and children are to be found outside the PMTCT-EID cascade. The 
WHO recommends opt-out screening for HIV in health care settings, meaning that an HIV test 
will be done routinely unless a patient explicitly refuses to take the test (WHO, 2007a). While 
opt-out HIV testing is generalized in most antenatal care settings, it is not as widespread in 
entry points where children at high risk of HIV seek for services: malnutrition units, 
tuberculosis clinics and in-patient wards (Ahmed et al., 2013, 2016; Chamla et al., 2013). Also, 
index testing is often forgotten. Testing children of adults living with HIV who are under care 
should be routine practice in all HIV clinics.  
On the patients’ side, it is important to consider the concerns of caregivers about paediatric 
HIV testing. Although most adults feel that HIV testing would benefit children, many fear the 
discrimination children may face in the community if they are infected (Buzdugan et al., 2012). 
Barriers to access ART 
Long waiting times, lack of integration and/or coordination with other child health services and 
difficulties with paediatric counselling and venipuncture are reasons caregivers cite for not 
accessing HIV services (Yeap et al., 2010). The two key service delivery enablers to overcome 
these barriers are task shifting and the integration of paediatric ART into other health 
programs (Penazzato et al., 2017). A systematic review published in 2014 suggested that 
nurse-managed paediatric HIV services had similar mortality and retention outcomes 
compared to physician-led clinics (Penazzato et al., 2014). To ensure the provision of quality 
paediatric HIV care and safely overcome the perception that paediatric HIV/AIDS care and 
treatment are inherently complex, task shifting, or better, sharing between physicians and 
non-physicians, should be carefully planned and accompanied by robust training and ongoing 
supportive supervision and mentoring. As nurses become better able to diagnose, manage and 
treat HIV-infected children, paediatric HIV services can be decentralized and integrated into 
either the standard child health services or, with the adult ART services. Given the lifelong 
need of ART of all children living and growing with HIV, family–centred approaches within ART 
services may be a more sustainable approach. 
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A major barrier to start and retain children on treatment is the limited paediatric antiretroviral 
options. The availability of new formulations is likely to lead to further improvements in 
adherence and retention (DNDi, 2013). Along with the development of new formulations, 
ensuring that commodities are in place and minimizing shortages and stock-outs are critical to 
ensure the scale-up of paediatric ART and the improvement of clinical outcomes and survival 
of HIV-infected children.  
1.3.1. Children living with HIV in Tanzania 
Tanzania is the fifth country in the world with more children living with HIV. In 2015, it was 
estimated that 91,000 children were HIV-infected and 6,500 new paediatric infection occurred 
(UNAIDS, 2015b).  
Global distribution of new HIV infections among children (aged 0–14 years), 2015 
 
Source: UNAIDS estimates 2016 
In 2014 only 29% of children (0-14 years) living with HIV in Tanzania received ART (UNAIDS, 
2015a). However, the National AIDS Control Program recommended in June 2015 to treat all 
HIV-infected children regardless of their CD4 counts and percentage and clinical stage. Due to 
this change in the recommendations, many children that were already under HIV care but not 
receiving ART were started on medication. According to UNAIDS, by the end of 2015, ART 
coverage among children in Tanzania was 56% (UNAIDS, 2015b). Although this represents a 
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praiseworthy improvement, there is still a long way ahead to reach the targets of 90% of ART 
coverage (UNAIDS, 2014a, p. 90) and zero new paediatric infections. 
1.3.2. Children and HIV drug resistance-associated mutations 
The roll-out of ART in resource-limited countries resulted in a reduction of HIV-related 
morbidities and mortality, and increased the life expectancy of infected adults and children 
(Puthanakit et al., 2007; Patel et al., 2008). Long-term treatment success and virological 
suppression is harder to achieve in children compared to adults (van Rossum, Fraaij and de 
Groot, 2002). Children present poorer virological response, which is associated to high viral 
loads before treatment, the risk of sub-therapeutic drug concentrations caused by limited 
paediatric drug formulations, variable pharmacokinetics, and fast changes in bodyweight 
derived from growth (Abrams et al., 1998; van Rossum, Fraaij and de Groot, 2002; Menson et 
al., 2006). The restriction of reliable HIV test for infants and the limited laboratory capacity to 
monitor treatment efficacy in most resource-limited settings in combination with often already 
advanced levels of immunosuppression at treatment initiation further aggravate treatment 
outcomes among children (Sigaloff et al., 2011; UNAIDS, 2013, p. 201). Together with a 
suboptimal adherence during childhood and adolescence, these factors promote the 
emergence of acquired HIV drug resistance mutations and reduce treatment options and the 
probability of virological suppression in this highly vulnerable population (Menson et al., 2006; 
Bratholm et al., 2010). 
Until very recently, in resource-limited settings the initiation of ART has been mostly based 
upon CD4 counts and clinical criteria, thus leading to treatment initiation in children with 
advanced immunosuppression, which are prone to treatment failure (Bratholm et al., 2010). In 
such settings, where paediatric formulations are scarce, it is common that children are 
prescribed halves of adult fixed-dose formulations, with the risk of an inaccurate dosage and 
subsequent sub-therapeutic drug levels. This, added to the low genetic barrier for some of the 
most often used drugs as nevirapine, causes an increased emergence of drug resistance 
mutations in children (Ellis et al., 2007; Bratholm et al., 2010).  
Adherence to ART is a major factor for the emergence of drug resistance mutations and 
consequent treatment failure (Vreeman et al., 2008; Bratholm et al., 2010). Children’s 
adherence depends on the caregiver, and the association between good adherence and a 
dutiful caregiver to achieve virological suppression is well established (Zoufaly et al., 2013).  
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CD4 counts are commonly used for treatment monitoring, but have low sensitivity as indicator 
for treatment failure, detecting only one third of children failing to treatment. Delaying the 
detection of failing treatments causes the accumulation of resistance mutations and limits 
future second-line treatment options (Mutwa et al., 2014). By performing regular virological 
monitoring patients would not be kept on a failing regimen and the development and 
accumulation of HIV drug resistance-associated mutations could be largely reduced. However, 
financial and technical limitations in many sub-Saharan African countries do not allow to 
perform such routine tests, thereby contributing to the emergence of HIV drug resistance 
mutations (Sigaloff et al., 2011).   
Virological success rates among children on ART vary widely between 40% and 81% (Sutcliffe 
et al., 2008b; Ciaranello et al., 2009). Drug resistance mutations are found in approximately 
90% of all children failing on first-line ART, being as frequent as in adults presenting treatment 
failure. However, since virological failure rates are higher among children, this translates into 
an overall higher rate of emergence of acquired drug resistances in children (Sigaloff et al., 
2011). The available data on acquired HIV drug resistance from East African countries are 
highly heterogeneous, reaching rates between 14% and 58% (Bratholm et al., 2010; Sigaloff et 
al., 2011; Wamalwa et al., 2013; Mutwa et al., 2014). 
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2. Specific introduction to this thesis 
2.1. Study 1 
The first study presented in this thesis is an assessment of the PMTCT circuit in Ifakara during 
the period 2010 - 2011. The aim was to identify the circuit gaps to develop a strategy to 
enhance the uptake of the PMTCT recommendations and improve the outcomes of HIV-
infected pregnant women and their offspring. 
2.2. Study 2 
The second study in this thesis evaluates the impact of a bundle of measures implemented to 
improve maternal and paediatric HIV care in Ifakara. The strategy designed was partially based 
in the assessment of Study 1. This study describes the baseline characteristics, clinical 
outcomes and retention in care of pregnant women and children enrolled in HIV care before 
(2008 – 2012) and after (2013 – 2014) the implementation of this bundle of measures.  
2.3. Study 3 
The third study of this thesis re-assesses the PMTCT cascade in Ifakara during the period 2014-
2015. This study evaluates the impact of the measures taken after the first assessment 
presented in Study 1 combined with the simplification of PMTCT guidelines (Option B+) 
adopted by the Government of Tanzania after the WHO recommendation.  
2.4. Study 4 
The forth study focuses on the outcomes of children and adolescents enrolled in the clinic by 
describing a case series to raise awareness of a potential threat to paediatric HIV programs in 
Africa: the acquisition of drug resistance-associated mutations in HIV-infected children. 
2.5. Study 5 
The fifth study presented builds on the findings of Study 4. This study describes the clinical, 
immunological and virological outcomes associated with ART in the absence of regular 
virological monitoring among children and adolescents attending the HIV clinic in Ifakara and 
determines the risk factors associated with virological failure and drug resistance-associated 
mutations development. 
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3. Objectives and Research Aims 
The general objective of this thesis is to improve our understanding of the challenges of 
PMTCT and paediatric HIV care in rural sub-Saharan Africa and to test a strategy with several 
interventions to improve the care of HIV-infected mothers, children and their families 
attending the Chronic Diseases Clinic of Ifakara. 
3.1. Study 1  
Uptake of Guidelines on Prevention of Mother-to-Child Transmission of HIV in Rural 
Tanzania - Time for change  
Objectives:  
- To describe the PMTCT cascade at the St Francis Referral Hospital in Ifakara. 
- To describe the uptake of the PMTCT recommendations at the St Francis Referral Hospital 
in Ifakara. 
Hypothesis: 
- There are gaps in the PMTCT circuit that prevent the optimal implementation of the 
recommendations. 
Specific aims: 
- To identify the different departments and health workers involved in the PMTCT service 
delivery in Ifakara. 
-  To identify the gaps in the PMTCT cascade and their possible causes. 
- To propose solutions adapted to the setting to bridge the identified gaps. 
Relevance: 
- This baseline assessment of the PMTCT cascade in Ifakara serves as the basis to design a 
strategy to improve the service delivery. 
3.2. Study 2 
An Integrated and Comprehensive Service Delivery Model to Improve Pediatric and Maternal 
HIV Care in Rural Africa  
Objectives: 
- To describe the One Stop Clinic of Ifakara: a package of measures to improve the quality of 
paediatric and maternal HIV care. 
- To assess the impact of the One Stop Clinic on the diagnosis, linkage into care, treatment 
coverage and retention of HIV-infected pregnant women and children in Ifakara. 
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Hypothesis: 
- The One Stop Clinic has contributed to improve the diagnosis, linkage into care, treatment 
coverage and retention of HIV-infected pregnant women and children in Ifakara. 
Specific aims: 
- To assess the number of new paediatric patients and pregnant women enrolled in care 
before and after the implementation of the One Stop Clinic. 
- To describe and compare the baseline characteristics of the newly enrolled children and 
pregnant women before and after the implementation of the One Stop Clinic. 
- To describe and compare the ART coverage before and after the implementation of the 
One Stop Clinic. 
- To describe and compare the ascertainment of tuberculosis and malnutrition before and 
after the implementation of the One Stop Clinic. 
- To describe and compare the retention in care 6 months post-enrolment before and after 
the implementation of the One Stop Clinic. 
- To describe the cohort of HIV-exposed infants that is being followed up since the 
implementation of the One Stop Clinic. 
Relevance: 
- This manuscript is important to assess if the service delivery model of the One Stop Clinic 
improves the maternal and paediatric HIV care in a rural African setting as Ifakara. 
3.3. Study 3 
Prevention of Mother-To-Child Transmission Option B+ Cascade in Rural Tanzania: the One 
Stop Clinic Model 
Objectives: 
- To describe the uptake of PMTCT Option B+ guidelines during its first year of 
implementation in St Francis Referral Hospital in Ifakara and compare it with the previously 
described PMTCT cascade (Study 1). 
Hypothesis: 
- The simplification of the PMTCT recommendations with Option B+ combined with the 
integrated service delivery of the One Stop Clinic have resulted in a better uptake of the 
PMTCT guidelines. 
Specific aims: 
- To assess the uptake of PMTCT Option B+ guidelines in Ifakara. 
- To compare this uptake with the previously described. 
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- To describe the current PMTCT circuit in St Francis Referral Hospital and identify the 
existing gaps and their possible causes. 
- To assess the retention in care through pregnancy and post-delivery period, the pregnancy 
outcomes and the MTCT of HIV rate. 
Relevance: 
- This manuscript assesses the impact of the simplification of the PMTCT recommendations 
combined with the One Stop Clinic service delivery model on the PMTCT cascade. 
3.4. Study 4 
A Case Series of Acquired Drug Resistance-Associated Mutations in HIV-infected Children: an 
Emerging Public Health Concern in Rural Africa 
Objectives:  
- To raise awareness about a scarcely reported emerging public health concern in sub-
Saharan Africa: the acquisition of drug resistance-associated mutation in HIV-infected 
children. 
Hypothesis: not applicable 
Specific aims: 
- To present a well-characterised series of children from the One Stop Clinic of Ifakara with 
treatment failure due to the acquisition of drug-resistance mutations. 
Relevance: 
- This case series raises concerns about a scarcely reported threat for the success of 
treatment of children living with HIV.  
3.5. Study 5 
Development of HIV Drug Resistance and Therapeutic Failure in Children and Adolescents in 
Rural Tanzania – An Emerging Public Health Concern  
Objectives: 
- To objectively describe the clinical, immunological and virological outcomes associated with 
ART in the absence of regular virological monitoring among children and adolescents 
attending the One Stop Clinic of Ifakara and included in the KIULARCO cohort. 
Hypothesis: 
- Similarly to the unpublished data from the Tanzanian CDC, the virological failure rate 
among children in KIULARCO is around 40%. 
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- In approximately 90% of all children with virological failure, HIV drug resistance mutations 
can be identified. 
- Virological failure and the presence of drug resistance-associated mutations are associated 
with (i) time since ART initiation, (ii) treatment adherence, (iii) under-dosage of drugs, and 
(iv) vital status of the parents. 
Specific aims: 
- To assess the prevalence of virological failure among the study patients. 
- To assess the prevalence of HIV drug resistance-associated mutations among the study 
patients. 
- To describe the clinical and immunological stage of the study patients at ART initiation and 
at the most recent visit. 
- To compare the current drug resistance-associated mutations profiles with the available 
pre-ART sample to confirm the acquisition of resistances. 
- To determine risk factors associated with virological failure and drug resistance-associated 
mutations development. 
Relevance 
- This study confirms the suspected high rates of virological failure among 
children/adolescents compared to adults and identifies the risk factors associated with it 
and HIV drug resistance mutations. By identifying these risk factors, measures to prevent 
virological failure and drug resistance mutations as well as to timely detect failing children 
can be developed.  
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4. Methods 
4.1. Study site 
All the studies presented in this thesis are based on work undertaken at the Chronic Diseases 
Clinic of Ifakara. The clinic, located at the Kilombero district, southern Tanzania, was the first 
rural HIV care and treatment clinic accredited to provide HIV services in the country. It is part 
of the Saint Francis Referral Hospital and works in cooperation with the Ifakara Health 
Institute, the Swiss Tropical and Public Health Institute and the Department of Infectious 
Diseases and Hospital Epidemiology of the University Hospitals of Basel and Bern, Switzerland. 
All patients diagnosed with HIV within the hospital or diagnosed at a peripheral health centre 
and transferred for further treatment are referred to the clinic to receive HIV care and 
treatment according to the National AIDS Control Program. 
Since 2004, all HIV-infected patients attending the clinic are invited to participate in the 
Kilombero and Ulanga Antiretroviral Cohort (KIULARCO). KIULARCO was originally developed 
for monitoring and evaluating ART roll-out. The current objectives of the KIULARCO cohort are 
to: (i) provide patient and cohort-level information on the outcomes of HIV treatment; (ii) 
provide cohort-level information on opportunistic infections and non-AIDS co-morbidities; (iii) 
evaluate aspects of HIV care and treatment that have national or international policy 
relevance; and (iv) provide a platform for studies on improving HIV care and treatment, 
including clinical trials (Letang et al., 2017; Vanobberghen et al., 2017). 
The Ifakara Health Institute institutional review board and the National Health Research Ethics 
Review Committee of the National Institute for Medical Research of Tanzania provided ethical 
approval for KIULARCO, including for sample collection, cryopreservation and analysis of 
collected data. Written informed consent is sought from all participants at registration at the 
Chronic Diseases Clinic of Ifakara; for children and adolescents younger than 18 years, 
informed consent is sought from caregivers. 
The rural districts of Kilombero and Ulanga, in the Morogoro region of southern Tanzania, have 
a population of approximately 700,000 people (Tanzanian NBS, 2012) and an estimated 40,000 
PLWHIV. The St Francis Referral Hospital is the largest health facility in the Kilombero district, 
is located in its main town, Ifakara, and serves as the referral hospital for the lower level 
hospital, health centers and dispensaries. 
Since 2004, almost 9,000 PLWHIV have been enrolled in KIULARCO, and 6,858 (76%) have 
received ART (Letang et al., 2017). 
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Kilombero and Ulanga districts in Tanzania 
4.2. Study 1 
Uptake of Guidelines on Prevention of Mother-to-Child Transmission of HIV in Rural 
Tanzania - Time for change  
Research question: What was the uptake of PMTCT recommendations in Ifakara during 2010 - 
2011? 
Study population: Pregnant women attended in the antenatal care clinic, the HIV clinic or the 
labour ward in St Francis Referral Hospital during 2010 - 2011. 
Study design: Situation analysis. Cross-sectional study retrieving data from the different 
stations where pregnant women receive health services at St Francis Referral Hospital. 
Measurements: Absolute number of pregnant women attending the different stations and 
proportions of HIV testing, access to antiretroviral drugs, adherence to the PMTCT protocols, 
etc. 
Statistical analysis plan: Purely descriptive study. 
Sample size calculation: not applicable. 
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4.3. Study 2 
An Integrated and Comprehensive Service Delivery Model to Improve Pediatric and Maternal 
HIV Care in Rural Africa  
Research question: What has been the impact of the package of measures implemented in 
Ifakara to improve maternal and paediatric HIV care? 
Study population: HIV-infected pregnant women and children, and HIV-exposed infants 
enrolled in the KIULARCO from January 1st, 2008 to December 31st, 2014. 
Study design: Prospective cohort study comparing the periods before (2008 - 2012) and after 
(2013 - 2014) the implementation of the package of measures. 
Measurements: Number of new paediatric patients and pregnant women enrolled in 
KIULARCO every year, baseline characteristics, incidence of tuberculosis and malnutrition, ART 
coverage and retention in care. Number of HIV-exposed infants enrolled, clinical 
characteristics and MTCT rate. 
Statistical analysis plan: Baseline characteristics are summarized and reported with 
appropriate statistical measures. Comparisons between both periods are made using Chi-
square and Wilcoxon rank sum test for categorical and continuous variables respectively. 
Sample size calculation: not applicable. 
4.4. Study 3 
Prevention of Mother-To-Child Transmission Option B+ Cascade in Rural Tanzania: the One 
Stop Clinic Model 
Research question: What was the uptake of PMTCT Option B+ recommendations in Ifakara 
during its first year of implementation (4/2014 - 3/2015)? How does it compare to the 
previously described (Study 1)? 
Study population: Pregnant women attended in the antenatal care clinic, the Chronic Diseases 
Clinic of Ifakara (and enrolled in KIULARCO) or the labour ward in St Francis referral Hospital 
during the study period. HIV-exposed infants enrolled in the HIV clinic during the study period. 
Study design: Prospective cohort study. 
Measurements: Antental care clinic: number of women attended, tested for HIV, HIV 
prevalence. KIULARCO: number of newly-enrolled pregnant women, number of women 
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becoming pregnant during follow-up, clinical characteristics, pregnancy outcomes. Labour 
ward: number of women attended, tested for HIV, HIV prevalence. HIV-exposed infants: 
number of newly-enrolled infants, clinical characteristics, MTCT rate. 
Statistical analysis plan: Absolute number of pregnant women attending the different stations 
and proportions of HIV testing and HIV positivity (prevalence). Clinical characteristics from 
KIULARCO database are summarized and reported with appropriate statistical measures. 
Comparisons between the two periods are made using Chi-square or Fisher exact test and 
Wilcoxon rank sum test for categorical and continuous variables respectively. 
Sample size calculation: not applicable. 
4.5. Study 4 
A Case Series of Acquired Drug Resistance-Associated Mutations in HIV-infected Children: an 
Emerging Public Health Concern in Rural Africa 
Research question: not applicable. This manuscript is a description of a worrisome observation 
from the One Stop Clinic. 
Study population: Children detected throughout routine clinical care to present virological 
falirue. 
Study design: Case series: observational descriptive study. 
Measurements/exams: not applicable 
Statistical analysis plan: not applicable 
Sample size calculation: not applicable 
4.6. Study 5 
Development of HIV Drug Resistance and Therapeutic Failure in Children and Adolescents in 
Rural Tanzania – An Emerging Public Health Concern  
Research question: What is the prevalence and determinants of virological failure and HIV 
drug resistance-associated mutations among children and adolescents attending the One Stop 
Clinic of Ifakara and included in the KIULARCO cohort? 
Study population: HIV-infected children aged < 19 years, included in KIULARCO, who have 
been on ART for > 12 months. 
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Study design: Longitudinal study assessing virological failure and HIV drug resistance 
mutations among children and analysing prospectively collected data. 
Measurements/exams: Prevalence and predictors of virological failure and HIV drug resistance 
mutations. 
Statistical analysis plan: For data description, the numeric variables are displayed with 
medians and IQRs whereas the categorical variables are presented in proportions. Associations 
between considered variables and virological failure and HIV drug resistance mutations are 
assessed using multivariate logistic regression models. 
Sample size calculation: Sample size was calculated under the expectation that the prevalence 
of virological failure in our setting was 40% (similar to the unpublished Tanzanian CDC data 
(Ward, J et al., 2014)). This prevalence is between the previously reported in Tanzania (58% 
(Bratholm et al., 2010)) and the reported for resource-poor settings in a systematic review 
(24% (Sigaloff et al., 2011)). 
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5. Study 1: Uptake of Guidelines on Prevention of Mother-to-Child 
Transmission of HIV in Rural Tanzania - Time for change 
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Summary  
Guidelines on prevention of mother-to-child transmission (PMTCT) of HIV are inconsistently 
implemented in low-income countries. Strategies are needed to improve the uptake of these 
guidelines to prevent avoidable new HIV infections of infants. In 2010 the World Health 
Organization presented its new PMTCT guidelines, offering two options of short courses of 
antiretroviral prophylaxis: Option A and Option B. Option A consists of antenatal prophylaxis 
with zidovudine followed by intrapartum and postpartum prophylaxes with single dose 
nevirapine and zidovudine plus lamivudine, Option B recommends triple antiretroviral 
prophylaxis until finishing breastfeeding. Tanzania has adopted Option A, and it is currently 
implementing it. A new option termed Option B+ has emerged recently, which recommends 
providing lifelong antiretroviral treatment to all HIV-positive pregnant women.  
In this article, we discuss the likely impact of this last PMTCT strategy in rural Africa with an 
example of an observational cross-sectional analysis in a rural referral hospital in Tanzania 
aiming to assess the uptake of PMTCT recommendations. Gaps were identified at all steps of 
the PMTCT pathway.  
An effective uptake of PMTCT guidelines has shown to be extremely challenging in this setting. 
The continuously changing recommendations on PMTCT stress the need for a much simpler 
and effective approach. We argue in favor of implementing Option B+ in Tanzania. Financial 
challenges need to be faced, but Option B+ would help to overcome many barriers that 
prevent guidelines to be implemented in order to increase coverage and ultimately achieve 
the goal of “virtual elimination” of mother-to-child transmission in sub-Saharan Africa. 
Different options for preventing mother-to-child transmission of HIV 
More than two million children under the age of 15 are infected with Human 
Immunodeficiency Virus (HIV) worldwide, most of them in sub-Saharan Africa (UNAIDS, 
2010b). Mother-to-child transmission of HIV accounts for over 90% of these cases (UNAIDS, 
2010b),  ranging the risk of transmission from 25 to 48% in resource-limited settings (De Cock 
et al., 2000). 
Prevention of mother-to-child transmission (PMTCT) was shown to be effective in well-
resourced settings through the administration of antiretroviral prophylaxis to the mother 
during pregnancy, labour and delivery, and to the infant for the first six weeks of life (Connor 
et al. 1994).  Further evidence demonstrated that combined antiretroviral therapy (cART) 
given to the mother together with elective cesarean section and avoidance of breastfeeding 
reduced mother-to-child transmission to less than 1% (European Collaborative Study 2005). 
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Consequently, guidelines were developed for high and in low income countries (WHO, 2010a; 
EACS, 2011).  
The World Health Organization (WHO) issued the first recommendations on PMTCT in 
resource-limited settings in 2000. These recommendations were revised in 2004 with the 
adoption of simplified and standardized regimens. In 2006 and later in 2010 (WHO, 2010a), the 
guidelines were updated to incorporate new evidence and to be aligned with the global 
commitment to universal access.  
Guidelines for resource-limited settings are difficult to implement, partly due to the fragility of 
health systems in these countries. Lack of infrastructure and constraints on human and 
financial resources contribute to a poor uptake of evidence based interventions and, 
ultimately, to the impairment of clinical practice in these settings. Dissemination of changes in 
the guidelines is suboptimal and often takes time to be rooted among health workers and to 
change practices in rural sub-Saharan Africa (Nkonki et al. 2007). According to WHO, only 53% 
of pregnant women worldwide received any antiretroviral for PMTCT in 2009 (WHO, 2010c), 
with substantial differences across countries in sub-Saharan Africa (i.e. 1% in the Democratic 
Republic of the Congo versus 52% in Mozambique) (UNAIDS, 2010a). Importantly, having 
effective antiretroviral regimens and wide coverage is insufficient, being effective delivery 
programmes equally important (Barker, Mphatswe and Rollins, 2011; Ciaranello et al., 2012). 
Simplification of the existing programmes is urgently needed in order to bridge the gaps 
observed with current recommendations. 
In 2010 the WHO presented its new guidelines on PMTCT, recommending two PMTCT options: 
Option A and Option B. These two options include both treatment and prophylaxis 
components. In both options CD4 cell count is necessary to decide the eligibility of HIV-
infected pregnant women for lifelong cART. For all women who have CD4 cell counts ≤350 
cell/mm3 initiation of lifelong cART is recommended. For those women non eligible for lifelong 
cART while Option A recommends antenatal prophylaxis with zidovudine followed by 
intrapartum and postpartum prophylaxes with single dose nevirapine and zidovudine plus 
lamivudine, Option B recommends triple antiretroviral prophylaxis until after finishing 
breastfeeding. Recently a new option has emerged, termed Option B+ (WHO, 2012a). This 
option adapts a single, universal regimen both to treat HIV-infected pregnant women and to 
prevent mother-to-child transmission. In Option B+ all HIV-positive pregnant women are 
provided lifelong cART, regardless of the CD4 cell count. Option A might not bridge the 
implementation difficulties due to the changes in drugs delivered across the care continuum 
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(antenatal, delivery and postpartum). Option B and B+, while simplifying the drugs 
prescription, have a short-term drug cost greater than Option A. However, when having into 
account maternal and infant life expectancy and lifetime healthcare costs, option B is more 
effective and less expensive than Option A. Option B+ offers clinical benefits and economic 
value comparable with other widely used HIV interventions (Ciaranello et al., 2013). The three 
options are summarized in Table 1.  
Table 1. Options for preventing Mother-to-Child Transmission of HIV: Option A, Option B 
and Option B+ 
 Woman receives Infant receives 
Treatment (CD4 counts ≤ 
350 cells/mm
3
) 
Prophylaxis (CD4 counts > 
350 cells/mm
3
) 
Option A Triple ARVs starting as 
soon as diagnosed and 
continued for life 
Antepartum: AZT starting 
as early as 14 weeks 
gestation 
Intrapartum: at onset of 
labour, sdNVP and first 
dose of AZT/3TC 
Postpartum: daily AZT/3TC 
through 7 days 
postpartum 
Mother received prophylaxis: 
daily NVP from birth until 1 
week after cessation of all 
breastfeeding; if not 
breastfeeding through age 4–
6 weeks 
Mother is on treatment: daily 
NVP through age 4–6 weeks  
 
Option B Triple ARVs starting as 
soon as diagnosed and 
continued for life 
Triple ARVs starting as 
soon as 14 weeks 
gestation and continued 
intrapartum and through 
childbirth if not 
breastfeeding or until 1 
week after cessation of all 
breastfeeding 
Irrespective of mode of infant 
feeding: daily NVP or AZT 
from birth through age 4-6 
weeks  
Option B+ Same for treatment and prophylaxis Irrespective of mode of infant 
feeding: daily NVP or AZT 
from birth through age 4-6 
weeks  
Regardless of CD4 count, triple ARVs starting as soon 
as diagnosed and continued for life 
Note: “Triple ARVs” refers to the use of one of the recommended 3-drug fully suppressive treatment options. HIV: Human 
Immunodeficiency Virus; AZT: Zidovudine; sd NVP: single dose Nevirapine; 3TC: Lamivudine; NVP: Nevirapine. 
Several countries in sub-Saharan Africa are currently considering modifying their PMTCT 
guidelines.  Such a consideration should be decided on the basis of their implementation 
experience and a previous assessment on how they can better integrate, simplify and optimize 
the PMTCT programme in the existing HIV/AIDS care and treatment platform. 
The Tanzanian national guidelines on PMTCT were developed in 2004 and revised in 2007 
(Tanzanian MoHSW, 2007b). New guidelines recommending WHO option A were developed in 
June 2012 and plans are being devised to implement them nationwide (Tanzanian MoHSW, 
2012).  
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A cross-sectional survey in a referral hospital in Tanzania assessing the 
uptake of the current PMTCT recommendations – an example for 
problems encountered in rural sub-Saharan Africa 
In this review we illustrate encountered problems of PMTCT with findings of a recently 
performed survey conducted in March 2012 in a referral hospital in Tanzania. Data on PMTCT 
services delivered between January 2010 and December 2011 at St. Francis referral hospital in 
Ifakara, Kilombero district, Morogoro region, Southern Tanzania, were collected. Table 2 
summarizes the antiretroviral regimens recommended by the Tanzanian national guidelines on 
PMTCT at different steps. In this article, we will use this setting as a case-study to discuss the 
limitations on the implementation of guidelines, identify the gaps to be bridged, and envisage 
potential solutions, including the adoption of newer PMTCT strategies.  
Table 2. Recommended combination antiretroviral prophylaxis regimens to prevent mother-
to-child transmission of HIV according to the 2007 Tanzanian national guidelines for the 
Prevention of Mother-To-Child Transmission of HIV 
REGIMEN ANTENATAL INTRAPARTUM POSTPARTUM POSTNATAL 
Recommended AZT 300 mg twice 
a day starting at 
28 weeks of 
gestation or as 
soon as possible 
thereafter 
AZT at 300 mg at onset 
of labour and every 3 
hours until delivery 
sdNVP 200mg at onset 
of labour 
3TC 150 mg at onset of 
labour and every 12 
hours until delivery 
AZT 300 mg twice 
daily for 7 days 
3TC 150 mg twice a 
day for 7 days 
sdNVP 2mg/kg 
immediately after 
birth 
AZT 4mg/kg twice a 
day for 7 days 
Recommended if 
mother presents 
during labour 
 AZT at 300 mg at onset 
of labour and every 3 
hours until delivery 
sdNVP 200mg at onset 
of labour 
 
3TC 150 mg at onset of 
labour and every 12 
hours until delivery 
AZT 300 mg twice 
daily for 7 days 
 
3TC 150 mg twice a 
day for 7 days 
sdNVP 2mg/kg 
immediately after 
birth 
 
AZT 4mg/kg twice a 
day for 28 days 
Recommended if 
mother tests HIV 
positive 
immediately after 
delivery 
  Refer to Care and 
Treatment Clinic, 
do not give any 
antiretroviral 
sdNVP 2mg/kg 
immediately after 
birth 
AZT 4mg/kg twice a 
day for 28 days 
Recommended  if 
mother was on 
ART before 
pregnancy 
Continue ART prescribed before pregnancy. In the first trimester 
replace EFV with NVP 
AZT 4mg/kg twice a 
day for 7 days 
AZT: Zidovudine; sdNVP: single dose Nevirapine; 3TC: Lamivudine; ART: Antiretroviral Therapy; EFV: Efavirenz; NVP: Nevirapine. 
Source: Tanzanian national guidelines for the Prevention of Mother-To-Child Transmission of HIV. The United Republic of 
Tanzania, Ministry of Health and Social Welfare, 2007 [14] 
 
 30 
 
Setting at a rural referral hospital 
St. Francis referral hospital has 370 beds and is the most important health care facility in the 
Kilombero district. PMTCT services are provided between several departments in this hospital, 
including the Reproductive and Child Health Clinic; the Chronic Diseases Clinic of Ifakara; the 
Obstetrics department; and the Neonatology unit.  
The Reproductive and Child Health Clinic provides antenatal care to all pregnant women as 
well as vaccinations and outpatient care for children under-five years old. Care and treatment 
for all HIV-positive patients is provided at St. Francis referral hospital according to the National 
AIDS Control Programme through the Chronic Diseases Clinic of Ifakara. The Chronic Diseases 
Clinic of Ifakara works in cooperation with the Ifakara Health Institute, the Swiss Tropical and 
Public Health Institute and the Department of Infectious Diseases and Hospital Epidemiology 
of the University Hospital of Basel and Bern, Switzerland. All patients attending the Chronic 
Diseases Clinic of Ifakara since late 2004 are offered informed consent to be enrolled at the 
Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) (Stoeckle et al., 2006). This cohort 
comprises almost 6000 patients and is the largest peripheral HIV cohort in Tanzania.   
The Obstetrics department attends approximately 5000 deliveries per year and works closely 
with the Neonatology unit. 
PMTCT Circuit at St. Francis referral hospital and gaps identified 
Figure 1 shows the theoretical PMTCT pathway at St. Francis referral hospital. The 
departments involved in this process are the following: Reproductive and Child Health Clinic, 
Chronic Diseases Clinic of Ifakara, Obstetrics, and Neonatology. The following key steps of the 
PMTCT pathway were identified: 1) HIV counseling and testing; 2) CD4 count measurement 
and eligibility for cART; 3) antenatal antiretroviral prophylaxis; 4) intrapartum and postpartum 
prophylaxis; 5) postnatal prophylaxis for the infant; 6) follow-up of HIV-positive mothers; and 
7) follow-up of HIV-exposed infants. 
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Figure 1. Theoretical PMTCT of HIV care pathway at St. Francis Referral Hospital 
 
 
 
RCHC: Reproductive and Child Health Clinic; HIV: Human Immunodeficiency Virus; PMTCT: Prevention of Mother-
To-Child Transmission; CDCI: Chronic Disease Clinic of Ifakara; ART: Antiretroviral Therapy; ARV: antiretroviral; 
SFRH: St. Francis Referral Hospital. 
According to WHO and Tanzanian national guidelines, all pregnant women attending the 
Reproductive and Child Health Clinic for antenatal care have to be offered HIV counseling and 
testing.  Between January 2010 and December 2011, 4027 pregnant women attended the 
Reproductive and Child Health Clinic. Forty-four (1%) were already known to be HIV-infected. 
The remainder was offered HIV testing, with a rate of acceptance of 90.4% (3606/3983). Two 
hundred and seven of these 3606 women tested positive. Thus, the HIV prevalence among 
pregnant women attending antenatal services at St. Francis referral hospital during the study 
period was 6.9% (251/3647). Current Tanzanian guidelines recommend HIV seronegative 
women to be re-tested after three months in order to avoid falsely negative diagnoses during 
the “window period” after acute infection, but there was no information concerning the 
proportion of seronegative women who were re-tested. Information could only be extracted 
from randomly selected individual pregnancy cards, and none of the seronegative women 
assessed had a second test registered. 
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Those women who are newly diagnosed with HIV infection at St. Francis referral hospital must 
be referred to the Chronic Diseases Clinic of Ifakara. However, only 25.6% (53/207) of newly 
diagnosed women visited the clinic during 2010-2011 and were assessed for cART eligibility. 
Seventy-four percent (154/207) of HIV-infected women were not registered at the Chronic 
Diseases Clinic and thus cART eligibility criteria were not assessed. Consequently, all HIV-
positive pregnant women with unknown CD4 count were prescribed antenatal antiretroviral 
prophylaxis in the Reproductive and Child Health Clinic regardless of the eligibility criteria for 
cART initiation. According to the labour ward PMTCT log book the antenatal prophylaxis 
prescribed to all HIV-positive women was monotherapy with nevirapine, which was not a 
recommended option (Table 2). This contradicts the information collected at the Reproductive 
and Child Health Clinic regarding antenatal prophylaxis prescribed during the same period, 
which was registered to be zidovudine.  
All HIV-infected pregnant women are advised to deliver at St. Francis referral hospital to 
ensure optimal intrapartum and postpartum antiretroviral prophylaxis for the mother and 
postnatal prophylaxis for the infant. Between 20/03/2011 and 03/05/2011, 570 women 
delivered at the hospital. Almost 5% (28/570) and 80% (456/570) were known to be HIV-
positive and HIV-negative respectively. The HIV serostatus was unknown for 14.4% (82/570) of 
women. Of those, 2.4% (2/82) were tested during labour with one testing HIV-positive. In 
total, 5.9% (29/486) of all women with a known HIV serostatus giving birth at St. Francis 
referral hospital during that period tested positive.  
Concerning intrapartum prophylaxis, there was conflicting information between the register 
books and the interviews. The nurses interviewed did not appear to be aware of the latest 
recommendations on intrapartum prophylaxis, which include three drugs to be given at 
different intervals (Table 2). In contrast, 86% (25/29) of the HIV-positive women were 
registered to have been given correct prophylaxis with three drugs, and no information was 
registered for the remaining four women.  
Regarding postpartum prophylaxis no information was recorded for any women. The 
interviews to staff members of the labour and the obstetric wards, suggest a lack of clarity 
with regards to the responsible service for its administration.  
As postnatal prophylaxis, 83% (24/29) of the babies born from HIV-seropositive women were 
given single dose nevirapine, one (3.4%) received single dose nevirapine plus zidovudine for 
one week and no data was collected for the remaining four babies. This represents another 
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important gap in this pathway, since the postnatal prophylaxis recommended in the guidelines 
includes both single dose nevirapine plus zidovudine, very rarely administered at St. Francis 
referral hospital during the period assessed. 
After delivery, mother and child should be referred to the Chronic Diseases Clinic of Ifakara, 
where the follow-up must be carried out. During 2010-2011 only one woman with an infant 
younger than two months was registered at the Chronic Diseases Clinic. There is no 
information with regards to the number of the HIV-exposed infants attending the clinic during 
the same period. There is neither active case finding nor a standardized follow-up for HIV-
exposed infants in place. Consequently, the infant is visited together with the mother and 
information related to the exposed-non-infected child is not collected in any database.  
Figure 2 illustrates the gaps identified in the PMTCT algorithm. For every gap identified at 
different steps of the PMTCT pathway the possible causes were assessed and potential 
solutions were suggested. Table 3 summarizes the most likely causes and the proposed 
solutions to close the specific gaps. 
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Figure 2. Main gaps identified at PMTCT of HIV care pathway at St. Francis Referral Hospital 
 
 
The gaps are colored in brown. RCHC: Reproductive and Child Health Clinic; HIV: Human Immunodeficiency Virus; 
PMTCT: Prevention of Mother-To-Child Transmission; CDCI: Chronic Disease Clinic of Ifakara; ART: Antiretroviral 
Therapy; ARV: antiretroviral; SFRH: St. Francis Referral Hospital. 
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Table 3. PMTCT care pathway: observed gaps, possible causes, and potential solutions 
STEP INVOLVED OBSERVED GAP POSSIBLE CAUSES POTENTIAL SOLUTIONS 
HIV testing at 
RCHC 
Not all seronegative pregnant women are re-tested after 3 months 
of the 1st HIV negative serology 
Unawareness about the “window period” after the 
primary HIV infection 
CME. Refreshing seminars for all the staff involved in the 
antenatal care  
SOP 
CDCI After being diagnosed HIV-positive, most pregnant women do not 
attend the CDCI, so CD4 count is not performed and ART eligibility is 
not assessed  
Pregnant women do not seem to feel comfortable 
attending the CDCI. According to the nurses’ interviews, 
they may feel ashamed due to stigma. 
Integrate the HIV-positive pregnant women care  into the RCHC 
Option B+ 
Antenatal 
prophylaxis 
There is a discordance between the  ARV drugs prescribed in the 
RCHC and the ARV drugs registered in the labour ward books 
Probable mistake when filling the books at the labour 
ward 
CME. SOP  
Option B+ 
Delivery There is not enough information to assume that intrapartum 
prophylaxis is correctly administered 
Doses and frequency of the ARV are not easy to 
remember  
CME. SOP. 
Poster with the intrapartum prophylaxis  
Identify a staff member responsible for checking the availability 
of ARV drugs in the labour ward  
Option B+ 
Post-Delivery There is no data supporting that postpartum prophylaxis is being 
administered in the hospital 
The staff does not appear  to clearly know who is 
supposed to administer it (labour ward vs. obstetric 
ward) 
Lack of availability of ARV drugs in labour 
ward/obstetric ward 
Doses and frequency  of the ARV are not easy to 
remember 
Clearly assign responsibilities and duties 
SOP 
Identify a staff member responsible for checking the availability 
of ARV drugs in the labour ward/obstetric ward 
Poster with the postpartum prophylaxis. Counsel the mother 
about ARV prophylaxis. 
Option B+ 
Perinatal period Postnatal prophylaxis is not always correctly administered after 
discharge 
The staff does not seem to clearly know who is 
supposed to administer it (labour ward vs. obstetric 
ward vs. neonatal unit ) 
Lack of availability of ARV syrups  
 
Doses and frequency are not easy to remember 
Because the sooner the dose is given the greater the protective 
effect: labour ward should be the responsible 
Identify a staff member responsible for checking the availability 
of ARV syrups in the labour ward  
Poster with the postnatal prophylaxis.  Counsel the mother 
about ARV prophylaxis for the baby  
SOP 
Option B+ 
Exposed infants 
follow up 
There is not a standardized follow up for the exposed infants 
 
The Guidelines do not specify about where the follow 
up should be done, what frequency, etc 
 
Integrate the HIV-exposed infants follow up into the existing 
under-five health services.  
SOP 
Generate special files for the exposed infants. Attach these files 
to the mothers’ CDCI files. 
PMTCT: Prevention of Mother-To-Child Transmission; RCHC: Reproductive and Child Health Clinic; HIV: Human Immunodeficiency Virus; CME: Continuous Medical Education; SOP: Standard Operating Procedures; ART: 
Antiretroviral Therapy; ARV: Antiretroviral; AZT: Zidovudine; 3TC: Lamivudine; NVP: Nevirapine;  
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Propositions to increase the uptake of current and upcoming PMTCT 
guidelines - Time for change 
The uptake of the guidelines in sub-Saharan Africa is known to be poor. The aim of this case 
presentation was to illustrate the quality of PMTCT provision at a rural Tanzanian referral 
hospital by providing a snapshot of the reality in the field and to identify existing gaps and 
potential ways to bridge them at an operational level. Our findings should help to develop new 
potential strategies to be tested in a prospective fashion with the aim of improving the uptake 
of PMTCT guidelines in rural Tanzania and other similar settings in sub-Saharan Africa. 
Moreover, simpler and more effective approaches need to be taken into account. 
In St. Francis referral hospital, all the services and most resources needed for a proper 
functioning of the Tanzanian national PMTCT program were in place. However, several gaps 
were observed that prevented the current Tanzanian recommendations to be optimally 
implemented. This is worrisome, since it may ultimately result in an increasing rate of HIV 
infection among infants.  
The most important gaps identified in the PMTCT care pathway were: a) no re-testing of 
seronegative pregnant women in late pregnancy; b) suboptimal follow-up of HIV-infected 
pregnant women, including irregular assessment of cART eligibility; c) inconsistencies in the 
prescription of antiretroviral prophylaxes; and d) lack of a standardized follow-up of HIV-
exposed infants. 
As mentioned, the Tanzanian Government has adopted Option A for the new PMTCT 
Guidelines. Lower short-term costs might justify the adoption of this strategy in Tanzania. 
However, the drug prices have been reduced since 2010, when the WHO recommendations 
were published, and they are expected to further decrease, narrowing the cost difference 
between Option A and B. Concerns are raised about the lack of simplification when 
transitioning from the former recommendations to Option A. Even if the higher CD4 count 
threshold for cART eligibility, the earlier initiation of antenatal prophylaxis and the longer 
postnatal prophylaxis for breastfeeding infants are definitely welcome modifications, the 
complexity of the circuit remain high and might prevent the correct implementation in the real 
world, as shown in the case presented. Simpler strategies are needed to increase the coverage 
and the efficacy of these programs. Better infrastructure and human resources must 
accompany these new strategies to avoid logistic problems as drug stock-outs (Pasquet et al., 
2010) and overburdened health staff. 
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Malawi adopted in 2011 Option B+, for its ease of implementation and potential prevention 
benefit (Schouten et al., 2011). Likewise, other countries, such as Uganda and Swaziland, are 
also considering to move to Option B+. Using the case presented as a starting point, we are 
now going to discuss every gap observed and envisage what would be the situation if Option 
B+ was the adopted PMTCT recommendation in Tanzania.  
HIV testing was conducted once and not repeated during the third trimester among those 
women who were initially seronegative. In a South African study (Moses et al., 2008), 3% of 
initially seronegative pregnant women were detected to be HIV-infected in late pregnancy, 
showing the relevance of re-testing during the third trimester. Acute HIV infection during 
pregnancy is associated with high rates of vertical transmission due to the extremely high HIV 
RNA levels achieved during this phase of the infection, which is associated with higher 
probabilities of vertical transmission (Garcia et al., 1999). Option A, B or B+ would not bridge 
this gap, since the awareness of the importance of re-testing has to be spread through 
educational efforts. 
Regarding the assessment of the cART eligibility, the current Tanzanian guidelines during the 
time the analysis was performed recommended offering cART to all pregnant women with CD4 
counts ≤200 cells/mm3 or ≤350 cells/mm3 in case of WHO stage 3 or 4. However, our analysis 
shows that after being diagnosed HIV-positive, most pregnant women were not assessed for 
cART eligibility. Instead, most were offered antiretroviral prophylaxis regardless of CD4 cell 
count. We have to take into account the possibility of some women attending another clinic 
than the Chronic Disease Clinic of Ifakara, but we do not consider this is a common or 
representative situation. With Option B+, all HIV-positive pregnant women would receive 
cART, avoiding suboptimal antiretroviral prophylaxis to women in need of cART for their own 
health. 
In relation to the antenatal prophylaxis prescribed, inconsistencies in the antiretroviral 
regimens administered and the records in different services were observed. Concerning 
intrapartum prophylaxis, the Tanzanian PMTCT guidelines recommended using a combination 
of zidovudine, lamivudine, and nevirapine. Our findings show again irregularities in this crucial 
step. According to a study conducted in Malawi, skilled attendance at birth appeared to be an 
important determinant of correct intrapartum prophylaxis (Kasenga, Hurtig and Emmelin, 
2007). In our setting interviews with midwives revealed a suboptimal knowledge on the 
recommended regimens and doses. Postpartum and postnatal prophylaxes are poorly 
implemented in sub-Saharan Africa (Mirkuzie, Hinderaker and Mørkve, 2010; Geddes et al., 
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2011; Kirsten et al., 2011). Likewise, data on postpartum prophylaxis was inexistent in our 
hospital and only 1 out of 29 newborns received correct postnatal prophylaxis. In case 
antenatal and intrapartum prophylaxes are correctly administered, between one-third and 
one-half of all mother-to-child transmission of HIV is estimated to occur during the postpartum 
period, mostly through breastfeeding (WHO, 2007b). Thus, a good and updated knowledge on 
postpartum and postnatal prophylaxes among staff working at maternity wards would make 
possible to maximize the chance of mother-baby pairs of getting appropriate and timely 
medications. However, frequent staff turnover and attendance by junior clinicians pose 
additional obstacles to the capacitation and continuous medical education of attending staff. 
With Option B+ the differences between antenatal, intrapartum, and postpartum prophylaxes 
disappear. Since the moment the pregnant women is diagnosed to be HIV-positive, she is 
prescribed lifelong cART, including pregnancy, delivery and breastfeeding periods. This is much 
simpler than the current guidelines and the coming Option A. Thus, adopting Option B+ the 
gaps born from the complexity of the drug combinations of different periods for prophylaxis 
would be avoided, as well as many infant infections derived from the poor uptake of the more 
complex recommendations. Concerns about drug adherence have been raised due to the fact 
that some women will be asymptomatic and feel healthy. As seen in a Brazilian study, we 
expect pregnant women to be highly motivated to protect their babies, especially if they are 
periodically counseled and a simple regimen with not many pills per day is prescribed (WHO, 
2007b). Extra counselling focused on minimizing the possibility of treatment interruption 
between pregnancies and its consequences might be necessary for asymptomatic mothers 
after the delivery and the breastfeeding period. 
Similarly, postnatal prophylaxis would be simplified with Option B+. With this option, all HIV-
exposed infants receive antiretroviral prophylaxes for four to six weeks, regardless of the 
feeding method. On the contrary, with the current recommendations and with the coming 
Option A, there are different regimens depending on the feeding method, which again add 
complexity to their implementation in the field. 
Follow-up of HIV-exposed infants is notoriously weak in sub-Saharan Africa and it leads to 
under-diagnosis of HIV (Braitstein et al., 2010), and our analysis confirms these findings in our 
setting. According to data from WHO, in 2010, only 28% of the HIV-exposed infants received 
an HIV test within the first two months of life among 65 reporting countries (WHO, 2011). 
Concurring with other studies from Kenya and Mozambique (Azcoaga-Lorenzo et al., 2011; 
Cook et al., 2011), a recent study from Ethiopia showed that slightly more than 50% of HIV-
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exposed infants were followed-up at six weeks and less than one-third had documented an HIV 
test result. Remarkably, this low coverage of HIV testing occurred in the frame of an 
immunization coverage of more than 80% among HIV-exposed infants (Mirkuzie et al., 2011), 
suggesting specific problems related with HIV testing. Integration of the follow-up of HIV-
exposed infants into the existing under-five child health clinics would maximize the 
opportunities of getting a prompt diagnosis and timely treatment for HIV-infected children. 
Unfortunately, the lack of a standardized follow-up of HIV-exposed infants cannot directly be 
bridged by implementing Option B+. However, by providing Option B+ it is probable that the 
follow-up of HIV-exposed infants will improve, since more mothers will get medical care. 
Moreover, with this option, fewer infants are expected to be infected, so the number of 
undiagnosed infants will decrease.  
Based on our findings several programmatic solutions can be proposed to increase the uptake 
of current and upcoming PMTCT guidelines. The implementation of the guidelines should be 
combined with a comprehensive package including educational and logistic interventions to be 
easily and affordably implemented in St. Francis referral hospital and other similar settings in 
sub-Saharan Africa. Analogously, Youngleson et al. implemented a “change package” to 
improve PMTCT program in a sub-district of Western Cape, South Africa, including maximizing 
the use of existing resources, reducing duplication, and developing patient-centered 
approaches. As a consequence of this program, significant improvements were achieved, with 
a decrease of the perinatal transmission rate from 7.6% to 5% (Youngleson et al., 2010). The 
logistics of implementation would be easier if Option B+ was adopted, mainly due to a 
reduction on the training requirements. As a consequence the likelihood of a successful 
implementation would be greatly increased. 
Furthermore, apart from the simplification of the PMTCT programme and its better 
implementation, lifelong cART for HIV-infected pregnant women (Option B+) has additional 
benefits. By adopting this strategy, future pregnancies will be protected since the conception, 
and sexual transmission of HIV to a serodiscordant partner will be significantly reduced (Cohen 
et al., 2011). All women will require cART at some point, with Option B+ they will merely start 
it earlier. In this view, Option B+ can be placed in the frame of the idea of “treatment as 
prevention”, which has garnered tremendous interest and hope (Cohen et al., 2011; Shelton, 
2011).    
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Conclusions 
In summary, we strongly believe that it is time to move forward and argue in favor of Option 
B+ strategy in Tanzania and other sub-Saharan Africa settings. Option B+ is one of the most 
exciting developments in the prevention of vertical transmission and pediatric HIV in the 
recent years. Financial and operational challenges will have to be bridged and the feasibility, 
the cost-benefit and the public health impact will need to be assessed in those countries 
implementing Option B+. Data from solid scientific studies is still needed to definitively support 
Option B+. Reaching the WHO’s call to the “virtual elimination” of pediatric HIV, aiming to 
attain a mother-to-child transmission risk of less than 5% for the year 2015, will be, even in the 
best scenario, hard to achieve. Option B+ gives us for the first time the opportunity to think 
that this goal is achievable at a global scale. Strong political will and strong support from 
governments and public health authorities will be needed to achieve this milestone in the 
history of the HIV pandemic. 
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6. Study 2: An Integrated and Comprehensive Service Delivery 
Model to Improve Pediatric and Maternal HIV Care in Rural 
Africa 
 
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):e67-e75  
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Abstract 
Background: Strategies to improve HIV diagnosis and linkage into care, antiretroviral 
treatment coverage and treatment outcomes of mothers and children are urgently needed in 
sub-Saharan Africa. 
Methods: From 12/2012, we implemented an intervention package to improve Prevention of 
Mother-To-Child Transmission (PMTCT) and pediatric HIV care in our rural Tanzanian clinic, 
consisting of:  a) creation of a PMTCT and pediatric unit integrated within the reproductive and 
child health clinic; b) implementation of electronic medical records; c) provider-initiated HIV 
testing and counseling in the hospital wards; and d) early infant diagnosis test performed 
locally. To assess the impact of this strategy, clinical characteristics and outcomes were 
compared between the period prior (2008-2012) and during/after the implementation (2013-
2014).  
Results: After the intervention, the number of mothers and children enrolled into care almost 
doubled. Compared to the pre-intervention period (2008-2012), in 2013-2014 children 
presented lower CD4% (16 vs. 16.8, p=0.08) and more advanced disease (WHO stage 3/4 72% 
vs. 35%, p<0.001). The antiretroviral treatment coverage rose from 80% to 98% (p<0.001), the 
lost to follow-up rate decreased from 20% to 11% (p=0.002) and mortality ascertainment 
improved. During 2013-2014, 261 HIV-exposed infants were enrolled and the early mother-to-
child transmission rate among mother-infant pairs accessing PMTCT was 2%. 
Conclusion: This strategy resulted in an increased number of mothers and children diagnosed 
and linked into care, a higher detection of children with AIDS, universal treatment coverage, 
lower loss to follow-up, and an early mother-to-child transmission rate below the threshold of 
elimination. This study documents a feasible and scalable model for family-centered HIV care 
in sub-Saharan Africa. 
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Introduction 
Globally, 1.8 million children live with HIV (UNAIDS, 2016b), more than 90% of them residing in 
sub-Saharan Africa. Mother-To-Child Transmission (MTCT) accounts for over 90% of the 
infections (UNAIDS, 2013). Most of the newly infected children are found among those not 
reached by Prevention of MTCT (PMTCT) programs, and offering them timely diagnosis is vital. 
Systems to promote HIV testing for children outside the PMTCT programs need to be 
enhanced (Fergusson and Tomkins, 2009; Hesseling et al., 2009; Cohen, Lungu and van 
Oosterhout, 2010; Kranzer et al., 2014).  
Antiretroviral treatment (ART) initiation and retention in care are essential for HIV-infected 
children (Newell et al., 2004; Violari et al., 2008; Cotton et al., 2013). However, ART coverage 
among children in low and middle-income countries was only 25% in 2012 (UNAIDS, 2013). 
Training healthcare providers in pediatric HIV/AIDS is needed to bridge this gap, ensure high-
quality programs and expand access to care and treatment among children (Kline et al., 2009; 
Essajee et al., 2013; Green et al., 2014). Moreover, fragmentation of health services hinders 
the access to key populations, and integration of services is recommended (Tonwe-Gold et al., 
2009; Lindegren et al., 2012; Gupta et al., 2013; WHO, 2014b). 
In 2014, the UNAIDS presented its “90-90-90 target” for 2020:  i) 90% of people living with HIV 
will know their HIV status, ii) 90% of people with diagnosed HIV infection will receive ART, iii) 
90% of people receiving ART will be virologically suppressed (UNAIDS, 2014a). In order to move 
towards this goal, special efforts need to be taken for the pediatric population given the 
challenges associated with timely diagnosis, ART coverage and retention in care. 
In Tanzania, in 2013, 73% of HIV-infected pregnant women received PMTCT services and the 
estimated MTCT rate was 16% (UNAIDS, 2014), with 23,000 new pediatric infections 
(Tanzanian MoHSW, 2014). There are 250,000 children living with HIV, and ART coverage is 
dramatically lower than among adults, 26% versus 68% (UNAIDS, 2013). 
Previous data from our clinic revealed several gaps in the care pathway of HIV-infected 
mothers and their children (Gamell et al., 2013). In response to these challenges, we adopted a 
package of interventions to improve the care of HIV-infected children, mothers and their 
families attending our clinic. 
The aim of this study was to evaluate the impact of this strategy on outcomes among both 
children and pregnant women over time. 
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Methods 
This is a prospective cohort study evaluating the clinical outcomes of children and pregnant 
women before and during the implementation of a bundle of measures to improve the quality 
of HIV care in rural Tanzania. 
Study setting and population 
The Chronic Diseases Clinic of Ifakara is a rural HIV clinic in the Kilombero district, southern 
Tanzania. It is part of the Saint Francis Referral Hospital and works in cooperation with the 
Ifakara Health Institute, the Swiss Tropical and Public Health Institute and the Department of 
Infectious Diseases and Hospital Epidemiology of the University Hospitals of Basel and Bern, 
Switzerland. All patients diagnosed with HIV within the hospital or diagnosed at a peripheral 
health centre and transferred for further treatment are referred to the clinic to receive HIV 
care and treatment according to the National AIDS Control Program. Since 2004, all HIV-
infected patients attending the clinic are asked for informed consent to be enrolled in the 
Kilombero and Ulanga Antiretroviral Cohort (KIULARCO). This cohort study obtained ethical 
approval from the Ifakara Health Institute ethical review board, the Tanzanian National 
Institute for Medical Research, the Tanzanian Commission for Science and Technology and the 
Ethical Review Board of the Canton of Basel, Switzerland. 
The cohort comprises more than 8,000 patients and is the largest rural HIV cohort in Tanzania . 
PMTCT Option B+ was implemented in April 2014 (Tanzanian MoHSW, 2013b).  
In this study, we included all HIV-infected children (≤15 years) and pregnant women enrolled in 
the cohort between January 1, 2008 and December 31, 2014. For HIV-exposed infants, we 
included infants enrolled from January 1, 2013 until December 31, 2014, since no information 
was collected before this period. 
Description of the intervention 
From December 2012, a bundle of measures to improve the PMTCT and Pediatric HIV services 
were introduced, namely: a) creation of the One Stop Clinic of Ifakara: a PMTCT and Pediatric 
unit integrated within the Reproductive and Child Health Clinic; b) implementation of 
electronic medical records; c) implementation of provider-initiated HIV testing and counseling 
(PITC) in the hospital wards; and d) early infant HIV diagnosis (EID) test locally (See Table, 
Supplemental Digital Content 1). 
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Table, Supplemental Digital Content 1. Measures implemented to improve the care of HIV-
infected pregnant women, children and their families  
Year Month Implemented measure to improve the clinical care of pregnant women and 
children living with HIV and their families 
2012 December Introduction of new report forms to systematically and comprehensively collect 
clinical, drug and laboratory information 
2013 January Implementation of a standardized follow-up for HIV-exposed infants 
January - March Creation of a PMTCT and Pediatric HIV clinical team 
April Integration of PMTCT and HIV services for children and their families within the 
Reproductive and Child Health Clinic. Inauguration of the One Stop Clinic: 
antenatal, immunization, under-five and HIV services are offered the same day 
under the same roof. 
May Launch of the electronic data collection system OpenMRS: the clinic becomes 
paperless 
2014 January Provider Initiated Testing and Counseling is implemented in the inpatient wards of 
the St Francis Referral Hospital 
March Pro-viral HIV DNA PCR for Early Infant Diagnosis is established at the Ifakara Health 
Institute laboratory 
April Implementation of PMTCT Option B+ guidelines in Ifakara 
July A professional counselor joints the One Stop Clinic to coordinate all counseling 
activities including pre- and post-test, adherence, and disclosing sessions to HIV-
infected children and adolescents, among others 
PMTCT: Prevention of Mother-To-Child Transmission 
 
a) Establishment of the One Stop Clinic of Ifakara 
We created a unit to address the special needs of HIV-infected children and pregnant women. 
As in most HIV clinics in sub-Saharan Africa, prior to the intervention, infants, children and 
pregnant women were not assigned to specific clinicians and could be seen by different 
clinicians at each visit. Also, there was no family-centered approach and different family 
members were required to visit the clinic on different days. Additionally, clinicians based at our 
clinic were previously not in charge of the HIV-infected patients admitted in the hospital 
wards. 
To establish and implement the One Stop Clinic, we pursued two steps. 
Step 1: Creation of a PMTCT and Pediatric HIV team 
From January to March 2013, two clinicians, a nurse and a midwife were identified from the 
existing staff of the hospital. In July 2014 a counselor was newly hired and joined the team. All 
staff was provided with specific training and appointed to take care of HIV-infected children 
and pregnant women and HIV-exposed infants in both the outpatient clinic and the hospital 
wards.  
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Step 2: Integration within the Reproductive and Child Health Clinic 
In April 2013 the care of HIV-infected children, pregnant women, HIV-exposed infants and 
their families was transferred to the Reproductive and Child Health Clinic. We intended to 
maximize the opportunities to diagnose women and children, facilitate their linkage into care, 
and improve retention by offering a range of services in a single day and place (Figure 1). 
Figure 1. The One Stop Clinic of Ifakara integrates health services for HIV-infected children, 
pregnant women, HIV-exposed infants and their families in a rural Tanzanian hospital 
 
 
PITC: Provider Initiated HIV Testing and Counseling 
b) Electronic medical records for HIV-infected patients 
The Open Medical Record System (OpenMRS, http://openmrs.org/) was adopted to implement 
an electronic data collection system at our clinic (Wolfe et al., 2006). In December 2012 
different questionnaires were introduced to systematically and comprehensively collect 
clinical, laboratory, and drug prescription information, and to minimize missing data and data 
entry mistakes. In May 2013 the clinic became paperless. 
c) Provider-Initiated HIV Testing and Counseling 
Provision of PITC had been recommended in Tanzania since 2007 but sub-optimally 
implemented in most settings, including our hospital (Tanzanian MoHSW, 2007a). In January 
2014, our clinic joined efforts with the hospital administration to institutionalize PITC. Since 
then, all patients admitted in the pediatric and maternity wards are offered HIV testing 
through an opt-out strategy. 
d) Early Infant Diagnosis Testing 
Following the national recommendations, HIV-exposed infants are tested for HIV at 4-6 weeks 
of life or thereafter as soon as enrolled. Pro-viral DNA PCR is used for infants ≤9 months. For 
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those aged 9-18 months HIV rapid antibody tests are used for screening and, if positive, pro-
viral DNA PCR is performed (Tanzanian MoHSW, 2013b). 
Since March 2014 pro-viral HIV DNA PCR for EID is performed at the Ifakara Health Institute 
laboratory applying an in-house nested PCR protocol executed on a GeneAmp PCR System 
9700 (Life Technologies, USA) using GoTaq DNA Polymerase (Promega, USA). Previously we 
had used the national EID circuit, which was often challenged by frequent stock outs of the kits 
to collect and store the samples and by the unreliable transport to one of the only four 
national referral laboratories. 
Statistical analysis 
Baseline characteristics of children and pregnant women were summarized according to year 
with appropriate statistical measures. Baseline is defined as the time of enrollment into the 
cohort. 
To assess the impact of the interventions listed above, both the baseline characteristics and 
the clinical outcomes were compared in children and pregnant women separately between the 
period prior to the intervention (2008-2012) and during/after the implementation of the 
intervention (2013-2014). Baseline and follow-up comparisons between both periods were 
made using chi-square and Wilcoxon rank sum test for categorical and continuous variables 
respectively. Also, we compared the notified cases of tuberculosis and malnutrition between 
the time periods by estimating the overall Mantel-Haenszel rate ratio. Finally, we described 
the characteristics of the HIV-exposed infants enrolled and reported the early MTCT rate. Test 
statistics and 95% confidence intervals were presented. Data was analyzed using Stata version 
13 (StataCorp, College Station, TX, USA).  
Results 
Cohort characteristics 
A total of 200 HIV-infected pregnant women and 547 HIV-infected children were enrolled 
during the study period. Table 1 summarizes the baseline characteristics of the patients per 
year of enrolment. Pregnant women were enrolled at a median age of 30.3 years (interquartile 
range (IQR) 25.3-34.5), 20% were classified as WHO stage 3/4, and median CD4 was 340 cell/µL 
(IQR 147-494). Among children, 48% were female, with a median age of 4.4 years (IQR 1.5-8.3) 
and 48% presented with WHO stage 3/4. The median CD4 percent was 16.7% (IQR 8.7-28). 
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Table 1. Baseline characteristics of HIV-infected children and pregnant women newly enrolled in care from 2008 to 2014 
 2008 2009 2010 2011 2012 2013 2014 Total 
Pregnant women n=21 n=9 n=27 n=27 n=26 n=42 n=48 N=200 
 Age, years, median (IQR) 30.7 (26.5, 35.9) 30.5 (26.6, 33.4) 29 (26.2, 34.9) 29.5 (25.6, 34.6) 29.6 (24.0, 33.9) 30.8 (24.8, 34.9) 29.9 (24.2, 34.1) 30.3 (25.3, 34.5) 
 WHO stage (%)
a
         
  1 or 2 12 (57) 7 (78) 23 (88) 25 (96) 23 (92) 30 (71) 37 (77) 157 (80) 
  3 or 4 9 (43) 2 (23) 3 (12) 1 (4) 2 (8) 12 (29) 11 (23) 40 (20) 
 
Absolute CD4 counts, median 
(IQR) 
b
 
318 (228, 499) 164 (114, 520) 368 (310, 513) 491 (317, 556) 390 (75, 741) 290 (48, 454) 335 (142, 450) 340 (147, 494) 
Children n=127 n=126 n=49 n=45 n=56 n=54 n=90 N=547 
 Female (%) 56 (44) 63 (50) 24 (49) 21 (47) 31 (55) 23 (43) 45 (50) 263 (48) 
 Age, years, median (IQR) 5.7 (1.9, 9.5) 3.1 (1.3, 6.6) 4.1 (1.1, 8.3) 4.4 (1.9, 8.0) 5.1 (1.8, 9.4) 2.5 (1.3, 7.9) 4.2 (1.2, 8.3) 4.4 (1.5, 8.3) 
 WHO stage (%)
c
         
  1 or 2 81 (65) 86 (72) 27 (61) 20 (45) 24 (50) 8 (17) 23 (26) 269 (52) 
  3 or 4 43 (35) 33 (28) 17 (39) 24 (55) 24 (50) 39 (83) 65 (74) 245 (48) 
 
Absolute CD4 counts, median 
(IQR) 
d
 
490 (192, 848) 565 (263, 1145) 576 (108, 1142) 424 (24, 1061) 473 (172, 549) 493 (187, 805) 688 (338, 1086) 518 (192, 979) 
 Percent CD4 , median (IQR) 
e
 14.9 (4.4, 21.7) 20.2 (9.9, 35.4) 15.6 (7.1, 34.1) 32.0 (14.8, 64.4) 14.7 (11.0, 21.8) 13.0 (5.0, 21.0) 18.0 (10.0, 26.0) 16.7 (8.7, 28) 
a WHO stage missing for 3 pregnant women 
b Absolute CD4 counts missing for 58 pregnant women 
c WHO stage missing for 33 children 
d Absolute CD4 counts missing for 156 children 
e Percent CD4 missing for 164 children 
IQR: interquartile range; WHO: World Health Organization
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Outcomes of pregnant women  
The median number of women enrolled per year increased from 26 (IQR 21-27) in 2008-2012 
to 45 (IQR 42-48) in 2013-2014 (p=0.05) (Figure 2A). After the intervention, there was a trend 
towards a higher WHO stage 3/4 (26% in 2013-2014 versus 15% in 2008-2012, p=0.08) and 
lower CD4 counts (median 315 cells/µL versus 370 cells/µL, p=0.06). ART coverage among 
those eligible was above 98% during the whole study period. In 2013-2014, most women were 
initiated on a fixed-dose combination of tenofovir/lamivudine or emtricitabine/efavirenz, as 
expected due to the changes of the national guidelines. There were no major differences in 
retention in care, although lost to follow-up declined after 2012 (26.5% versus 30.9%) (Table 
2). 
Table 2. Comparison of the clinical characteristics, antiretroviral treatment coverage and 
regimens, and retention in care of patients enrolled before and after the intervention 
 2008 - 2012 2013 - 2014 Effect Estimate p-value 
Pregnant women n=110 n=90   
 WHO stage (%)   3.16
b
 0.08 
  1 or 2 93 (84.6%) 67 (74.4%)   
  3 or 4 17 (15.5%) 23 (25.6%)   
 Absolute CD4 counts, median (IQR) 370 (178-556) 315 (117-450) 1.91
a 
0.06 
 ART coverage 
d
, n/N (%) 51/52 (98.1%) 68/69 (98.6%) 0.04
b
 0.84 
  
Time to ART initiation 
e
, days,  
      median (IQR) 
0 (0-4) 1.5 (0-10) -1.81
a 
0.07 
 Initial ART regimen (%)   96.32
b
 <0.001 
  D4T/3TC/NVP or AZT/3TC/NVP 36 (46.8%) 3 (4.7%)   
  AZT/3TC/EFV 31 (40.3%) 2 (3.1%)   
  TDF/FTC/EFV 
g 
or TDF/3TC/EFV 
h 
9 (11.7%) 58 (90.6%)   
  PI - based regimen 0 1 (1.6%)   
 Retention in care 6 months after enrolment 
f
   1.23
i
 0.68 
  Lost to follow-up 34 (30.9%) 18 (26.5%)   
   Died 1 (0.9%) 1 (1.5%)   
  Transferred to another clinic 7 (6.4%) 7 (10.3%)   
  Active follow-up 68 (61.8%) 42 (61.8%)   
Children n=403 n=144   
 Age, years, median (IQR) 4.5 (1.6 – 8.6) 3.2 (1.3 – 8.1) 1.41
a
 0.16 
 Referred from     
  Voluntary testing 307 (76.2%) 71 (49.3%) 35.88
b
 <0.001 
  Provider initiated testing 41 (10.2%) 25 (17.4) 5.12
 b
 0.02 
  PMTCT / EID Program 9 (2.3%) 8 (6.4%)  0.04
i
 
  Transferred from other facilities 19 (4.8%) 24 (19.2%) 26.24
 b
 <0.001 
 WHO stage   59.48
b
 <0.001 
  1 or 2 262 (65.0%) 40 (27.8%)   
  3 or 4 141 (35.0%) 104 (72.2%)   
 Percent CD4, median (IQR) 16.8 (8.7-30.0) 16 (9-22) 1.73
a 
0.08 
 Absolute CD4 counts, median (IQR) 490 (170-906) 560 (264-1053) -1.39
a 
0.16 
 Tuberculosis     
  Cases notified 72 53 3.96 (2.7-5.9)
c 
<0.001 
  Incidence (per 100 persons-years) 12.18 103.09   
 Malnutrition      
              Cases notified 23 67 11.22 (5.9-21.5)
c
 <0.001 
              Incidence (per 100 persons-years) 4.13 145.90   
              % cases severe malnutrition 26.1 62.7   
 ART coverage 
d
, n/N (%) 
215/270 
(79.6%) 
101/103 
(98.1%) 
19.56
b
 <0.001 
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Time to ART initiation 
e
, days,  
      median (IQR) 
1 (0-16) 11 (2-19) -2.89
a 
0.004 
 Initial ART regimen (%)   43.93
b
 <0.001 
  NVP-based regimen 175 (60.1%) 48 (47.5%)   
  EFV- based regimen 114 (39.2%) 36 (35.6%)   
  PI - based regimen 2 (0.7%) 17 (16.8%)   
 Retention in care 6 months after enrolment
 f
    15.29
b
 0.002 
  Lost to follow-up 82 (20.4%) 11 (10.8%)   
  Died 23 (5.7%) 16 (15.7%)   
  Transferred to another clinic 26 (6.5%) 9 (8.8%)   
  Active follow-up 272 (67.5%) 66 (64.7%)   
a Z-score from a two-sample Wilcoxon rank-sum test 
b Pearson chi-square test of association 
c Mantel-Haenszel estimates of the rate ratio and 95% confidence interval 
d ART coverage: patients meeting criteria to start and starting within 90 days. Excludes patients who started ART prior to meeting 
criteria or those starting ART without meeting criteria. 
e Days between meeting criteria to start ART and ART initiation in those starting within 90 days. Excludes patients who started ART 
prior to meeting criteria or those starting ART without meeting criteria. 
f N=42 paediatric patients and n=22 pregnant women in the period after 2013 were not under care long enough be evaluated for 
retention in care.  
g First available in 2009 
h First available in 2013 
i Fisher’s exact test 
j In those who were not diagnosed with severe malnutrition 
 
WHO: World Health Organization; IQR: Interquartile range; ART: antiretroviral treatment; D4T: stavudine, 3TC: lamivudine, NVP: 
nevirapine; AZT: zidovudine; EFV: efavirenz; FTC: emtricitabine; PI: protease inhibitor; PMTCT: Prevention of Mother-To-Child 
Transmission; EID: Early Infant Diagnosis. 
 
Outcomes of children 
The number of children enrolled peaked in 2008 and 2009, following the national trends 
(Tanzanian MoHSW, 2013a), and increased sharply in 2014 in opposition to the tendency in the 
country (Figure 2B). As shown in Table 2, after the intervention, the proportion of children 
diagnosed through PITC, PMTCT/EID program, and transferred from other facilities increased 
significantly. In 2013-2014, children were enrolled with more advanced disease (WHO stage 
3/4 72.2% versus 35%, p<0.001) and immunosupression (median CD4 percent 16 versus 16.8, 
p=0.08). In total, 125 cases of tuberculosis were notified during the study period, 53 of them 
during 2013-2014, representing an 8.5-fold increase of the incidence of tuberculosis 
ascertainment, from 12.2 in 2008-2012 to 103.1 per 100 person-years in 2013-2014. The 
thorough nutritional assessment was reflected in the 35.6-fold increased incidence of 
malnutrition ascertainment, from 4.1 in 2008-2012 to 145.9 per 100 person-years in 2013-
2014. After the intervention, ART coverage increased from 79.6% to 98.1% (p<0.001). The time 
between meeting criteria to start treatment and ART initiation increased from one to eleven 
days (p=0.004). Children prescribed protease inhibitor-based regimens increased from 0.7% to 
16.8% (p<0.001) as a result of the adoption of the 2010 WHO ART guidelines by Tanzania in 
2012 combined with the increased diagnosis of children through the PMTCT/EID program. The 
lost to follow-up and documented mortality rates varied largely during the two periods. While 
the lost to follow-up rate decreased from 20.4% to 10.8%, the documented mortality increased 
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from 5.7% to 15.7%. However, remarkably all deaths in 2013-2014 happened among children 
diagnosed through PITC: 12/16 in the inpatient wards, 2/16 in the tuberculosis clinic, and 2/16 
in the outpatient department. Fifteen (15/16) were malnourished, 6/16 had tuberculosis and 
all died within 90 days after diagnosis, the majority (10/16) within six weeks. 
Figure 2. Number of newly enrolled pregnant women (A) and children (B) per year 
A: Number of pregnant women enrolled in care 
 
B: Number of children enrolled in care 
 
Characteristics of the HIV-exposed infants and early Mother-To-Child Transmission 
Since January 2013 all HIV-exposed infants <18 months are enrolled in our clinic. From January 
1, 2013 to December 31, 2014, 261 infants were enrolled. Table 3 summarizes the 
characteristics of these infants. Fifty-six percent (157/261) of the mothers were diagnosed 
before pregnancy, 33.3% (87/261) during pregnancy or delivery, and 10.3% (27/261) after 
delivery. Among the mothers diagnosed before or during pregnancy, 15.4% (36/234) did not 
receive a correct PMTCT intervention, all recruited before the integration of services. The 
overall early MTCT rate, defined as the rate of positivity of the first HIV test performed, was 
8.6%. Yet, it varied largely depending on the timing of the HIV diagnosis of the mother and the 
correctness of PMTCT (See Figure, Supplemental Digital Content 2). The MTCT rate of mother-
infant pairs diagnosed before or during pregnancy was 4.8% (11/231), being as low as 2% 
(4/195) for the 84.6% (195/234) of pairs who received a correct PMTCT intervention. However, 
the rate was 44% (11/25) for pairs diagnosed after delivery. Noteworthy, many infants in this 
last group were found to be HIV-exposed through PITC, when admitted with symptoms. By the 
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time of analysis, none of the breastfeeding infants with an initial negative test had 
seroconverted. 
Table 3. Characteristics of the 261 HIV-exposed infants enrolled during 2013 - 2014 
Characteristic  
Female gender, n/N (%) 120/261 (46.2) 
Age at enrolment, weeks, median (IQR) 6 (5-14) 
Time of mother’s HIV diagnosis, n/N (%)  
 Before pregnancy 147/261 (56.3) 
 During pregnancy, labour or delivery 87/261 (33.3) 
 After delivery 27/261 (10.3) 
Correct PMTCT intervention 
a
, n/N (%) 198/234 (84.6) 
Timely initiation of co-trimoxazole prophylaxis
 b
, n/N (%) 171/239 (71.6) 
Feeding practice during first 6 months of life n/N (%)  
 Exclusive breastfeeding 236/261 (90.4) 
 Formula milk 8/261 (3.1) 
 Animal’s milk 4/261 (1.5) 
 Mixed feeding 13/261 (5.0) 
Age at first early infant diagnosis test, weeks, median (IQR) 7 (6-16) 
Result of first HIV test performed, n/N 
c
 (%)  
 Negative 234/256 (91.4) 
 Positive 22/256 (8.6) 
Final HIV serostatus, n/N (%)  
 Not yet known 163/256 (63.7) 
 Uninfected 76/256 (29.7) 
 Infected 22/256 (8.6) 
  Correct PMTCT intervention 4 
  Incorrect/incomplete PMTCT intervention  7 
  
No PMTCT intervention (mother diagnosed after 
delivery) 
11 
Retention in care, n/N (%)  
 Retained 193/261 (74.0) 
 Dead 
d
 19/261 (7.3) 
 Transferred to another clinic 16/261 (6.1) 
 Lost to follow-up 
e
 33/261 (12.6) 
a Correctness according to the national PMTCT guidelines applicable during the pregnancy. Applicable only for 
mother-infant pairs diagnosed before or during pregnancy, labour or delivery (n = 234). 
b Infants initiating prophylaxis between 4 and 8 weeks of life. We include 239 infants: 231 born from mothers 
diagnosed before or during pregnancy, labour or delivery and 8 infants born from mothers diagnosed after 
delivery and before the infant was 8 weeks old. Three infants born from mothers diagnosed before or during 
pregnancy died or were lost to follow-up before 4 weeks of age and were excluded. 
c Five infants were never tested with pro-viral HIV DNA PCR: 3 died before 4 weeks of age and 2 were lost to 
follow-up before 4 weeks of age. 
d Six of these infants were HIV-infected 
e Lost to follow-up was defined as > 90 days had passed since their next scheduled visit  
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Figure, Supplemental Digital Content 2. Early mother-to-child transmission rate among HIV-
exposed infants enrolled during 2013-2014 
 
*All the mothers in this group were attended before the HIV care and treatment services were integrated within the Reproductive 
and Child Health Clinic 
PMTCT: Prevention of Mother-To-Child Transmission 
 
After EID was implemented in Ifakara in March 2014, the turnaround time for results -time 
between sample collection and delivery of results to caregivers - decreased from 7 months in 
2013, to 13 and 35 days for positive and negative results, respectively. 
Discussion 
The implementation of the One Stop Clinic of Ifakara combined with the improved efficiency of 
a paperless clinic and the rollout of PITC and EID resulted in: a) an increased number of 
pregnant women and children diagnosed and linked into care; b) an increased detection of 
children with AIDS; c) universal ART coverage; d) lower loss to follow-up and better 
ascertainment of mortality; and e) a proof that elimination of MTCT can be achieved in rural 
Tanzania.  
The intervention resulted in an increased number of pregnant women and children diagnosed 
and linked into care. This is an effect of the active case-finding approach of our strategy and 
the presence of a PMTCT and Pediatric HIV team, which is well-integrated and coordinated 
with the outpatient clinic and the hospital wards. The opt-out approach for HIV testing during 
antenatal care visits has been in place in our hospital since 2008. However, in 2010-11 only 
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25% of newly diagnosed women were linked to HIV services (Gamell et al., 2013). Through the 
One Stop Clinic the number of women diagnosed and linked into care increased substantially, 
with the most likely impact of preventing new pediatric infections. 
Diagnosing children outside the PMTCT programs remains challenging (Horwood et al., 2010; 
Ahmed et al., 2013; Chamla et al., 2013). Measures to identify HIV-infected children must be 
implemented in parallel to the efforts to achieve universal PMTCT and the elimination of 
MTCT. In our study, the increased number of children enrolled in 2014, was mainly attributable 
to PITC but also to the enrollment of children diagnosed in other facilities and admitted with 
severe disease and the implementation of EID locally. Also, it is possible that as a result of an 
increased awareness among the staff, there was an expansion of family-centered testing using 
parents as index cases. Children enrolled after 2012 presented with more advance disease and 
immunosuppression, reflecting the high yield of infants and children enrolled from the 
inpatient wards (Kankasa et al., 2009; McCollum et al., 2010; Mutanga et al., 2012) and 
probably a better clinical assessment by a specially trained team (Kline et al., 2009). The 
incidence of HIV has decreased over the last years in Tanzania (UNAIDS, 2013). Thus, we 
presume that before the intervention, some children were admitted and eventually died 
without being diagnosed with HIV and therefore enrolled in our cohort. The improvement of 
EID is expected to increase the identification of asymptomatic HIV-infected infants. However, 
given the low MTCT among mother-infant pairs that received an appropriate PMTCT 
intervention, the few infants diagnosed during the routine follow-up did not have an impact on 
the proportion of children with advanced disease at diagnosis. On the contrary, the 
implementation of local HIV DNA PCR testing allowed us to confidentially diagnose children < 
18 months admitted in the hospital with advance disease. Diagnosing and offering health-
restoring care and treatment to children with AIDS is one of the major achievements of our 
strategy. However, it highlights the high percentage of late presenters in sub-Saharan Africa 
(Lahuerta et al., 2014) and the need to expand the case-finding approaches to places where 
large number of infants and children congregate, such as immunization clinics, schools and the 
community, to increase early diagnosis and improve outcomes (Ahmed et al., 2013). 
ART coverage among eligible children increased from 79.6% to 98.1%. This achievement is 
especially remarkable since, to date, similar coverage rates in Africa have only been reported 
by urban programs (Anaky et al., 2010; Leyenaar et al., 2010). For children meeting criteria, the 
time to initiation of drugs increased from one to eleven days, likely reflecting a better 
 56 
 
ascertainment of opportunistic infections and improved pre-ART counseling to children and 
caregivers. 
After initiated on ART, children need to be retained, adhere to treatment and get the support 
needed to face the challenges of growing with HIV (Kellerman and Sugandhi, 2013; Bernays et 
al., 2014; Lowenthal et al., 2014). Integration of PMTCT and Pediatric HIV services with 
reproductive and child care, and family-centered approaches have proven effective to improve 
retention (Myer and Akugizibwe, 2009; Rochat et al., 2011; Essajee et al., 2013).  In our cohort, 
the lost to follow-up rate decreased from 20.4% to 10.8%. However, we could not fully assess 
the contribution of mortality to these cases (Geng et al., 2015). The increased documented 
mortality after the intervention can be explained by the increased number of children with 
AIDS and a better ascertainment of death. Known risk factors for mortality are low CD4 
percent, WHO stage 3/4 disease, severe malnutrition and tuberculosis (Eley et al., 2006; Bong 
et al., 2007; Sutcliffe et al., 2008), all common among children registered in 2013-14. High 
fatality rates have been reported in pediatric African cohorts. In Malawi, the 12-months 
mortality after diagnosis through PITC was 20% (McCollum et al., 2011), same as for children 
with tuberculosis-HIV co-infection (Buck et al., 2013). In Zambia, mortality of malnourished 
children was 46%, with HIV-infected children being 80% more likely to die (Munthali et al., 
2015). Although the lost to follow-up rate decreased in our clinic, the reported early mortality 
emphasizes once more the need for strategies to timely diagnose children that fell through the 
cracks of the PMTCT programs. Moreover, the availability of pediatric antiretroviral 
formulations is likely to lead to further improvements in adherence and retention (DNDi, 
2013).  
The MTCT rate for mother-infant pairs reached by PMTCT in our clinic achieved the goal of 
virtual elimination (<5%). These low transmission rates combined with the finding that all 
mothers attended after the establishment of the One Stop Clinic received a complete PMTCT 
intervention confirm the programmatic benefits of integrating services. The dramatic 
reduction of the turnaround time of EID results leverages the decentralization of this test in 
order to facilitate the timely initiation of life-saving treatment for infected infants (Violari et 
al., 2008). 
This study has some limitations. First, although we believe that given the comprehensive 
nature of the intervention, its positive impact has a good chance to be maintained over time, a 
longer follow-up will be needed to measure the long-term impact of the strategy on the clinical 
outcomes and retention in care. Second, it is challenging to distinguish the impact of the 
 57 
 
specific interventions, as they were implemented as a bundle. Third, tuberculosis might have 
been over-diagnosed, since, despite having Xpert MTB/RIF (Cepheid, Sunnyvale, CA) in our 
clinic (Haraka et al., 2015), confirming childhood tuberculosis is challenging and most 
diagnoses were based on symptoms and radiological findings. Forth, it is possible that some 
cases ascertained as lost to follow-up had died. Finally, given the short follow-up time, we 
could not assess the final MTCT rate. Strengths of our study include the comprehensive clinical 
data and the prospective character of the evaluation. 
In conclusion, the creation of One Stop Clinic of Ifakara combined with a comprehensive 
electronic data collection system and the implementation of PITC and EID resulted in an 
increased number of mothers and children diagnosed and linked into care, a higher detection 
of children with AIDS, universal ART coverage, better retention in care and ascertainment of 
mortality, and an early MTCT rate below the elimination threshold. This strategy may provide a 
feasible and scalable model for delivering high-quality family-centered HIV care in Tanzania 
and achieve the 90-90-90 target. 
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Abstract  
Background: Strategies to improve the uptake of Prevention of Mother-To-Child Transmission 
of HIV (PMTCT) are needed. We integrated HIV and maternal, newborn and child health 
services in a One Stop Clinic to improve the PMTCT cascade in a rural Tanzanian setting. 
Methods: The One Stop Clinic of Ifakara offers integral care to HIV-infected pregnant women 
and their families at one single place and time. All pregnant women and HIV-exposed infants 
attended during the first year of Option B+ implementation (04/2014-03/2015) were included. 
PMTCT was assessed at the antenatal clinic (ANC), HIV care and labour ward, and compared 
with the pre-B+ period. We also characterised HIV-infected pregnant women and evaluated 
the MTCT rate. 
Results: 1,579 women attended the ANC. Seven (0.4%) were known to be HIV-infected. Of the 
remainder, 98.5% (1,548/1,572) were offered an HIV test, 94% (1,456/1,548) accepted and 38 
(2.6%) tested HIV-positive. 51 were re-screened for HIV during late pregnancy and one had 
seroconverted. The HIV prevalence at the ANC was 3.1% (46/1,463). Of the 39 newly 
diagnosed women, 35 (90%) were linked to care. HIV test was offered to >98% of ANC clients 
during both pre- and post-B+ periods. During the post-B+ period, test acceptance (94% versus 
90.5%, p<0.0001) and linkage to care (90% versus 26%, p<0.0001) increased. Ten additional 
women diagnosed outside the ANC were linked to care. 82% (37/45) of these newly-enrolled 
women started antiretroviral treatment (ART). After a median time of 17 months, 27% (12/45) 
were lost to follow-up. 79 women under HIV care became pregnant and all received ART. After 
a median follow-up time of 19 months, 6% (5/79) had been lost. 5,727 women delivered at the 
hospital, 20% (1,155/5,727) had unknown HIV serostatus. Of these, 30% (345/1,155) were 
tested for HIV, and 18/345 (5.2%) were HIV-positive. Compared to the pre-B+ period more 
women were tested during labour (30% versus 2.4%, p<0.0001). During the study, the MTCT 
rate was 2.2%.  
Conclusions: The implementation of Option B+ through an integrated service delivery model 
resulted in universal HIV testing in the ANC, high rates of linkage to care, and MTCT below the 
elimination threshold. However, HIV testing in late pregnancy and labour, and retention during 
early ART need to be improved.  
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Introduction 
Mother-To-Child Transmission (MTCT) accounts for over 90% of new paediatric HIV infections 
(UNAIDS, 2010b). The World Health Organization (WHO) has issued several prevention of 
MTCT (PMTCT) recommendations for low and middle-income countries since 2001 (WHO, 
2004, 2012b). As a result of the scale-up of PMTCT interventions, there has been a 70% decline 
of new HIV infections among children between 2000 and 2015. However, in 2015, 23% of HIV-
infected pregnant women did not receive effective antiretroviral regimens for PMTCT and 
150,000 children acquired HIV (UNAIDS, 2016b). 
Since 2012, the WHO recommends using lifelong antiretroviral therapy (ART) for all pregnant 
and breastfeeding women regardless of CD4 counts and clinical stage, and provision of 
nevirapine or zidovudine to all HIV-exposed infants for four to six weeks regardless of the 
feeding method. These recommendations are known as “Option B+”.   
In Tanzania, Option B+ was rolled out from September 2013 (Tanzanian MoHSW, 2013b). The 
MTCT rate in 2014 was 9% (UNAIDS, 2015a). In the Saint Francis Referral Hospital (SFRH) of 
Ifakara, in rural south-west Tanzania, Option B+ was deployed in April 2014. In 2012, an 
assessment of the PMTCT circuit had identified several gaps, namely: (a) poor linkage into HIV 
care of newly diagnosed HIV-infected pregnant women; (b) no re-testing of seronegative 
women in late pregnancy;  and (c) lack of a standardised follow-up of HIV-exposed infants 
(Gamell et al., 2013). To bridge these gaps, an integrated and comprehensive service delivery 
model to improve maternal and paediatric HIV care was implemented in parallel to Option B+ 
(Gamell, Glass, et al., 2016; Muri et al., 2016).  
The current study describes the PMTCT cascade and uptake of Option B+ guidelines 
implemented through this service delivery model. 
Methods 
This is a prospective cohort study describing the PMTCT cascade and uptake of Option B+ 
guidelines in the SFRH. The uptake of PMTCT recommendations was compared with the one 
previously described in 2012 (Gamell et al., 2013). We also assessed the MTCT rate, 
characterised HIV-infected mothers and analyzed the differences between newly diagnosed 
pregnant women and women who became pregnant while being under HIV care.  
Study setting and population 
The SFRH is the largest healthcare facility in the rural Kilombero district, serving a population 
of 600,000 inhabitants and an estimated 30,000 people living with HIV (Tanzanian NBS, 2012). 
HIV care and treatment is offered within the hospital at the Chronic Diseases Clinic of Ifakara 
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(CDCI). The clinic works in collaboration with the Ifakara Health Institute, the Swiss Tropical 
and Public Health Institute and the Department of Infectious Diseases and Hospital 
Epidemiology of the University Hospitals of Basel and Bern, Switzerland. Since 2004, all 
patients attending the clinic are invited to participate in the Kilombero and Ulanga 
Antiretroviral Cohort (KIULARCO) (Haraka et al., 2015; Letang et al., 2015; Ramírez-Mena et al., 
2016). Written informed consent is sought from all participants; for children and adolescents 
aged < 18 years, informed consent is sought from caregivers. The KIULARCO study obtained 
ethical approval from the Ifakara Health Institute ethical review board, the National Institute 
for Medical Research of Tanzania, the Tanzanian Commission for Science and Technology and 
the ethical review board of Northwest Switzerland. It is the largest rural HIV cohort in 
Tanzania, with over 9,000 patients ever enrolled. Patients receive care according to the 
National AIDS Control Program (Tanzanian MoHSW, 2015). 
In December 2012 the One Stop Clinic of Ifakara was created, a maternal and paediatric family-
oriented HIV unit integrated within the Reproductive and Child Health Clinic. The services 
delivered include: antenatal care (ANC), postpartum maternal and infant care, cervical cancer 
screening, child’s growth and health monitoring, expanded program of immunizations, 
nutritional assessment and tuberculosis and HIV care and treatment (Figure 1). Details about 
the organization, functioning and staff of the One Stop Clinic have been published elsewhere 
(Gamell, Glass, et al., 2016; Letang et al., 2017). 
Figure 1: The One Stop Clinic of Ifakara integrates health services for HIV-infected pregnant 
women, children, HIV-exposed infants and their families in a rural Tanzanian hospital 
 
PITC: Provider Initiated HIV Testing and Counseling 
In this study we included all pregnant women and HIV-exposed infants attended in the ANC 
station, labour ward and/or the CDCI in SFRH during the first year of Option B+ 
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implementation, from April 1st, 2014 to March 31st, 2015. Data from HIV-infected pregnant 
women was analysed by February 11th, 2016. For HIV-exposed infants, given the long 
breastfeeding period, retention in care and final HIV serostatus was analysed as per June 30th, 
2016. HIV-infected pregnant women transferred to the One Stop Clinic from other facilities 
were excluded. Lost to follow-up was defined as not having visited the clinic 60 days after the 
last scheduled date for HIV-infected mothers and 90 days for HIV-exposed infants. 
 
Statistical analysis 
Characteristics of pregnant women were summarised using proportions and medians. The 
comparison of data from ANC and labour ward during the pre-B+ and post-B+ periods was 
done using proportion differences. Comparisons between newly enrolled pregnant women 
and women who became pregnant while being under care were made using Chi-square and 
Wilcoxon rank-sum tests for categorical and continuous variables, respectively.  Fisher exact 
test was used to compare proportions of women’s follow-up status. Finally, we described the 
characteristics of the HIV-exposed infants enrolled and reported the MTCT rate. SAS 9.3 was 
used for data analysis (SAS Institute Inc., Cary, NC, USA).  
Results 
Implementation of a new PMTCT care pathway 
Since 2013 comprehensive PMTCT services are delivered within the Reproductive and Child 
Health Clinic (WHO, 2012b; Tanzanian MoHSW, 2013b) and coordinated by the One Stop 
Clinic. These services involve different hospital units: the ANC, the HIV clinic and the labour 
ward. Option B+ services include: 1) routine HIV counselling and testing for pregnant women 
and male partners; 2) comprehensive antenatal care; 3) lifelong ART for HIV-positive pregnant 
and breastfeeding women; 4) safe delivery practices; 5) postpartum care for mothers and 
infants; 6) antiretroviral and co-trimoxazole prophylaxis for HIV-exposed infants; 7) counselling 
for safe infant feeding practices; 8) early infant HIV diagnosis and treatment for HIV-infected 
infants; 9) male partner and family involvement. Figure 2 illustrates the PMTCT care pathway 
at SFRH. 
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Figure 2: Current Prevention of Mother-To-Child Transmission of HIV care pathway at Saint 
Francis Referral Hospital 
 
ART: antiretroviral treatment 
 
PMTCT at the Antenatal Clinic 
From April 1st, 2014 to March 31st, 2015, 1,579 women attended the ANC and 0.44% (7/1,579) 
were previously known to be HIV-infected. Ninety-eight percent of women with unknown HIV 
serostatus (1,548/1,572) were offered an HIV test and 94% (1,456/1,548) accepted. Thirty-
eight (38/1,456, 2.6%) were found to be HIV-positive. Among the seronegative women 3.6% 
(51/1,418) were re-tested for HIV during late pregnancy and one (2%) had seroconverted. In 
total, 46 women were identified as HIV-infected in the ANC, for an overall HIV prevalence of 
3.1% (46/1,463). Compared to the period January 2010 – December 2011, acceptance of HIV 
testing improved, (94% versus 90.5% %) after Option B+ implementation (p<0.0001), and the 
HIV prevalence at the ANC decreased from 6.9% to 3.1% (p<0.0001; Table 1). 
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Table 1: Changes in the uptake of the prevention of mother-to-child transmission of HIV 
recommendations before and after Option B+ implementation 
PMTCT step Description Pre-Option B+ period Post-Option B+ period p-value 
Assessment 
of HIV status 
in antenatal 
care 
 
01/01/2010 – 
31/12/2011 
01/04/2014 - 31/03/2015 
 
Number of women attended at 
the ANC 
4027 1579 
 
Pregnant women with HIV 
positive status known, n/N (%) 
44/4027 (1.1) 7/1579 (0.4) 0.0213 
Pregnant women offered an HIV 
test, n/N (%) 
3983/3983 (100) 1548/1572 (98.5) 0.0107 
Pregnant women accepting the 
HIV test, n/N (%) 
3606/3983 (90.5) 1456/1548 (94.1) <0.0001 
Pregnant women tested HIV 
positive in the ANC, n/N (%) 
207/3606 (5.7) 39/1456 (2.7) <0.0001 
Prevalence of HIV among 
pregnant women attended at the 
ANC, n/N 
251/3650 (6.9) 46/1463 (3.1) <0.0001 
Enrolment in 
HIV care 
 
01/01/2010 – 
31/12/2011 
01/04/2014 - 31/03/2015 
 
Women newly diagnosed at ANC 
and enrolled, n/N (%) 
53/207 (25.6) 35/39 (89.7) <0.0001 
PMTCT at 
labour ward 
 
20/03/2011 - 03/05/2011 01/04/2014 - 31/03/2015 
 
Number of deliveries 570 5727 
 
Women with HIV positive status 
known at admission, n/N (%) 
28/570 (4.9) 168/5727 (2.9) 0.01 
Women with unknown HIV status 
at admission, n/N (%) 
82/570 (14.4) 1155/5727 (20.2) <0.0001 
 
Women tested for HIV 
during labour & delivery, 
n/N (%) 
2/82 (2.4) 345/1155 (29.9) <0.0001 
 
Women tested HIV-
positive during labour & 
delivery, n/N (%) 
1/2 (50) 18/345 (5.2) 
 
Prevalence of HIV among women 
attended at labour ward, n/N (%) 
29/486 (6.0) 186/4917 (3.8) 0.0188 
HIV-exposed newborns receiving 
the recommended postnatal 
prophylaxis, n/N (%) 
1/29 (3.5) 154/184 (83.7) <0.0001 
PMTCT: Prevention of mother-to-child transmission; ANC: antenatal care clinic 
Pregnant women receiving HIV care at the One Stop Clinic 
During the study period, 124 HIV-infected pregnant women attended the One Stop Clinic. 
Forty-five of them had been newly diagnosed with HIV during the current pregnancy, and 79 
were under HIV care when pregnancy was reported. 
Newly diagnosed HIV-infected pregnant women 
Of the 39 pregnant women newly diagnosed in the ANC, 35 (90%) were enrolled into HIV care, 
a significant increase from the period 01/2010-12/2011 (90% versus 26%, p<0.0001) (Table 1). 
Another ten women were newly diagnosed and enrolled in HIV care during the study period: 
7/10 from the obstetric ward and 3/10 from the voluntary counselling and testing unit. The 
clinical characteristics and pregnancy outcomes of these 45 women are summarized in Table 2. 
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Median age at enrolment was 28.4 years (interquartile range (IQR) 22.2-31.8), median CD4 
counts 334 cells/µL (IQR 166–509), and 89% presented with WHO stage 1/2. Seventeen 
women (38%) were aware of their male partner HIV serostatus: 7/45 (16%) reported their 
male partner was HIV-positive and 10/45 (22%) HIV-negative. Thirty-seven women (82%) 
initiated ART after a median of 3 days (IQR 0–7). After a median follow-up time of 17.2 months 
(IQR 14.8–21.2), 28/45 (63%) women were under active follow-up at the One Stop Clinic, 4/45 
(9%) had been transferred to another facility, 1/45 (2%) had died and 12/45 (27%) were lost to 
follow-up. Pregnancy outcomes were recorded for 35/45 women: 6/35 (17%) had an abortion, 
miscarriage or neonatal death, and the remainder delivered alive babies. 
Women under HIV care who became pregnant 
Seventy-nine women under HIV care became pregnant during the study period. The median 
time since enrolment was 55 months (IQR 15–74). At the time of HIV diagnosis, their median 
CD4 counts were 265 cells/µL (IQR 134-495) and 79% presented WHO stage 1 or 2 (Table 2).  
When pregnancy was reported, 60% (47/79) were aware of their male partner’s serostatus: 
39% (31/79) reported their male partner was HIV-positive and 20% (16/70) HIV-negative. Most 
women (86%, 68/79) had started ART before pregnancy. The remaining 11 women initiated 
ART after a median of 2 days of their pregnancy report (IQR 0–5). After a median follow-up of 
19.1 months (IQR 14.5–21.8), 81% (64/79) women were under active follow-up at the One 
Stop Clinic, 9% (7/79) had been transferred to another facility, 4% (3/79) had died and 6% 
(5/79) were lost to follow-up. Pregnancy outcomes were recorded for 95% (75/79) of women: 
12% (9/75) had an abortion, miscarriage or neonatal death and the rest delivered alive babies 
(Table 2). 
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Table 2: Characteristics of HIV-infected women enrolled in HIV care during pregnancy and 
women enrolled before pregnancy 
Characteristics 
New HIV 
diagnosis during 
pregnancy (N = 
45) 
Women under HIV care 
who became pregnant 
during follow-up (N = 79) 
p-value 
Time since enrolment (months), median (IQR) - 55 (15 - 74)  
Age at pregnant report (years), median (IQR) 28.4 (22.2 - 31.8) 34 (29 - 36) <0.0001 
CD4 count at enrolment (cells/µL), median (IQR)  334 (166 - 509) 265 (134 - 495) 0.46 
WHO clinical stage at enrolment, n (%)  
 
0.05 
 
   Stage 1/2 40 (88.9) 59 (78.7)  
 
   Stage 3/4 5 (11.1) 16 (21.3)  
Partner HIV serostatus at pregnancy report, n (%)  
 
0.02 
 
Positive 7 (15.6) 31 (39.2)  
 
Negative 10 (22.2) 16 (20.3)  
 
Not tested / Unknown 21 (46.7) 19 (24.1)  
 
Not applicable 
a
 7 (15.6) 13 (16.5)  
ART status at pregnancy report  
 
 
 
Not on ART, n (%) - 11 (13.9)  
 
On ART, n (%) - 68 (86.1)  
 
 
Time on ART at pregnancy report (months), 
median (IQR) 
- 45.3 (16.3 - 72.1)  
 
 ART regimen at pregnancy report, n (%)  
 
 
 
  NVP-based regimen - 19 (27.9)  
 
  EFV-based regimen - 41 (60.3)  
 
  PI-based regimen - 8 (11.8)  
ART-naïve pregnant women initiated on ART, n/N (%) 37/45 (82.2) 11/11 (100)  
Time to ART initiation after pregnancy report (days), 
median (IQR) 
b
 
3 (0 - 7) 2 (0 - 5)  
Follow up time at time of analysis (months), median 
(IQR) 
17.2 (14.8 - 21.2) 19.1 (14.5 - 21.8)  
Retention in care at time of analysis, n (%)  
 
0.02 
 
Active follow up 28 (62.2) 64 (81.0)  
 
Died 1 (2.2) 3 (3.8)  
 
Lost to follow-up 12 (26.7) 5 (6.3)  
 
Transfer to another clinic 4 (8.9) 7 (8.9)  
Pregnancy outcome
 c
, n (%)   
 
0.05 
 
Live born singleton 27 (77.1) 64 (85.3)  
 
Live born twins 2 (5.7) 2 (2.7)  
 
Abortion, miscarriage or neonatal death 6 (17.1) 9 (12.0)  
a Non applicable refers to women who denied having a male partner 
b Applies to 37/45 (N=37) of the newly diagnosed women and to women under HIV care who were not on ART at pregnancy report 
(N = 11) 
c For 10 newly diagnosed women and 4 women under HIV care at pregnancy report, pregnancy outcome was nor recorded (they 
died, were lost to follow-up or were transferred to another clinic before delivery) 
 
IQR: interquartile range; WHO: World Health Organization; ART: antiretroviral treatment; NVP: nevirapine; EFV: efavirenz; PI: 
protease inhibitor. 
 
Figure 3 shows the PMTCT cascade for newly diagnosed women (3A) and women becoming 
pregnant while under HIV care (3B). Compared to newly diagnosed women, those who were 
under HIV care at pregnancy report were older (34 versus 28.4 years, p<0.0001), had similar 
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CD4 counts at HIV diagnosis (265 versus 334, p=0.46), higher proportion of WHO clinical stage 
3/4 (21% versus 11%, p=0.05), better knowledge of their male partner serostatus (60% versus 
38%, p=0.02), lower lost to follow-up rate (6% versus 27%, p=0.02), and better pregnancy 
outcomes (proportion of live born babies 88% versus 83%, p=0.05)  (Table 2).  
Figure 3: Retention through the PMTCT cascade for women newly diagnosed with HIV during 
the current pregnancy (3A) and women who became pregnant while being under HIV care (3B) 
 
* Women known to be HIV-infected (n=7) have not been included 
** Women retained in care at the One Stop Clinic or transferred to another facility were considered to be under active follow-up  
 
PMTCT: prevention of mother-to-child transmission of HIV; ANC: antenatal care clinic; ART: antiretroviral treatment; VCT: 
voluntary counselling and testing 
 
PMTCT at the labour ward 
The labour ward at SFRH attends women from several ANCs and receives the referrals from 
lower level facilities. During the study period 5,727 women delivered at the hospital. At 
admission, 80% (4,572/5,727) had their HIV status documented (168 HIV-positive) and for 20% 
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(1,155/5,727) it was unknown. Thirty percent (345/1,155) of women in this latest group were 
tested for HIV during labour, 5.2% (18/345) were HIV-infected. Overall, 3.8% (186/4,917) of 
women with known HIV serostatus giving birth at SFRH were HIV-infected. None of the women 
with a documented HIV-negative test during pregnancy was re-tested during labour. The 
comparison of the uptake of recommendations between our previous assessment and the 
current period is presented in Table 1. During the post-B+ period the number of women 
presenting at labour with unknown HIV status increased (20% versus 14%, p<0.0001), but the 
HIV testing rate of these women increased (30% versus 2.4%, p<0.0001). Similarly to the ANC, 
the HIV prevalence among pregnant women attended at the labour ward was lower than in 
2010-11 (3.8% versus 6.0%, p=0.02). 
HIV-exposed infants and mother-to-child transmission 
During the study period, 135 HIV-exposed infants born from mothers diagnosed with HIV 
before pregnancy or during pregnancy or delivery were enrolled at the One Stop Clinic (Table 
3). Sixty-two percent (83/135) of the mothers were diagnosed before pregnancy. Eighty eight 
percent (119/135) of the mothers received correct drugs for PMTCT and 75% (101/135) of the 
infants got the recommended postnatal prophylaxis. Median age at the time of the first HIV 
test was 6 weeks (IQR 5-11). By the time of analysis 2.2% (3/135) infants were HIV-infected (all 
diagnosed at first HIV test), 66.7% (90/135) were uninfected, and 31.1% (42/135) had a first 
negative HIV test but were still breastfeeding when last visited. Remarkably, none of the 
followed infants with an initial negative test seroconverted during the study period. Fifteen 
months after the last infant included was enrolled, the lost to follow-up rate was 14% (19/135) 
and 6% (8/136) infants had died (2 were HIV-infected).  
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Table 3: Characteristics of the 135 HIV-exposed infants born from mothers diagnosed before 
pregnancy or during pregnancy, labour and delivery 
Characteristic 
 
Female gender, n (%) 63 (46.7) 
Time of mother’s HIV diagnosis, n (%) 
 
 
Before pregnancy 83 (61.5) 
 
During pregnancy/delivery 52 (38.5) 
Correctness of mother’s ART for PMTCT, n (%) 
 
 
Correct 119 (88.2) 
 
Incorrect 16 (11.9) 
Correctness of infant’s postnatal ARV prophylaxis, n (%) 
 
 
Correct 101 (74.8) 
 
Incorrect 34 (25.2) 
Age at first HIV test (weeks), median (IQR) 6 (5 - 11) 
Timely initiation of co-trimoxazole prophylaxis, n (%) 
a
 108 (84.4) 
Infant feeding during the first 6 months of life, n (%) 
 
 
Exclusive breastfeeding 123 (91.1) 
 
Replacement feeding 4 (3.0) 
 
Animal’s milk 2 (1.5) 
 
Mixed feeding 6 (4.4) 
Final serostatus of children, n (%) 
 
 
HIV negative 90 (66.7) 
 
HIV positive 3 (2.2) 
 
Not yet known 
b
 42 (31.1) 
Retention in care at time of analysis, n (%) 
 
 
Active follow up 103 (76.3) 
 
Lost to follow-up 19 (14.1) 
 
Transferred to another clinic 5 (3.7) 
 
Died 
c
 8 (5.9) 
 
HIV-positive 2 
 
a For 7 infants the correctness of CPT initiation was not applicable, since they were enrolled after the age of 6 weeks 
b 19/42 infants were lost to follow-up after a first negative HIV test; 23/42 infants had a first negative HIV test but were still 
breastfeeding at the time of analysis 
c Causes of death: 1 septicaemia (HIV-infected); 1 acute respiratory failure (HIV-infected); 1 congenital hydrocephaly; 1 spina 
bifida;  1 Kwashiorkor malnutrition (and suspected tuberculosis); 1 bacterial pneumonia; 2 unknown. 
 
ART: antiretroviral treatment; PMTCT: prevention of mother-to-child transmission; ARV: antiretroviral; IQR: interquartile range. 
 
During the same period 24 HIV-exposed infants born from mothers who were diagnosed after 
delivery were enrolled. Most of these mothers had attended an ANC during pregnancy but 
were not offered an HIV test. The MTCT rate in this group was 46% (11/24). Most of these 
infants and their mothers were identified in the hospital wards, when admitted with 
malnutrition, advanced HIV disease or opportunistic infections.  
Discussion 
This is the first study to evaluate the Option B+ cascade in Tanzania. Option B+ delivered 
through the One Stop Clinic model dramatically improved linkage to HIV care after diagnosis in 
the ANC and resulted in over 90% of enrolled women receiving ART. Retention throughout the 
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PMTCT pathway was challenging for newly diagnosed HIV-infected pregnant women. The 
observed MTCT rate (2.2%) was below the national average (9%) and the 5% threshold 
established for elimination of MTCT of HIV in breastfeeding populations (WHO, 2014a). 
Nevertheless, gaps such as the poor uptake of HIV testing in the labour ward and an almost 
inexistent HIV re-screening during late pregnancy remained and need to be urgently 
addressed.  
Improvement in enrolment to HIV care. The rate of HIV testing in the ANC was > 90% both in 
the pre-B+ and the post-B+ periods. This is reassuring, since failure to detect HIV-infected 
mothers in the ANC is estimated to be responsible for 54% of paediatric HIV infections in 
resource-limited settings (Centers for Disease Control and Prevention (CDC), 2013). Enrolment 
to HIV care from ANC increased from 26% during January 2010 to December 2011 to 90% 
during April 2014 to March 2015. In two large urban centres in Malawi, the enrolment to 
PMTCT/HIV care from the ANC increased from 61% in the pre-B+ period to 87% in the post-B+ 
period (Kim et al., 2015). However, a study from Uganda found that after Option B+ 
implementation, only 25% of women diagnosed in rural ANC settings were linked to HIV care. 
Health workers interviewed in that study suggested improving competence in HIV counselling 
and integration of PMTCT and chronic HIV care within the routine reproductive and child care 
as potential solutions to poor linkage (Mugasha et al., 2014). Thus, we attribute the improved 
linkage to HIV care, not to Option B+ itself, but to the integration of antenatal and HIV services  
within the same clinic and the specialised counselling delivered through the One Stop Clinic. 
The main challenge: retention through the PMTCT cascade. In our study, Option B+ was 
challenged by the losses of newly diagnosed HIV-infected women along the PMTCT cascade. As 
seen in other settings (Kim et al., 2015), a substantial proportion of newly enrolled women 
(8/45, 18%), were lost to follow-up before ART initiation. High rates of early attrition are also 
seen in places where same day diagnosis and treatment initiation is the standard of care (van 
Lettow et al., 2014; Chan et al., 2016). These findings indicate that women may need time to 
adjust to the HIV diagnosis and understand the benefits of lifelong ART. After ART initiation, 
recently diagnosed women continued to drop from care, although at a lower rate: 86.5% 
(32/37) were retained after a median of 17.2 months. This result is better than the one 
reported in a recent publication from Malawi, where retention after ART initiation in the 
context of Option B+ was 68.5% at 12 months, 61% at 24 months and 56.3% at 36 months 
(Haas et al., 2016). While the size of our study population was small, our better results suggest 
that the unhurried start of ART and continued counselling combined with joint visits for 
maternal care, PMTCT/HIV care and infant growth monitoring and immunization may be 
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responsible for the lower attrition. The better retention of women becoming pregnant while 
being under HIV care must be capitalized and peer-mother programs should be common in all 
settings (Tenthani et al., 2012; Shroufi et al., 2013). Importantly, the uniqueness of Option B+ 
challenges may be coming to an end, since many countries are implementing the “test and 
treat” strategy for all HIV-infected individuals (WHO, 2016). Thus, lessons learned from the 
implementation of Option B+ should serve to enhance not only PMTCT but also ART programs 
in sub-Saharan Africa.  
The elimination of new paediatric HIV infections: a met target. The MTCT rate observed at the 
One Stop Clinic was 2.2%, achieving the target of <5% established for populations in which 
breastfeeding is common (WHO, 2014a). Therefore, unlike previously reported (Wudineh and 
Damtew, 2016), the virtual elimination of new paediatric HIV infections seems feasible in a 
rural setting under programmatic circumstances. The lost to follow-up rate of infants after a 
minimum of 15 months since enrolment was 14%, much lower than the average 34% reported 
for sub-Saharan African settings at only 3 months post-delivery (Sibanda et al., 2013). We 
believe that the integrated service delivery model combined with continued counselling after 
delivery are responsible for these results. In line with our findings, a cluster-randomized 
clinical trial conducted in Nigeria showed that integration of mother and infant services 
resulted in better provision of PMTCT and a significant increase in retention (Aliyu et al., 2016). 
This success is shadowed by the infants identified as HIV-exposed after delivery. In most cases, 
these infants were enrolled after being admitted with symptoms and a high proportion was 
HIV-infected. This finding provides evidence that some mothers are still not captured by 
PMTCT programs. Thus, in parallel to Option B+ efforts, case-finding approaches are necessary 
to timely diagnose HIV-infected children outside the PMTCT pathway (Ahmed et al., 2013). 
Testing gaps. Twenty percent of women attended the labour ward with unknown HIV 
serostatus. Since over 95% of women in the region attend at least one antenatal visit 
(Tanzanian NBS, 2011), we attribute this finding to test shortages in some district health 
facilities. Intrapartum HIV testing is crucial for maximizing PMTCT programs, but, worryingly, 
only a third of women with unknown serostatus were tested during labour. Reasons for the 
low HIV testing at the labour ward are the substantial workload of the health workers and the 
frequent staff turnover, which hinder the efficacy of the PMTCT training and messages 
delivered to midwifes and nurses working there. Furthermore, HIV re-screening during late 
pregnancy was anecdotic in our setting. A second HIV test during the last trimester of 
pregnancy is recommended based on its cost-effectiveness (Soorapanth et al., 2006) and the 
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increased risk of HIV acquisition during pregnancy (Gray et al., 2005). In our hospital, 2% of 
women re-tested for HIV in late pregnancy had seroconverted. With this seroconversion rate, a 
total of 28 women may have been silently infected during pregnancy. Having re-screened all 
women would have resulted in a 72% increase in the number of women diagnosed in the ANC 
and an opportunity to prevent their infants to become infected. Re-screening and intrapartum 
testing can act as safety nets to ensure the success of PMTCT. Continuous education of the 
attending staff and a strengthen supply chain of tests are crucial to bridge these testing gaps. 
This study has some limitations. First, we did not include mother-infant pairs, but pregnant 
women and HIV-exposed infants enrolled during the study period. The number of infants 
enrolled in a year exceeded the number of women. This is due to yearly variations and 
transferred and orphan infants, but also to some mothers from peripheral facilities preferring 
their infants to receive comprehensive care at the One Stop Clinic. Still, a significant proportion 
of the infants were born from mothers enrolled during the study, and the uptake of the 
guidelines could be satisfactorily assessed. Second, an important part of women delivering at 
SFRH did not attend the local ANC, and complete antenatal data was not available for them. 
Third, it is possible that some women ascertained as lost to follow-up self-transferred to 
another facility, as it is common in district high level facilities as ours (Koole et al., 2014; 
Wilkinson et al., 2015). Finally, since 14% of the HIV-exposed infants were lost to follow-up 
while breastfeeding, it is possible that the MTCT rate of 2.2% underestimates the true 
transmission rate. However, even presuming a 15% transmission through the breast milk 
among the lost to follow-up infants, the cohort MTCT rate would still be below 5%.  
The strength of this study is being the first one to comprehensively analyse the Option B+ 
cascade in a Tanzanian setting, including all the steps of the PMTCT pathway and the long 
follow-up time for both mothers and infants.  
Conclusions 
In summary, Option B+ was successfully implemented in this rural African setting through an 
integrated service delivery model. Most diagnosed women were linked into HIV care, received 
appropriate ART and the MTCT rate was below 5%. However, important testing gaps that may 
have left women undiagnosed were observed. The One Stop Clinic is a feasible, inexpensive 
and scalable Option B+ delivery model that could be extrapolated to similar rural settings. 
Despite the success, caution is warranted and additional strategies to ensure universal HIV 
testing for pregnant and delivering women and to improve early ART retention of newly 
diagnosed women are crucially needed. 
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Abstract 
The acquisition of drug-resistance mutations among African children living with HIV on 
antiretroviral treatment has been scarcely reported. This threatens the overall success of 
antiretroviral programs and the clinical outcomes of children in care. We present a well-
characterized series of children from rural Tanzania with acquired drug-resistance mutations 
to contribute to the better understanding of this emerging public health concern. 
Introduction 
There are few data on the acquisition of drug-resistance mutations among African children 
living with HIV on antiretroviral treatment (ART). Overall, in resource-limited settings, HIV-1 
treatment failure in children is estimated to be 40% (Sigaloff et al., 2011). Virologic 
suppression and long-term treatment success are harder to achieve than in adults(Sutcliffe et 
al., 2008). This is mostly due to high pre-ART viral loads (VL), poorer virologic response, and 
risk of sub-therapeutic drug concentrations caused by limited paediatric drug formulations, 
variable pharmacokinetics, and rapid changes in body weight (Abrams et al., 1998; van 
Rossum, Fraaij and de Groot, 2002; Walker et al., 2004; Menson et al., 2006; Collaboration of 
Observational HIV Epidemiological Research Europe (COHERE) Study Group et al., 2008; 
Sigaloff et al., 2011). These factors, often associated with suboptimal adherence, may promote 
the emergence of drug-resistance mutations. Only one study from Kenya has described the 
pattern of acquired drug-resistance mutations in African children presenting ART failure (van 
Rossum, Fraaij and de Groot, 2002; Wamalwa et al., 2013). In Tanzania, a small study found a 
virologic failure (VF) rate of 58%, 100% with drug-resistance mutations (Bratholm et al., 2010). 
The emergence of acquired drug-resistance mutations in children threatens ART programs in 
sub-Saharan Africa and needs to be studied further. We present a well-characterised series of 
children from a rural Tanzanian setting with treatment failure due to the acquisition of drug-
resistance mutations.  
Material and methods 
Study setting and population 
The children in this study attend the Chronic Diseases Clinic of Ifakara (CDCI), in the Saint 
Francis Referral Hospital. The CDCI works in cooperation with the Ifakara Health Institute, the 
Swiss Tropical and Public Health Institute, and the University Hospitals of Basel and Bern. 
Patients attending the CDCI are offered informed consent to be enrolled in the Kilombero and 
Ulanga Antiretroviral Cohort (KIULARCO) (Haraka et al., 2015). The KIULARCO study received 
ethical clearance from the corresponding ethical review boards in Tanzania and Switzerland. 
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This is the largest peripheral HIV cohort in Tanzania with almost 8000 patients. In 01/2013 a 
Paediatric and Prevention of Mother-To-Child Transmission (PMTCT) unit, named “The One 
Stop Clinic of Ifakara”, was established within the CDCI. By 03/2015, 340 children and 
adolescents were under active follow-up. Care and treatment for patients is provided 
according to the National AIDS Control Program. CD4 counts are used to routinely monitor the 
ART response. VL is requested by clinicians after treatment failure is suspected due to poor 
immunological or clinical evolution. In case VL is detectable, HIV drug-resistance genotyping is 
performed. 
Clinical data 
At each visit, clinical, laboratory and pharmacy data are collected electronically. Adherence is 
estimated using self-reported adherence and pill counting and considered “suboptimal” if 
<95% of the prescribed pills have been taken. The individual prescriptions were reviewed to 
assess their adequacy. For children transferred from other facilities, ART dosage was checked 
by direct observation of their drugs at the enrolment visit.  
Viral load and genotypic resistance testing 
Blood samples were collected in 8mL BD Vacutainer EDTA collection tubes. Plasma HIV RNA VL 
and HIV drug-resistance genotypes were determined at the Ifakara Health Institute laboratory. 
Cell-free plasma was collected by centrifugation at 956rcf for 5 minutes and frozen at -800C 
until testing for VL or drug-resistance genotyping. HIV RNA from plasma was extracted using 
the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany), following the manufacturer’s 
protocol. Viral RNA quantification was performed with the TaqMan® RNA-to-CT™ 1-Step Kit 
(Life Technologies) using the StepOne Real Time PCR system (Life Technologies), with a 
detection limit of 200 viral RNA copies/mL. HIV drug-resistance genotyping was performed by 
Sanger sequencing on an ABI Genetic Analyser (4-capillary model 3130) using a validated in-
house PCR protocol (Masimba et al., 2013). 
HIV-1 drug-resistance was predicted according to the Stanford University’s HIV Drug 
Resistance Database Program version 6.2.0 (http://hivdb.stanford.edu). 
Results 
We present a series of children with acquired drug-resistance mutations: 10/12 enrolled in the 
CDCI at HIV diagnosis and 2/12 (#11, #12) transferred to our clinic after ART initiation. Six 
patients (#1 - #6) were identified through a previous cross-sectional analysis within KIULARCO. 
The remaining six children were identified prospectively after presenting unsatisfactory 
evolution: patients #7, #8 and #9 presented poor CD4 increase, although they did not meet the 
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WHO criteria of immunological failure; patient #10 presented clinical failure; patient #11 had 
been exposed to low doses of antiretrovirals; and patient #12 presented with both 
immunological and clinical failure. 
Clinical characteristics 
The clinical characteristics of the patients are summarized in Table 1. Median age at ART 
initiation was 6.4 years (IQR 5.3, 9.4). Ten children were orphans. None was diagnosed through 
a PMTCT program, either had documented exposure to PMTCT. Remarkably, 10/12 children 
were born before 2006, year in which the first PMTCT intervention was scaled-up to our 
district. All children were initiated on a non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based regimen. During follow-up, 7/12 had been exposed to more than one first-line regimens, 
mostly due to unavailability of drugs. In 3/7 cases, children were switched back and forth more 
than once. Only one child (#12) was treated for tuberculosis before presenting treatment 
failure. Median time on ART at the time when VF was detected was 3.7 years (IQR 3.2, 5.3). 
Most patients (11/12) presented VL >1000 copies/mL. Suboptimal adherence was common 
(7/12). Information about the correctness of the antiretroviral dosages prescribed was 
available for 10/12, and 7/10 had been exposed to sub-therapeutic doses for periods ranging 
from two months to three years. All prescription errors were due to failure to adjust the doses 
to the current weight, affecting in most cases all the regimen drugs. Only 4/12 children met 
the WHO criteria for clinical and/or immunological failure: patients #6 and #12 presented both 
immunological and clinical failure with persistent CD4 levels below 100 cell/mm3 and severe 
malnutrition; patient #4 had persistent CD4 levels below 100 cell/mm3; and patient #10 
presented clinical failure due to severe malnutrition and although the CD4 evolution was 
unsatisfactory he did not met the WHO criteria for immunological failure. 
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Table 1. Clinical characteristics and antiretroviral drug resistance mutations of twelve children living with HIV in rural Tanzania 
Child Age at 
ART 
initiation 
(years) 
Orphan 
status 
Baseline HIV 
genotyping 
CD4 count in 
cell/mm3 
(and % ) at 
ART 
initiation 
1st line ART 
regimens 
prescribed 
Number of 
1st line 
ART 
switches 
History of 
suboptimal 
adherence 
Under 
dosage of 
drugs 
Time on ART 
when DRM 
detected 
(years) 
VL at the time 
of treatment 
failure 
detection 
(copies/mL) 
NNRTI resistance 
mutations 
NRTI resistance 
mutations 
2
nd
 line regimens VL ≥ 6 months 
after switched to 
2
nd
 line 
(copies/mL) 
1 4.5 
Maternal 
orphan 
No DRM 238 (7%) d4T/3TC/NVP NA Yes Yes 4.6 5,396 
A98G, K103N, 
V108I, K238T 
M41L, V75M, 
M184V, L210W, 
T215Y 
TDF/FTC/LPV/r Not done * 
2 4.9 
Double 
orphan 
No DRM 425 (13%) 
d4T/3TC/NVP 
AZT/3TC/NVP 
TDF/3TC/EFV 
3 No Yes 3.4 330 Y181C M184V TDF/FTC/LPV/r undetectable 
3 13.2 
Non 
orphan 
No DRM 317 (10%) 
AZT/3TC/EFV 
TDF/3TC/EFV 
1 Yes No 2.7 22,071 
V90IV, K103N, 
P225H 
Y115FY, M184MV AZT/3TC/ATV/r N/A † 
4 6.1 
Paternal 
orphan 
No DRM 152 (12%) d4T/3TC/NVP NA No Yes 1.2 174,546 
A98G, K103N, 
V108I, K 238T 
M41L, V75M, 
M184V, L210W, 
T215Y 
TDF/FTC/LPV/r 345 
5 11.7 
Paternal 
orphan 
No DRM 124 (12%) 
d4T/3TC/NVP 
AZT/3TC/NVP 
 
1 Yes No 3.3 1,340 
K101E, Y181C, 
H221Y 
- 
TDF/FTC/ATV/r 
TDF/FTC/LPV/r 
N/A ǂ 
6 11.5 
Paternal 
orphan 
No DRM 16 (1%) 
AZT/3TC/EFV 
AZT/3TC/NVP 
 
2 Yes Yes 4.0 22,623 K103KN 
M184IMV, 
L210LW 
TDF/FTC/LPV/r 
ABC/3TC/LPV/r 
124,276 
7 8.7 
Double 
orphan 
Not done § 375 (12%) 
AZT/3TC/EFV 
 
NA No Yes 5.8 1,478 - M184V 
TDF/FTC/ATV/r 
TDF/FTC/LPV/r 
N/A ‖ 
8 6.6 
Maternal 
orphan 
No DRM 331 (10%) 
AZT/3TC/EFV 
 
NA Yes N/A 3.3 31,000 L100I, Y188L M184V TDF/FTC/LPV/r N/A  ǂ ¶ 
9 0.8 
Non 
orphan 
Not done § # 66 (2%) 
d4T/3TC/NVP 
AZT/3TC/NVP 
 
2 No No 5.1 5,648 K101E, G190A 
M41L, D67N, 
T69L, V75M, 
M184V, L210W, 
T215Y 
TDF/FTC/LPV/r undetectable 
10 5.4 
Maternal 
orphan 
Not done § 201 (3%) 
d4T/3TC/NVP 
AZT/3TC/EFV 
1 Yes N/A 7.0 3,775 
V90I, K103N, 
V108I, K238T 
M41L, D67G, 
K70R, V75M, 
M184V, L210W, 
T215F, K219E 
TDF/FTC/LPV/r N/A ** 
11 5.8 
Double 
orphan 
N/A †† 
158 (no % 
information) 
AZT/3TC/EFV 
 
NA Yes Yes 1.8 Not done * 
A98AG, K101P, 
K103N, E138AE 
M184V, T215F TDF/FTC/LPV/r Not done * 
12 7.0 
Double 
orphan 
N/A †† 
No 
information 
AZT/3TC/EFV 
ABC/3TC/EFV 
1 No Yes 7.3 386,400 
A98G, K103S, 
G190A, Y318F 
M41L, D67N, L74I, 
M184V, L210W, 
T215Y 
TDF/FTC/LPV/r N/A ‖ 
* VL not done due to a technical problem 
† The patient opted to stop ART 
ǂ At the time of the manuscript writing the patient had not yet completed 6 months on second-line ART 
§ Pre-ART sample was not available 
 ‖ The patient was transferred to another facility before completing 6 months on second-line ART  
¶ VL was done six weeks after having been switched to 2nd line and is was 260 copies/mL 
# The mother’s pre-ART sample genotype did not show DRM mutations 
** The patient interrupted ART three times since switched to second-line ART 
†† The patient initiated ART in another facility and pre-ART sample was not available 
ART: antiretroviral treatment; VL: viral load; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside/nucleotide reverse transcriptase inhibitor; d4T: stavudine; AZT: zidovudine; 3TC: lamivudine; FTC: emtricitabine; ABC: 
abacavir; TDF: tenofovir; NVP: nevirapine; EFV: efavirenz; LPV/r: ritonavir-boosted lopinavir; ATV/r: ritonavir-boosted atazanavir 
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Genotypic resistance profile 
Ten children carried virus with double resistance to NNRTIs and nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTIs). None harboured major resistance to Protease Inhibitors (PIs) (Table 
1). 
NRTI mutations were seen in 11/12 patients, mostly M184V (10/11). Six children harboured 
thymidine analogue mutations, the majority (5/6) carrying ≥2. NNRTI mutations were observed in 
11/12 children, being K103N the commonest (5/11). 
Pre-ART plasma samples were available for 7/10 patients enrolled at HIV diagnosis. None of them 
presented pre-ART drug-resistance mutations, suggesting that they developed these mutations after 
treatment initiation. For another patient (#9), diagnosed together with her mother after cessation of 
breastfeeding, a pre-ART sample from the mother did not show resistance-associated mutations. The 
remaining four children presented history of poor adherence and/or under-dosage of drugs, 
rendering the acquisition of resistance mutations likely. 
Outcome 
All patients were switched to a PI boosted with ritonavir (PI/r) + 2NRTIs regimen. Based on the 
resistance testing the regimens prescribed contained no predicted active NRTI in 5/12 cases and one 
predicted active NRTI in 6/12 cases. Only one patient obtained a regimen with two active NRTIs.  
By the time of the analysis 6/12 children were under active follow-up and had completed six months 
of second-line ART with good self-reported adherence and compatible pill counting, 2/12 had not 
completed six months on the PI/r-based regimen, 1/12 had interrupted ART repeatedly, 2/12 had 
been transferred, and 1 had stopped ART (Table 1). 
VL was performed in 4/6 children who had completed six months on second-line ART and 3/4 
presented satisfactory VL reduction. The remaining patient, aged 17, presented a VL five-fold higher 
than the one when VF was detected, but HIV genotyping showed no drug-resistance mutations, 
suggesting low compliance with ART.  
Discussion 
This case series raises concern about a scarcely reported emerging public health concern in sub-
Saharan Africa. To our knowledge, only one study from Kenya has described the pattern of acquired 
drug-resistance mutations in children failing ART in Africa (Wamalwa et al., 2013). In this cohort 
study 34% (34/100) of patients presented VF, of whom 68% (23/34) had drug-resistance mutations, 
14/23 harbouring multiclass mutations. Similar to our findings, the commonest mutations were 
M184V and K103N. Factors related to VF in children, such as suboptimal adherence, non-parental 
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caregiver, and ART regimen switches (Sigaloff et al., 2011; Zoufaly et al., 2013; Mutwa et al., 2014) 
were common among our patients. Furthermore, we have identified a frequently overlooked factor: 
the prescription of inadequate doses of antiretrovirals. Awareness needs to be raised among health 
workers and tools to facilitate the prescription of paediatric formulations need to be widely 
disseminated and routinely used (ICAP, 2006). 
Importantly, 8/12 children did not meet the WHO criteria of clinical or immunological failure (WHO, 
2013) despite presenting with multi-class drug-resistance mutations, thus emphasising the urgent 
need for routine VL monitoring in children.  
Four patients had VL monitored six months after switching. One teenager had a very high VL but no 
evidence of drug-resistance mutations, suggesting that both self-reported and pill-counting 
adherence were inaccurate. This case reminds the difficulties of some adolescents to adhere to ART. 
Strategies to improve disclosure of infection status and adherence need to be further developed in 
partnership with teenagers. 
Most patients (11/12) could not receive three active second-line drugs. Recent studies show that the 
rates of virologic suppression after switching to a PI/r + 2NRTIs regimen remain high despite 
resistance to both NRTI and NNRTI (Wamalwa et al., 2013; Paton et al., 2014). However, these 
findings require further confirmation in children, who present a higher rate of acquired drug-
resistance mutations and face the challenges of longer exposure to ART than adults. Yet, in most 
African settings, few paediatric regimens are available and advocating for child-friendly formulations 
is necessary. The inclusion of integrase inhibitors such as dolutegravir in paediatric ART programs in 
resource-limited settings needs to be explored urgently. The upcoming clinical trial PENTA 20 
(www.clinicaltrials.gov) may provide key information to support its roll-out in Africa. 
This study has limitations. First, it presents a small number of patients. However, given the scarcity of 
published data on acquired drug-resistance mutations in children in Africa, it provides a valuable 
insight into this public health concern. Second, we are unable to assess the prevalence of acquired 
drug-resistance mutations. However, preliminary results of an ongoing study in our cohort identified 
25% prevalence of VF among children on ART (L Muri, personal communication). Finally, it is possible 
that the mutations in the pre-ART plasma samples dropped below the level of detection of the 
genotypic assay used and we were not able to detect them. 
In conclusion, after a decade of successful rollout of ART in Africa, children and adolescents still 
represent an underprivileged population. ART coverage is lower and failure rates are higher than in 
adults. Children living with HIV have peculiarities and needs that must be acknowledged by the often 
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overwhelmed health workers, and specific policies targeting the paediatric population should be 
implemented. Moreover, VL is not available in most African treatment centres, leading invariably to a 
late recognition of failure and development of multi-class drug-resistance mutations. New classes of 
antiretrovirals and their adequate paediatric formulation are urgently needed to ensure the long-
term survival of millions of children living with HIV in sub-Saharan Africa. 
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Abstract  
Objective: To investigate the prevalence and determinants of virologic failure (VF) and acquired drug 
resistance-associated mutations (DRM) in HIV-infected children and adolescents in rural Tanzania. 
Design: Prospective cohort study with cross-sectional analysis. 
Methods: All children ≤18 years attending the paediatric HIV Clinic of Ifakara and on antiretroviral 
treatment (ART) for ≥12 months were enrolled. Participants with VF were tested for HIV-DRM. Pre-
ART samples were used to discriminate acquired and transmitted resistances. Multivariate logistic 
regression analysis identified factors associated with VF and the acquisition of HIV-DRM. 
Results: Among 213 children on ART for a median of 4.3 years, 25.4% failed virologically. ART-
associated DRM were identified in 90%, with multiclass resistances in 79%. Pre-ART data suggested 
that >85% had acquired key mutations during treatment. Suboptimal adherence [OR=3.90; 95%CI 
1.11-13.68], female sex [OR=2.57; 95%CI 1.03-6.45], and current non-nucleoside reverse 
transcriptase inhibitor-based ART [OR=7.32; 95%CI 1.51-35.46 compared to protease inhibitor-based] 
independently increased the odds of VF. CD4+ T cell percentage [OR=0.20; 0.10-0.40 per additional 
10%] and older age at ART initiation [OR=0.84per additional year-of-age; 95%CI 0.73 to 0.97] were 
protective(also in predicting acquired HIV-DRM). At the time of VF, less than 5% of the children 
fulfilled the WHO criteria for immunologic failure. 
Conclusion: VF rates in children and adolescents were high, with the majority of ART-failing children 
harbouring HIV-DRM. The WHO criteria for immunologic treatment failure yielded an unacceptably 
low sensitivity. Viral load monitoring is urgently needed to maintain future treatment options for the 
millions of African children living with HIV. 
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Background 
In 2015, 1.8 million children were living with HIV worldwide, the vast majority in sub-Saharan Africa 
(SSA) (UNAIDS, 2014, 2016b). The roll-out of antiretroviral therapy (ART) in resource-limited 
countries has resulted in a reduction of HIV-related morbidities and mortality and an increased life 
expectancy of infected adults and children (Puthanakit et al., 2007; Patel et al., 2008). However, 
globally only 49% of the children in need have access to treatment (UNAIDS, 2016b). In addition to 
the low ART coverage in children, long-term treatment success and virologic suppression are harder 
to achieve in this population (van Rossum, Fraaij and de Groot, 2002), mostly due to high pre-ART  
viral loads and the risk of sub-therapeutic drug concentrations caused by limited paediatric drug 
formulations, variable pharmacokinetics, and continuous bodyweight changes (Abrams et al., 1998; 
Menson et al., 2006; Sigaloff et al., 2011).  
The lack of reliable HIV rapid tests for infants and the limited treatment monitoring in most resource-
limited settings, often combined with advanced immunosuppression at ART initiation, further 
aggravate treatment outcomes (Sutcliffe et al., 2008; Bratholm et al., 2010). Together with the 
challenge of adherence during childhood and adolescence, these factors promote the emergence of 
HIV drug-resistance mutations (HIV-DRM) (Simoni et al., 2007; Sigaloff et al., 2011). Moreover, 
although multiple studies confirm that immunological and clinical criteria fail to timely detect 
treatment failure among children and adolescents (Kantor et al., 2009; van Oosterhout et al., 2009; 
Mutwa et al., 2014), most resource-limited settings do not have plasma HIV RNA viral load (VL) 
monitoring available (WHO, 2010b). Given the limited ART options in SSA, the emergence of newly 
acquired HIV-DRM in children is likely to lead to poor clinical outcomes including a reduced survival. 
Two recent systematic reviews on the effectiveness of ART among children found virologic success 
rates of 40% to 81% after twelve months on treatment (Sutcliffe et al., 2008; Ciaranello et al., 2009). 
Recently, not yet published data collected by the Tanzanian CDC comparing fifteen different settings 
across the country demonstrated a high average virologic failure (VF) rate of 38.8% among children, 
with HIV-DRM found in 84.4% of the failing children. 
We assessed the prevalence and determinants of VF and acquired HIV-DRM after long-term ART 
exposure within a large paediatric HIV cohort in rural Tanzania. 
Patients and methods 
Study site and population 
All data were prospectively collected from participants enrolled in the Kilombero and Ulanga 
Antiretroviral Cohort (KIULARCO) after getting informed consent from the patient or caregiver if 
younger than 19 years. This ongoing, open, prospective cohort is comprised of all patients enrolled at 
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the Chronic Diseases Clinic of Ifakara, which serves as a Care and Treatment Centre for HIV/AIDS 
patients within the Saint Francis Referral Hospital. This is the largest health care facility in the 
Kilombero district, in southern Tanzania, providing treatment and care for a population of 
approximately 600,000 inhabitants and estimated 38,000 people living with HIV. Established in 2004, 
this was the first rural clinic accredited to be a Care and Treatment Centre of the National AIDS 
Control Program in the country, and over 9000 patients have been enrolled into care. Since 2013 the 
Chronic Diseases Clinic has a family-centred unit named the “One Stop Clinic of Ifakara”, where care 
to HIV-infected children, mothers and their families is provided by a specially trained team (Gamell, A 
et al., 2015a, 2015b). 
At each clinical visit, comprehensive clinical data is systematically collected through electronic 
medical records. Blood samples are drawn at routine clinic visits before ART initiation, two weeks, 3 
months and every 6 months thereafter. Plasma is cryopreserved at -80ºC (Mossdorf et al., 2011; 
Vanobberghen, F et al., 2015a, 2015b).  
All HIV-infected children and adolescents aged ≤18 years enrolled in KIULARCO and who had been on 
ART for at least twelve months were included in this study.  
Viral load testing and HIV genotyping 
Blood samples were collected in 8mL BD Vacutainer EDTA collection tubes. Cell-free plasma was 
collected by centrifugation at 956 g for 5 minutes and frozen at -800C until testing for HIV RNA VL or 
viral drug-resistance. Assays for VL and sequencing for HIV drug-resistance were performed at the 
Ifakara Health Institute laboratory inIfakara.HIV RNA from 400µL plasma was extracted using the 
NucleoSpin® Virus kit (Macherey-Nagel, Oensingen, Switzerland) according to the manufacturer’s 
protocol. Viral RNA quantification was performed using a validated in-house protocol [23]with the 
Brilliant III Ultra-Fast QRT-PCR Master Mix (Agilent Technologies, La Jolla CA, USA) using the 
StepOneTM Real-Time PCR System (Applied Biosystems, Foster City CA, USA), with a detection limit of 
200 viral RNA copies/mL of plasma. HIV drug-resistance genotyping was performed by Sanger 
sequencing on a 3130 Genetic Analyser 4-capillary model (Applied Biosystems, Foster City CA, USA) 
using a validated in-house PCR protocol (Masimba et al., 2013). 
Statistical analysis 
The primary outcomes were VF, defined as a viral RNA level of ≥1000 copies/mL after at least twelve 
months on ART, and the acquisition of major HIV-1 DRM in failing patients. For data description, the 
numeric variables were displayed with medians and interquartile ranges (IQRs) whereas the 
categorical variables were presented in proportions. Associations between considered variables and 
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VF and HIV-DRM were assessed using multivariate logistic regression models. All analyses were 
performed using STATA, version 14 (Stata Corporation, College Station, TX, USA). 
Ethical approval 
The KIULARCO study received ethical approval from the Ifakara Health Institute Institutional Review 
Board, the National Institute for Medical Research of Tanzania, the Tanzanian Commission of Science 
and Technology, and the Ethics Committee of the University and State of Basel. 
Results 
Characteristics of study population 
At the time of analysis, 241 children and adolescents had been on ART for longer than 12 months. 
Twenty-eight patients were excluded due to several causes (Figure 1). The remaining 213 children 
contributed 902.2 person-years of follow-up. The characteristics of the study participants are 
described in Table 1. The median age was eleven years (IQR 7.5 – 14.4) and 43% were female. Fifty-
five per cent were classified as WHO clinical stage 3 or 4, the median CD4 percentage was 12.2% (IQR 
6.3-19.3) and 12.4% reported prior antiretroviral exposure at the time of enrolment in the cohort.  
Figure 1. Profile of the paediatric study cohort at the Chronic Disease Clinic Ifakara in Ifakara, 
Morogoro, Tanzania, with virologic outcomes and the presence of drug resistance mutations 
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Initial regimen consisted mostly of co-formulated zidovudine (AZT)/ lamivudine(3TC) with a non-
nucleoside reverse transcriptase inhibitor (NNRTI) in 54.9% children, whereas stavudine (d4T) / 3TC 
with nevirapine (NVP) was used in39% of the participants. At the time of investigation, the median 
time on ART was 4.45 years (IQR 2.4 – 6.0), 84% were on an NNRTI-based regimen and 15% (32/213) 
on a boosted protease inhibitor (PI)-based regimen, 28 of them as a second-line treatment. The 
decision to switch to a second-line regimen had been based on clinical and immunological criteria, as 
VL monitoring had not been available for routine monitoring of treatment success. Eighty-six percent 
reported good adherence to ART (defined as no missed doses during the last four weeks) and 23.5% 
had experienced ART regimen changes due to drugs unavailability or shortage, with a median of 
three regimen switches (range 0-16). Ten children (4.7%) were reported to be lost to follow-up since 
the last clinical visit. 
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Table 1. Characteristics of children and adolescents enrolled in the Kilombero and Ulanga 
Antiretroviral Cohort that had been on antiretroviral treatment for at least 12 months. 
Characteristics n Overall cohort 
(N=213) 
Virologic success 
(n=159) 
Virologic failure 
(n=54) 
Female (%) 213 92 (43.2) 65 (40.9) 27 (50) 
Age, years (IQR) 213 11.0 (7.5-14.4) 11.2 (7.6-13.8) 10.3 (7.2-15.2) 
Age at ART initiation, years (IQR) 206 6.4 (3.1-9.5) 6.3 (3.9-9.3) 7.2 (2.5-9.7) 
Time on ART, years (IQR) 209 4.45 (2.4-6.0) 4.5 (2.4-6.1) 4.1 (2.5-5.6) 
Any prior ART exposure (%) 193 24 (12.4) 19 (13.1) 5 (10.4) 
Current CD4 count in cells/µL, median (IQR) 176 636 (440-901) 680 (477-911) 485 (364-881) 
CD4 count in cells/µL at pre-ART, median (IQR) 139 295 (123-561) 292 (134-523) 318 (78-643) 
Current CD4 percent, median (IQR) 171 29 (23-34.1) 30.2 (24.8-35.9) 24.4 (15-29) 
CD4 percent at pre-ART, median (IQR) 137 12.2 (6.3-19.3) 13 (7-18.6) 9.8 (2.7-21.5) 
Current WHO clinical stage 3-4 (%) 209 141 (67.5) 104 (67.1) 37 (68.5) 
WHO clinical stage 3-4 at pre-ART (%) 186 102 (54.8) 79 (57.3) 23 (57.9) 
Distance to CTC (km) 183 1 (1-25) 1 (1-25) 1 (1-33) 
Good adherence
1
 (%) 213 184 (86.4) 142 (89.3) 42 (77.8) 
Lost to follow-up since last visit
2
 (%) 213 10 (4.7) 7 (4.4) 3 (5.6) 
Initial ART regimen (%) 
     d4T+3TC+NVP 
     AZT+3TC+NVP 
     AZT+3TC+EFV 
     Others 
195  
76 (39) 
37 (19) 
70 (36) 
12 (6) 
 
58 (39.5) 
24 (16.3) 
56 (38.1) 
9 (6.1) 
 
18 (37.5) 
13 (27.1) 
14 (29.2) 
3 (6.2) 
Current ART regimen (%) 
     PI-based regimen  
     NNRTI-based regimen 
     Others 
213  
32 (15.0) 
179 (84.0) 
2 (1.0) 
 
24 (15.1) 
135 (84.9) 
0 (0) 
 
8 (14.8) 
44 (81.5) 
2 (3.7) 
Number of regimen switches (IQR) 213 3 (2-5) 3 (2-5) 4 (2-5) 
ART change due to stock-out (%) 213 50 (23.5) 36 (22.6) 14 (25.9) 
BMI for age z-score (IQR) 209 -0,74 (-1,42 to -0,03) -0,82 (-1,5 to -0,12) -0,57 (-1,39 to 0,16) 
Weight for height z-score
3
 (IQR) 14 0,21 (0,01 to 1,08) 0,14 (0,1 to 0,76) 
(n=9) 
0,71 (0,08 to 1,1) 
(n=5) 
1
Defined as any missed dose during the last four weeks, reported by the patient or their caregiver 
2
Last visit more than 6 months + 60 days 
3
Includes only children < 5 years (n=14) 
IQR: interquartile range; ART: antiretroviral treatment; CTC: care and treatment centre; d4T: stavudine; 3TC: lamivudine; NVP: 
nevirapine; AZT: zidovudine; EFV: efavirenz, PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; BMI: body 
mass index. 
Virologic outcome 
At the time of investigation, 159/213 (74.6%) participants had viral plasma levels below the WHO 
threshold for VF (<1000 copies/mL). In total, 92/213 children and adolescents (43.2%, 95% CI 36.5 – 
49.8) had detectable HIV-1 in plasma. Fifty-four children (25.4%, 95% CI 19.5 - 31.2) had VF with a 
median VL of 20615 copies/mL, and 38 (17.8%, 95% CI 12.7 – 23.0) had detectable viral plasma levels 
below the WHO threshold: 26 (12.2%) <500 copies/mL, and 12 (5.6%) between 500 and 1000 
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copies/mL. Forty-six of the 54 patients with VF were on a first-line ART regimen and eight on second-
line treatment. Patients presenting VF were switched to a new ART regimen according to the 
genotype produced during this study. 
Immunologic response after ART initiation and virologic outcome 
The average number of CD4+ T cell percentage (CD4%) measurements from the 213 participants was 
six (range 1-16). The median CD4% rose from 12.2%at ART initiation to 26%after twelve months on 
treatment, reaching a maximum of 30.5% after 60 to 66 months on ART. By comparing the CD4% 
recovery of patients with and without VF (Figure2), the immune cell recovery in those with VF tended 
to be diminished, reaching only 22%after 12 months, compared to 27.5%among patients without VF. 
This difference, however, did not reach statistical significance. Although there was a trend for lower 
CD4% among participants with VF, they also showed a median CD4% recovery after ART initiation, 
which remained stable at or above 20%. In this group, the median CD4% after treatment initiation 
never dropped below the threshold of 10%, a criteria of immunological failure in children below five 
years (WHO, 2013), and the median CD4+ T cell count stabilised above 500 cells/µL. 
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A. Participants without virologic failure 
 
 
 
n= 
 
  
108    84      94      83      78      68      60      48      56      59      61     54      45       94  
 
 
Figure 2. CD4+ T cell percentage 
recovery among the 213 children 
analysed within this study.  
 
The horizontal line within each box 
represents the median CD4+ cell 
percentage, the top and bottom of 
the box mark the 75th and the 25th 
percentiles, respectively. The upper 
and lower bound of the whiskers 
represent the largest and lowest 
values within the 75th percentile + 
1.5x IQR and the 25th percentile – 1.5x 
IQR, respectively. Data points beyond 
these intervals are shown as filled 
circles and represent outliers. A.) All 
participants with virologic success are 
represented in the plot, showing a 
stable CD4+ percentage recovery after 
ART initiation. B.) Participants with 
virologic failure are illustrated within 
this plot, showing an initial CD4+ 
percentage recovery, which is less 
stable than the one from patients 
without VF, though.  The time on ART 
always includes the interval from the 
previous month up to the one 
indicated below the axis (e.g. 6= >0 & 
≤6). 
 
B. Participants with virologic failure 
 
 
 
n= 
  
32        29      33     26      25      33     22     21      26      15      16       10     14      30 
 
 
Predictors of virologic failure 
NNRTI-based ART at the time of analysis (OR=7.32 [95% CI 1.51-35.46], p= 0.013), suboptimal 
adherence (OR=3.90 [95% CI 1.11-13.68], p= 0.034), and female sex (OR=2.57 [95% CI 1.03-6.45], p= 
0.044) were independently associated with VF. Higher CD4 counts (OR=0.20 per additional 10% [95% 
CI 0.10 - 0.41], p< 0.001) and older age at ART initiation (OR=0.84 per additional year of age at 
treatment initiation, [95% CI 0.73-0.97], p = 0.017) were protective of VF (Table2). 
  
 94 
 
Table 1. Predictors of virologic failure and acquired HIV drug resistance mutations among children and adolescents attending the Chronic Disease Clinic in 
Ifakara using logistic regression analysis. 
 Virologic Failure Acquisition of HIV-DRM 
 Univariate Multivariate Univariate Multivariate 
 OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p 
Female 1.45 0.78 – 2.69 0.244 2.57 1.03–6.45 0.044 1.82 0.89 – 3.70 0.101 3.99 1.40 – 11.41 0.010 
Current CD4
+
 percentage per 
additional 10 percent 
0.40 0.26 – 0.62 <0.001 0.20 0.10 - 0.40 <0.001 0.48 0.31 – 0.75 0.001 0.18 0.09 – 0.40 <0.001 
CD4
+
 cell percentage at ART 
initiation per additional 10 
percent 
0.97 0.71 – 1.33 0.870 - - - 1.15 0.83 – 1.58 0.404 - - - 
WHO clinical stage 3-4 at ART 
initiation 
0.69 0.36 – 1.33 0.264 0.73 0.29 - 1.86 0.513 0.75 0.36 – 1.55 0.430 0.78 0.27 – 2.21 0.640 
Age at ART initiation per each 
additional year 
1.02 0.94 – 1.10 0.671 0.84 0.73–0.97 0.017 0.96 0.87 – 1.05 0.354 0.81 0.68 – 0.95 0.009 
Poor adherence
1
 2.39 1.06 – 5.39 0.037 3.90 1.11 - 13.68 0.034 2.15 0.85 – 5.40 0.104 3.72 0.90 – 15.34 0.069 
BMI-for-age Z score
2
 1.11 0.86 – 1.42 0.433 0.97 0.70 - 1.35 0.875 1.11 0.84 – 1.47 0.465 0.99 0.69 – 1.41 0.954 
Initial ART regimen compared to        
d4T+3TC+NVP 
AZT+3TC+NVP 
AZT+3TC+EFV 
Others 
 
 
1.75 
0.81 
1.07 
 
 
0.74 – 4.11 
0.37 – 1.77 
0.26 – 4.40 
 
 
0.203 
0.591 
0.921 
 
 
2.13 
1.09 
1.72 
 
 
0.56 – 8.10 
0.36 – 3.30 
0.23 – 12.58 
 
 
0.269 
0.884 
0.596 
 
 
1.82 
1.24 
1.82 
 
 
0.65 – 5.08 
0.52 – 3.00 
0.42 – 7.80 
 
 
0.254 
0.627 
0.421 
 
 
2.96 
1.79 
3.76 
 
 
0.69 – 12.79 
0.50 – 6.41 
0.45 – 31.30 
 
 
0.145 
0.371 
0.220 
NNRTI-based ART regimen 
compared to PI-based  
0.78 0.35 – 1.76 0.553 7.32 1.51 – 35.46 0.013 1.54 0.50 – 4.72 0.450 10.73 1.75 – 65.70 0.010 
Orphan (single or double) 0.67 0.32 – 1.41 0.287 0.63 0.21 – 1.86 0.398 0.65 0.29 – 1.49 0.310 0.89 0.26 – 3.04 0.846 
ART switch by stock-out 1.20 0.59 – 2.44 0.623 1.39 0.45 – 4.33 0.571 0.99 0.43 – 2.26 0.975 1.38 0.38 – 4.98 0.624 
Number of ART switches
3
 1.04 0.94 – 1.16 0.400 0.99 0.82 – 1.20 0.944 1.01 0.90 – 1.14 0.867 0.93 0.75 – 1.16 0.535 
Distance to clinic
4
 1.01 0.91 – 1.12 0.854 - - - 1.00 0.99 – 1.01 0.825 - - - 
Transferred to CDCI after 
treatment initiation 
0.77 0.27 – 2.19 0.626 - - - 0.83 0.26 – 2.59 0.743 - - - 
1
 Defined as any missed dose during the last four weeks, reported by the patient or their caregiver 
2
 Per each additional unit increase of the z-score 
3 
Per each additional number of regimen switch 
4 
Per each additional kilometre distance to the hospital 
ART: antiretroviral treatment; CTC: care and treatment centre; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT: zidovudine; EFV: efavirenz, PI: protease inhibitor; NNRTI: non-nucleoside 
reverse transcriptase inhibitor; BMI: body mass index; CDCI: Chronic Disease Clinic of Ifakara. 
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HIV drug resistance mutations 
The viral genome was successfully sequenced from 52/54 children and adolescents with VF. Forty-
seven (90.4% [95% CI 82.4 - 98.4]) harboured at least one major HIV-DRM at the time of VF. Among 
patients with HIV-DRM, resistance to nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) 
and NNRTI was found in 80.8% (95% CI 70.1 - 91.5) and 90.2%(95% CI 82.0- 98.4),respectively. 
Seventy-nine per cent (95% CI 67.7 - 89.9) had major drug resistance against both drug classes. 
Thirteen patients presented with minor PI-associated drug resistance mutations, which did not limit 
the activity of any PI, and no major PI-associated drug resistance mutations were found.  
The most common resistance mutations were M184V/MV, triggering high-level resistance to 3TC and 
emtricitabine, found in 40/52 (77%) patients; K103N/KN, causing high-level resistance to efavirenz 
and NVP, in 25/52 (49%); and Y181C/YC/V, leading to high-level resistance against NVP, in 16/52 
(31%). Eighteen patients (34.6%) had detectable thymidine analogue resistance mutations (TAMs), 
including M41L, D67N, K70R, T215F/Y and K219Q/E, with T215F/Y being the most common and 
found in 13 (25%) children. Notably, the K65R mutation was present in three adolescents, who had 
no history of tenofovir disoproxil fumarate (TDF) exposure (Table 3).From the 52 available viral 
genomes from HIV-1 infected children and adolescents, 44.2% (23/52) were subtype C, 32.7% (17/52) 
subtype A, 21.2% (11/52) subtype D, and the pol gene of one child (1.9%) consisted of a subtype A 
protease and subtype D reverse transcriptase. This subtype distribution was consistent with the 
reported viral subtype circulation in treatment-naïve patients in Ifakara from 2009 (Masimba et al., 
2013). 
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Table 2. Detected drug resistance mutations and respective number of children and adolescents after 
experienced virologic failure, by drug class. 
From the 54 patients with VF, 52 were successfully genotyped. Mutations occurring also as mixtures with the wild type 
sequence are indicated by an asterisk. 
Acquisition of drug resistance mutations after treatment initiation 
Additional data was available from 44/47 participants with detected HIV-DRM to verify the 
acquisition of the mutations after ART initiation. Twenty-one (47%) had an available pre-ART plasma 
sample, which was used to genotype the virus prior to ART exposure. Five of 21 patients harboured 
DRM but only one child was on an inactive treatment regimen at ART initiation. For another ten 
patients, we analysed stored samples from their mothers, who were still on a first-line ART. All were 
virologically suppressed, arguing against a vertical transmission of the respective drug resistant-
viruses and suggesting that HIV-DRM emerged only after treatment initiation. Of the remaining 13 
children, only CD4+ T cell count and percentage data was available for assessing treatment efficacy. 
No pre-ART sample of these children had been stored, and their mothers either had been switched to 
second-line ART or were dead. Eight out of these 13 patients demonstrated stable or increasing CD4+ 
T cell counts and percentages after treatment initiation, suggesting initial drug activity, thereby 
further decreasing the likelihood of vertical transmission of a resistant virus. The remaining five 
children experienced no elevation of CD4+ T cell counts or percentages or even showed declining 
values, which suggest either poor adherence to ART or transmission of a resistant virus from their 
mothers. Taken together, these data suggest that at least 86.4% of participants (38/44, 95% CI 76.2 - 
96.5) acquired treatment-specific DRM after initiation of ART.  
NRTI-associated DRM 
HIV drug resistance mutations Number of patients with mutations 
M184V* 
T215F/Y 
K219Q/E 
K70R 
D67N 
M41L 
T69N/D/G 
K65R, L210W 
A62V 
V75M 
40 (77%) 
13 (25%) 
11 (21%) 
10 (19%) 
9 (17%) 
5 (10%) 
4 (8%) 
3 (6%) 
2 (4%) 
1 (2%) 
NNRTI-associated DRM 
HIV drug resistance mutations Number of patients with mutations 
K103N* 
Y181C*/V 
G190A* 
E138A/G/Q 
K101E/P 
V108I 
A98G 
V90I*, L100I/V, Y188L, P225H* 
K238T 
V106M,  V179D, H221Y, M230L 
F227L 
25 (49%) 
16 (31%) 
12 (24%) 
10 (20%) 
9 (18%) 
7 (14%) 
5 (10%) 
4 (8%) 
3 (6%) 
2 (4%) 
1 (2%) 
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Risk factors for the acquisition of HIV-DRM 
Table 2 summarizes the predictors of acquired DRM. NNRTI-based compared to PI-based current 
regimens (OR=10.73 [95% CI 1.75 – 65.70], p= 0.01) and female gender (OR=3.99 [95% CI 1.40 – 
11.41], p=0.01) increased the odds of HIV-DRM. Additionally, poor adherence showed a trend 
towards increased odds in acquiring HIV-DRM (OR=3.72 [95% CI 0.90 – 15.34], p=0.069). Older age 
(OR=0.81per each additional year [95% CI 0.68 – 0.95], p=0.009) and higher CD4 percentages 
(OR=0.18 per additional 10% [95% CI 0.09 – 0.40], p<0.001) showed a protective effect.  
Sensitivity and specificity of WHO immunological criteria to detect treatment failure 
The current WHO immunological criteria of treatment failure for children (CD4+ T cell count below 
200 cells/µL or CD4+ T cell percentage below 10% for children under five years of age and CD4+ T cell 
count below 100 cells/µL for children aged 5 to 15 years) correctly classified 2/54 (3.7%) children 
with VF. The sensitivity of the immunological criteria after including adolescents (CD4+ T cell count 
dropping to the pre-ART level or below) to detect VF rose to 14%. As only one patient would have 
been mistakenly classified with VF, the specificity of these WHO criteria reached 99.3%.  
Discussion 
To our knowledge, this is one of the first studies to comprehensively assess VF and the acquisition of 
HIV-DRM among a large paediatric population in SSA. Key findings are a high rate of both VF and 
acquired HIV-DRM after a median of over 4 years on ART and an increased risk of both VF and HIV-
DRM among participants receiving NNRTI, those with younger age at ART initiation and female 
patients.  
The VF rate of 25.4% exceeded by far the 9.1% failure rate observed for the adult population in the 
same cohort (Erb, S et al., 2015), emphasizing the great challenge to successfully suppress HIV in 
paediatric patients. However, the high VF rate found in our study is comparable to previous reports 
from similar East and West African settings (Kamya et al., 2007; Emmett et al., 2010; Sigaloff et al., 
2011; Kebe et al., 2013; Wamalwa et al., 2013; Mutwa et al., 2014; Salou et al., 2016). Of note, it is 
significantly lower than the actual national Tanzanian average of 38.8% elaborated by the Tanzanian 
CDC (Ward, J et al., 2014), which could be partially attributed to the specialised counsellors and 
clinicians in our paediatric unit. 
The prevalence of HIV-DRM of 90.4% in children and adolescents with VF in our cohort is comparable 
with similar settings (Sigaloff et al., 2011; Kebe et al., 2013; Salou et al., 2016) and the adult 
population in our clinic [32]. The multi-class resistances, present in almost 80% of all failing patients 
dramatically limits future treatment options and represents an important public health concern. The 
presence of the K65R mutation in three patients is also concerning, as this triggers resistance to TDF 
and abacavir (but not zidovudine) again limiting future treatment options. The observed prevalence 
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of TDF-resistances in our setting was, however, much lower than in a recently published multicentre 
cohort study of patients failing to first-line ART (TenoRes Study Group, 2016). Interestingly, the three 
patients with the multi-class resistance triggering K65R mutation had not been exposed to TDF. As 
already highlighted in other studies, stavudine (compared to zidovudine) may also select this multi-
class resistance mutation (Nouhin et al., 2013). Although stavudine is currently hardly used, this 
should be taken into account in patients previously treated with this drug. The absence of major PI 
mutations is reassuring. As PIs have a short half-life and a higher barrier to resistance, it has been 
suggested that they are less likely to allow the emergence of drug resistance mutations in early VF 
(Walmsley et al., 2002; Bangsberg, Moss and Deeks, 2004).Of note, patients on PI-based second-line 
treatment also received additional counselling. Overall, these results indicate that PI-based second-
line regimens potently suppress HIV in children and adolescents. However, new drug classes such as 
integrase inhibitors and new paediatric drug combinations are strongly needed in this setting to be 
able to treat individuals with multi-class resistant virus. Even children with active second-line 
regimen will eventually depend on new drug classes as they rely on ART for decades, with growing 
risk to fail on the second-line. Although recycled NRTIs show residual activity in adult populations 
(SECOND-LINE Study Group et al., 2013; Paton et al., 2014), these results cannot be extrapolated to 
paediatric populations.  
In 86.4% of the patients with HIV-DRM, the resistant viral variants likely emerged after ART initiation. 
However, as imperfect adherence of the mother during pregnancy would lead to the possible 
archiving of drug resistant proviruses, it cannot be excluded that in these cases viral minorities 
carrying resistance-associated mutations were also transmitted to the offspring. Such virus would 
then only emerge once drug pressure with the respective drug was applied. As stated above, 
although this possibility cannot completely be ruled out, our analysis renders this explanation 
unlikely for most of the observed resistance cases: no recorded failure of the mother, initial period of 
treatment success in the child, and paediatric regimen different from the mother’s therapy. 
Poor adherence predicted VF and showed a trend to predicting the acquisition of HIV-DRM. 
Adherence is dependent on drug, social, health system and health workers’ factors (Bikaako-Kajura et 
al., 2006; Sutcliffe et al., 2008). The development of new child-friendly drug formulations is needed. 
In addition, a functioning procurement and distribution system is crucial and tools to facilitate the 
prescription of paediatric drugs need to be widely disseminated and routinely used. In our cohort, 
the number of treatment switches significantly increased the odds for poor adherence (by 58%) and 
for being under-dosed for each additional change of treatment (by 50%) (Table S1). It is essential to 
minimise treatment switches in this context to improve adherence. 
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Table S1. Predictors for poor adherence (n=119) and being under-dosed (n=54) among children and adolescents from the Chronic Disease Clinic in Ifakara 
(CDCI). 
 Poor adherence Under-dosage 
 Univariate Multivariate Univariate Multivariate 
 OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p 
Female sex 0.66 0.29 – 1.48 0.311 0.75 0.18 – 3.04 0.684 0.44 0.14 – 1.38 0.158 0.78 0.17 – 3.56 0.743 
CD4
+
percentage per additional 10 
percent 
0.75 0.49 – 1.16 0.200 1.32 0.60 – 2.90 0.494 - - - - - - 
WHO clinical stage 3-4 at ART 
start 
1.79 0.76 – 4.21 0.186 1.49 0.40 – 5.57 0.554 0.45 0.13 – 1.52 0.199 0.24 0.05 – 1.25 0.091 
Age at ART start per additional 
year 
1.12 1.01 – 1.24 0.039 1.34 1.04 – 1.71 0.021 0.87 0.76 – 1.01 0.059 0.73 0.57 – 0.92 0.007 
BMI-for-age Z score
1
 1.12 0.81 – 1.56 0.497 0.98 0.58 – 1.65 0.943 0.82 0.54 – 1.25 0.343 0.90 0.50 – 1.61 0.711 
Initial ART regimen compared to 
d4T+3TC+NVP 
AZT+3TC+NVP 
AZT+3TC+EFV 
 
 
0.43 
0.90 
 
 
0.11 – 1.61 
0.38 – 2.17 
 
 
0.208 
0.821 
 
 
0.13 
2.90 
 
 
0.01 – 2.42 
0.66 – 12.86 
 
 
0.169 
0.161 
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
Current ART regimen compared to 
PI-based 
TDF-based 1
st
-line 
EFV-based 1
st
-line 
NVP-based 1
st
-line 
 
 
1.56 
1.30 
1.06 
 
 
0.38 – 6.47 
0.37 – 4.58 
0.31 – 3.58 
 
 
0.538 
0.685 
0.928 
 
 
5.48 
2.39 
3.43 
 
 
0.47 – 64.64 
0.29 – 19.99 
0.40 – 29.52 
 
 
0.177 
0.421 
0.262 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
Vital status of parents compared 
to both alive 
Double orphan 
Maternal orphan 
Paternal orphan 
 
 
1.38 
0.99 
0.86 
 
 
0.40 – 4.71 
0.31 – 3.20 
0.24 – 3.03 
 
 
0.608 
0.990 
0.808 
 
 
4.70 
0.18 
0.48 
 
 
0.65 – 34.13 
0.03 – 1.29 
0.07 – 3.40 
 
 
0.126 
0.088 
0.465 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
ART stop or change due to drug 
stock-out 
0.64 0.23 – 1.79 0.397 0.60 0.11 – 3.20 0.547 - - - - - - 
Number of ART switches
2
 1.14 1.01 – 1.28 0.028 1.58 1.20 – 2.07 0.001 1.21 1.00 – 1.47 0.048 1.53 1.12 – 2.08 0.008 
Distance to clinic
3
 1.00 0.99 – 1.01 0.976 0.99 0.97 – 1.01 0.439 - - - - - - 
1 
Per each additional unit increase of the z-score 
2 
Per each additional number of regimen switch 
3 
Per each additional kilometre distance to the hospital 
ART: antiretroviral treatment; CTC: care and treatment centre; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT: zidovudine; EFV: efavirenz, PI: protease inhibitor; NNRTI: non-nucleoside 
reverse transcriptase inhibitor; BMI: body mass index; CDCI: Chronic Disease Clinic of Ifakara. 
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Younger age at ART start, NNRTI-based regimens and female sex were identified as risk factors for 
VF and the acquisition of HIV-DRM. Sub-therapeutic drug levels in younger children due to 
difficulties to administer the drugs, faster metabolism, differences in pharmacokinetics and dose-
prescribing errors could explain this finding (van Rossum, Fraaij and de Groot, 2002; Menson et al., 
2006; Ellis et al., 2007; Wamalwa et al., 2013). Additional sub-group analysis revealed that 35.2% 
(19/54) of the study participants with VF were prescribed a drug dose below the recommended for 
the patient’s body weight at least once since ART was initiated, as previously highlighted by a 
study among this same paediatric population (Gamell, Muri, et al., 2016). Of note, after a 
dedicated paediatric unit had been established in our clinic, such dosing errors were eliminated. 
Children and adolescents on NNRTI-based regimens had much higher odds to experience VF and to 
acquire DRM than participants on PI-based regimens, again suggesting the good performance of PI 
regimens in suppressing HIV and preventing DRM. As mentioned above, the additional counselling 
in patients on PI-based second-line treatment might have slightly biased this finding. Girls were 
more vulnerable to VF and the development of HIV-DRM for reasons that could not be explained 
in the framework of this study, but indeed sex inequalities were also found in other recent studies 
from East Africa (Lazzerini et al., 2016). 
 The WHO criteria for immunological failure showed an alarmingly low sensitivity of 5% in children 
and 14% in adolescents. For most of the study participants with VF, the CD4+ T cell counts stayed 
above 20% and 500 cells/µL after initial immune cell recovery, values considerably higher than the 
WHO recommended criteria for immunological failure (WHO, 2013). A similar study from Rwanda 
revealed that even a threshold of <350 CD4+ T cells/µL to detect treatment failure had a very low 
sensitivity ranging from 19% to 32% (Mutwa et al., 2014). The late detection of patients with 
treatment failure leads to the accumulation of drug resistances and dramatically limits treatment 
options (Sigaloff et al., 2011, 2012). The implementation and up-scaling of VL monitoring is 
essential to maintain treatment options and optimize health outcomes in resource-limited setting 
with restricted treatment possibilities (Sutcliffe et al., 2008; Sigaloff et al., 2011; Salou et al., 
2016). 
A limitation of this study was the definition of VF as a single VL ≥1000 copies/mL, which has a 
lower sensitivity than the official WHO definition for VF. It is possible that children with lower VL 
also carry DRM, though. Furthermore, the use of population sequencing for genotyping might 
have led to an underestimation of drug resistance mutations also in pre-ART samples. Our 
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assessment for acquisition of DRM compared to transmitted DRM may have allowed some 
transmitted DRM to remain unnoticed by sequencing pre-ART samples. In addition, a suppressed 
VL of the mother on first-line treatment does not ultimately exclude transmission of DRM. 
In conclusion, our study found high rates of VF and emerging HIV-DRM in this paediatric 
population on long-term ART in rural Tanzania. Both VF and the emergence of HIV-DRM were 
associated with NNRTI use, younger age at ART initiation, poor adherence, and female sex. 
Moreover, our results reinforce the current knowledge about the low sensibility of the WHO 
criteria for immunological treatment failure in children and adolescents. These findings provide 
relevant information for clinicians and health policy makers and raise concerns about the 
effectiveness of current paediatric ART programmes in SSA, calling for a critical review of current 
guidelines. In particular, awareness needs to be raised in order to advocate for the strengthening 
of adherence strategies tailored to this vulnerable population, the development and widespread 
availability of new paediatric ART formulations, and the universal roll-out of routine VL monitoring 
for the millions of children and adolescents living with HIV in SSA. 
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10. Discussion  
The five studies presented in this thesis contribute to the understanding of the challenges of 
delivering PMTCT and paediatric HIV services in a rural sub-Saharan African setting, demonstrate 
the possibility of delivery changes, and measure the impact of a comprehensive service delivery 
model. The studies were designed to overcome service delivery barriers and improve the clinical 
care of HIV-infected mothers, children, and their families. Moreover, the acquisition of drug 
resistance-associated mutations among HIV-infected children, which is an emerging public health 
concern, is comprehensively characterized.  
The findings of this work are particularly timely, given the global commitment to eliminate new 
HIV infections among children, ensure that their mothers remain healthy and improve the HIV 
diagnosis and treatment for children. In African rural areas barriers to access HIV care are more 
evident and it is in these settings where innovative models to deliver HIV care are more needed. In 
addition, lessons learned from the implementation of Option B+ are of most value considering the 
recent evolution towards “test and start” for all PLWHIV.  
10.1. Strengths and limitations of the work included in this thesis 
This thesis is the result of an initial evaluation of the PMTCT implementation, one of the most 
critical interventions to control the HIV/AIDS pandemic in sub-Saharan Africa, followed by the 
design and evaluation of the impact of a strategy to improve the service delivered to HIV-infected 
pregnant women, mothers, children and their families. In addition, during the execution of this 
operational research work, a potential threat to paediatric ART programs in Africa could be 
identified and comprehensively characterised.  
One of the absolute strengths of this work is that through an operational agenda, real changes in 
the HIV care delivery model were implemented and sustained in Ifakara. The goal of a MTCT below 
5% was achieved. The Chronic Diseases Clinic of Ifakara is an invaluable platform to evaluate the 
impact of new policies on clinical outcomes with its open, ongoing cohort. The prospective 
character of the key studies and the comprehensive clinical data presented represent a main 
strength of the findings presented in this thesis. Study 3 is the first one to comprehensively 
analyse the Option B+ cascade in a Tanzanian setting. The analysis included all the steps of the 
PMTCT pathway and a long follow-up for both mothers and infants. Likewise, Study 5 is one of the 
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first studies to carefully assess virological failure and the acquisition of HIV drug resistance 
mutations among a large paediatric population in sub-Saharan Africa. 
The studies included in this work do have some limitations. First, a longer follow-up will be 
necessary to measure the long-term impact of the strategy on the clinical outcomes and retention 
in care. We consider this as a call for future research. Second, as interventions to improve 
maternal and paediatric HV care were implemented as a bundle, we cannot distinguish the impact 
of each specific intervention. Third, since 14% of HIV-exposed infants were lost to follow-up while 
breastfeeding, the reported 2.2% MTCT rate possibly underestimated the true HIV transmission 
rate. However, even presuming a 15% transmission through the breast milk among infants lost, 
the cohort MTCT rate would still be below 5%. Finally, for Study 5 we used as definition of 
virological failure a single viral load above 1000 copies/mL, and it is possible that children with 
lower viremia also carried drug resistance mutations. Future studies should conduct longer follow-
up in this ongoing cohort to measure the long-term impact of the strategy on the clinical outcomes 
and retention in care 
10.2. Discussion of key findings 
The initial PMTCT assessment, gaps identified and the strategy developed to improve 
maternal and paediatric HIV care in Ifakara 
Several gaps were identified along the PMTCT pathway implemented in Ifakara during the period 
2010 – 2011. All services and most resources needed for a proper functioning of the PMTCT 
program recommended by the Tanzanian authorities were in place, but major gaps prevented an 
optimal implementation. These gaps included: a) no re-testing of seronegative pregnant women 
during late pregnancy; b) poor linkage of HIV-infected pregnant women to HIV care; and c) lack of 
a standardized follow-up for HIV-exposed infants. 
Over 90% of women were tested for HIV during the antenatal care visits, but seronegative women 
were very rarely re-screened in late pregnancy. Similar findings are reported from South Africa 
(Technau et al., 2014). In HIV high-prevalence settings, re-testing for HIV in the third trimester is 
recommended based in its cost-effectiveness (Soorapanth et al., 2006) and the much higher MTCT 
risk among women with incident HIV infection (Drake et al., 2014). Studies from Botswana and 
South Africa have reported a rate of seroconversion during pregnancy of 1.3% and 4.2% 
respectively (Lu, L et al., 2011; Technau et al., 2014). In the absence of a maternal diagnosis, 
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infants cannot be captured by EID programs. HIV diagnosis and treatment initiation for these 
infants will consequently be delayed, with a significant effect on morbidity and mortality.  
During the first assessment of the PMTCT care pathway in Ifakara, only 25.6% of pregnant women 
newly-diagnosed with HIV in the antenatal care were enrolled to HIV care. This finding was 
especially surprising since the HIV clinic in St Francis Referral Hospital is located only few meters 
away from the antenatal care clinic. Reasons for not being linked into HIV care may have been 
related to poor post-test counselling and the perceived stigma of being seen while pregnant at the 
HIV clinic. Studies from neighbouring countries have reported non-disclosure, stigma, lack of male 
partner support and health worker attitudes as barriers to linkage to HIV care after testing positive 
in the antenatal care (Mugasha et al., 2014; Saleem, Kyeyagalire and Lunsford, 2014). The PMTCT 
guidelines at the time recommended different antiretroviral regimens depending on the 
immunological and clinical presentation (Tanzanian MoHSW, 2007b). Not being enrolled in HIV 
care meant that most women were not assessed for ART eligibility and even if a single 
antiretroviral drug was given during pregnancy, no postpartum follow-up existed.  
Another major gap identified was the absence of a standardised follow-up for HIV-exposed infants. 
Infants could not be ensured a correct postnatal antiretroviral prophylaxis, feeding counselling, 
and the performance of an EID test. It was thus impossible to estimate the MTCT rate. 
At the time of the first study, the uptake of guidelines in sub-Saharan Africa was known to be poor. 
This was partly due to the fragility of health systems, lack of infrastructure, and constrains on 
human and financial resources (Doherty, McCoy and Donohue, 2005; Nkonki et al., 2007; Both and 
van Roosmalen, 2010). Dissemination of changes in the guidelines was suboptimal and it often 
took time to be rooted among health workers and to change practices. According to WHO, in 
2009, only 53% of pregnant women worldwide received any antiretroviral drug for PMTCT (WHO, 
2010c), with substantial differences across countries in sub-Saharan Africa (i.e. 1% in the 
Democratic Republic of the Congo versus 52% in Mozambique). It was thus clear that having 
effective antiretroviral regimens was insufficient and effective delivery programs were equally 
important (Barker, Mphatswe and Rollins, 2011; Ciaranello et al., 2012). 
This first study illustrates that it is possible and important to measure the quality of the PMTCT 
provision in a rural setting like Ifakara, by providing a cross-sectional snapshot of the reality in the 
field. Gaps can be identified and potential ways to bridge them at an operational level can be 
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analysed. The study highlighted the need for much simpler and effective PMTCT programs, as 
Option B+. Moreover, the findings of this first assessment set the basis for the development of a 
new strategy to be tested in a prospective fashion with the aim of improving the care of HIV-
infected mothers and their families in rural Tanzania and other similar settings in sub-Saharan 
Africa.  
From December 2012 onwards, a bundle of measures were implemented at the Chronic Diseases 
Clinic of Ifakara to improve the HIV services delivered to PLWHIV. Measures affecting all patients 
were the implementation of electronic medical records in the HIV clinic and provider-initiated HIV 
testing and counselling in the hospital wards. Measures specifically targeting HIV-infected 
pregnant women, children and adolescents and their families, were the creation of a maternal and 
paediatric HIV unit integrated within the reproductive and child health clinic and the performance 
of pro-viral HIV DNA PCR locally. The maternal and paediatric unit was named the “One Stop Clinic 
of Ifakara”. Also, in September 2013, the Ministry of Health and Social Welfare changed the 
PMTCT guidelines and recommended Option B+. The new recommendations were progressively 
rolled out through the different districts, and in Ifakara were implemented through the One Stop 
Clinic from April 2014. 
Impact of the One Stop Clinic and the accompanying measures on the care provided to 
HIV-infected pregnant women, children and their families 
To assess the impact of the One Stop Clinic in combination with the other measures and the 
national implementation of Option B+, two studies (Study 2 and Study 3) were designed. Study 2 
compares the diagnosis, linkage to care, treatment coverage and retention of HIV-infected 
pregnant women and children before (2008 - 2012) and after (2013 - 2014) the One Stop Clinic. 
Study 3 describes the uptake of PMTCT Option B+ recommendations during its first year of 
implementation (4/2014 - 3/2015) and compares it with the previously described in Study 1, 
before the simplification of the guidelines and the integration of maternal and paediatric HIV care 
within the reproductive and child health clinic. 
The combined results of these two studies showed that the bundle of measures put into practice 
to improve maternal and paediatric HIV care in Ifakara in 2013, along with the national roll-out of 
Option B+ later in 2014 resulted in: a) increased number of pregnant women and children 
diagnosed and linked into care; b) increased detection of children with AIDS; c) ART coverage close 
to 100% among eligible children and pregnant women; d) improved retention in care; and e) MTCT 
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below the national average (9%) and below the 5% threshold established for elimination of MTCT 
of HIV in breastfeeding populations. Nevertheless, gaps such as the poor uptake of HIV testing in 
the labour ward and the almost inexistent HIV re-screening during late pregnancy remained. Also, 
the need for approaches to timely diagnose HIV-infected children outside the PMTCT program was 
made evident. 
Improvements of the PMTCT cascade and persisting challenges  
The strategy implemented in Ifakara resulted in an increased number of pregnant women 
diagnosed and linked into care. The HIV testing rate in the antenatal clinic was over 90% and 
linkage to care of newly diagnosed HIV-infected pregnant women, increased from 25.6% to 92%. 
Studies from neighbouring countries analysing the improvements after Option B+ implementation 
present inconsistent results. In two large urban centres in Malawi, the enrolment to PMTCT/HIV 
care from the antenatal care clinic increased from 61% in the pre-B+ period to 87% in the post-B+ 
period (Kim et al., 2015). However, in Uganda, only 25% of women diagnosed in rural antenatal 
care settings during the post-B+ period were linked to HIV care (Mugasha et al., 2014). Thus, we 
believe that the improvement achieved in Ifakara cannot be solely attributed to Option B+ itself, 
but to the integration of services and the counselling delivered through the One Stop Clinic.  
As much as the above achievements have to be celebrated, the unreliable HIV re-screening in late 
pregnancy and the low HIV testing uptake in the labour ward in Ifakara are worrisome. As already 
exposed above, in high prevalence settings, HIV seroconversion during pregnancy is not 
uncommon. Vertical transmission of HIV during primary infection is significantly increased. Thus, 
educational efforts are needed to implement HIV re-screening as routine practice in antenatal care 
clinics and maximise the benefits of PMTCT. Maternity and labour wards are also critical entry 
points to PMTCT that need attention. HIV testing uptake at delivery rooms has been reported to 
be low in African settings (Beltman et al., 2010; Ononge et al., 2014) and represent a missed 
opportunity to capture mother-infants pairs into PMTCT/EID. To mitigate these persisting gaps 
continuous training of health providers coupled with a functioning supply of HIV tests is needed. 
ART coverage among pregnant women attended at the One Stop Clinic under Option B+ 
recommendations was 90.6%. Importantly, two different subgroups of women have to be 
considered: (i) women under HIV-care who became pregnant; and (ii) women newly-diagnosed 
with HIV during pregnancy. Treatment coverage for the first group was 100%, but for the second 
group it was 75.5%. In our setting, an important proportion of newly diagnosed pregnant women 
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were lost along the very initial steps of the PMTCT circuit: 8% were not linked to HIV care after HIV 
diagnosis, and among those who did enrol, 18% did not return for completing pre-ART counselling 
and initiate treatment. Similar early attrition rates have been observed in other sub-Saharan Africa 
settings such as Malawi, where Option B+ was first introduced. A study comparing different 
models of Option B+ delivery found that in places where antenatal care and provision ART are 
located within the same health facility, approximately 20% of HIV-positive women visited at the 
antenatal care did not start ART (van Lettow et al., 2014). Also in Malawi, in two large urban health 
centres where HIV-infected women are initiated and followed on ART at the antenatal care clinic, 
the attrition rate before treatment initiation was 18% (Kim et al., 2015). Remarkably, data from 
rural health centres in the country showed a significantly lower ART uptake, with 44% of HIV-
infected women enrolled in antenatal care not starting treatment (Chan et al., 2016). These 
findings clearly indicate that largely asymptomatic pregnant women may need time to adjust to 
the HIV diagnosis and understand the benefits of lifelong treatment. 
After ART initiation, recently diagnosed women continued to drop from care, although at a lower 
rate: 86.5% were retained after a median of 17.2 months. This result is better than the one 
reported in a recent publication from Malawi, where retention after ART initiation in the context 
of Option B+ was 68.5% at 12 months, 61% at 24 months and 56.3% at 36 months (Haas et al., 
2016). Studies exploring the factors associated with lost to follow-up among women started on 
ART for PMTCT  found that common reasons for stopping ART included travel, lack of transport 
money, poor pre-ART counseling and drugs’ side effects (Tweya et al., 2014; Ebuy, Yebyo and 
Alemayehu, 2015). The better results from Ifakara suggest that the unhurried start of ART and 
continued counselling combined with joint visits for postpartum care, PMTCT/HIV care and infant 
growth monitoring and immunization are responsible for the lower attrition. Retention among 
women becoming pregnant while being under HIV care was clearly better, with 90% being 
retained after a median follow-up of 19 months. 
It is reported in the literature that whilst integration of services increases the rates of linkage to 
HIV care and ART start, retention after treatment initiation is significantly lower in comparison to 
settings where ART is provided outside the antenatal care (van Lettow et al., 2014; Chan et al., 
2016). This represents a downside of the full integration of PMTCT and antenatal care services. 
Furthermore, pregnant women who initiate ART on the same day of HIV diagnosis are less likely to 
return for a follow-up visit (Tenthani et al., 2014). These findings most probably show that, in a 
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single antenatal visit, women are not able to fully comprehend the consequences of a positive HIV 
test and the initiation of a lifelong treatment (Medley et al., 2004; de Bruyn and Paxton, 2005; 
Gebrekristos, Mlisana and Karim, 2005). To optimize the uptake of PMTCT throughout the 
pregnancy and breastfeeding periods, further operational research must focus on the optimal 
timing between HIV diagnosis and ART initiation and the counselling that is coupled with it. In 
addition, the better retention of women becoming pregnant while being under HIV care must be 
capitalized and peer-mother programs should be common in all sub-Saharan African settings 
(Tenthani et al., 2012; Shroufi et al., 2013; Foster et al., 2017).  
The elimination of mother-to-child transmission can be achieved in rural Africa   
The current MTCT rate in Ifakara is 2.2%. The <5% target established for populations in which 
breastfeeding is common (WHO, 2014a) has been achieved. Therefore, unlike previously reported 
(Wudineh and Damtew, 2016), we have shown that the virtual elimination of new paediatric HIV 
infections is feasible in a rural setting under programmatic circumstances. 
After the initial assessment of the PMTCT cascade, a standardized follow-up for HIV-exposed 
infants was organized and allowed for the description and outcomes analysis of this population. 
HIV-exposed infants are enrolled at the One Stop Clinic through two main different entry points. 
On one side there are infants identified through the PMTCT program. These are infants born from 
mothers enrolled in HIV care before delivery, either because they became pregnant while being 
under HIV care, either because they were diagnosed with HIV during the antenatal visits. On the 
other side, some infants younger than 18 months are identified through provider-initiated HIV 
testing and counselling, mostly when admitted in the hospital wards with symptoms. In most of 
these cases, mothers were not tested for HIV during pregnancy and are also diagnosed then.  
HIV-exposed infants enrolled from the PMTCT program in Ifakara had a virological test done at a 
median age of six weeks. Most of them (91%) were exclusively breastfeed, and had very low 
attrition, with a lost to follow-up rate of only 14% after a minimum of 15 months since enrolment. 
This is one of the highest retention rates described in sub-Saharan Africa, where the reported 
average lost to follow-up rate at only 3 months post-delivery is 34% (Sibanda et al., 2013). Studies 
reporting on retention of HIV-exposed infants at 12 - 18 months of age have reported losses of 
27% in Kenya (Nyandiko et al., 2010), 40% in urban South Africa (Chetty et al., 2012), and 24% in 
Zimbawe (Kurewa et al., 2011). The high retention in Ifakara must be attributed to the integrated 
service delivery model, with mother–infant pairs receiving different health services in one single 
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day and at one single place, the shortened turn-around time of EID results, and the continuous 
counselling that women receive during pregnancy and breastfeeding periods. To further improve 
retention and HIV-free survival of exposed infants, additional interventions with proven efficacy as 
mobile phone-based reminders and the promotion of male partner involvement should also be 
implemented in our setting (Ambia and Mandala, 2016).  
These successful results are shadowed by the number of children younger than 18 months that 
were identified to be HIV-exposed during hospital admission. Through provider-initiated HIV 
testing and counselling these infants and their mothers were enrolled in HIV care, but for many, 
prevention measures to avoid vertical transmission of HIV could not be offered: 46% of the infants 
were already HIV-infected. This highlights once more the value of testing for HIV infants and 
children who seek for health care.  This finding is also an evidence that in a region where 95% of 
women attend antenatal care (Tanzanian NBS, 2011), some women are not captured by PMTCT 
programs and drives us back to the testing gaps observed in late pregnancy and labour ward.  
Increased detection of children living with HIV, universal ART coverage and improved retention 
in care 
The number of children enrolled in care increased after the One Stop Clinic was established. 
Multiple factors are responsible for this finding. The implementation of provider-initiated HIV 
testing and counselling in the hospital wards is the main one. The performance of EID test locally, 
and the family-centred testing using parents as index cases also contributed to the increased 
identification of children living with HIV. Importantly, children diagnosed after the bundle of 
measures implementation, presented with more advanced disease and immunosuppression, 
reflecting the high yield of infants and children enrolled from the in-patients wards. Since the 
incidence of HIV has decreased over the last years in Tanzania, we presume that before the 
intervention, some children were admitted and eventually died without being diagnosed with HIV 
and therefore enrolled in our cohort. Diagnosing and offering health-restoring care and treatment 
to children with AIDS is one of the major achievements of our strategy. On the other hand, it 
highlights the enormous challenge that diagnosing children outside PMTCT programs represents. 
Beyond PMTCT/EID programs, evidence on the most effective strategies to identify and link HIV-
infected children to care is scarce (Horwood et al., 2010; Chamla et al., 2013; Busza et al., 2014). 
Case-finding approaches targeting places where large number of infants and children congregate 
are much needed (Ahmed et al., 2013; Essajee et al., 2017; Penazzato et al., 2017).  Testing in 
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places where children at high risk of HIV seek for health services is effective. Provider-initiated 
testing and counseling on inpatient wards has been shown to be an efficient approach to identify 
HIV-infected children in high HIV prevalence settings (Weigel et al., 2009; McCollum et al., 2011; 
Preidis et al., 2013; Ferrand et al., 2016) but is rarely implemented routinely (Kranzer et al., 2014). 
Children identified at paediatric wards, malnutrition units and tuberculosis clinics present with 
advance disease, and their treatment outcomes could have been better if identified before. Thus, 
along provider-initiated HIV testing in health care settings, new ways to promptly diagnose 
children must be sought. 
ART coverage among enrolled children according to the guidelines at each time period was 
assessed before and after the establishment of the One Stop Clinic. During the period 2008 - 2012 
79.6% of children meeting criteria were prescribed ART. After 2012, this rate raised to 98.1%. This 
universal coverage is remarkable since similar coverage rates in Africa had only been reported by 
urban programs (Anaky et al., 2010; Leyenaar et al., 2010).  
After enrolment and eventual ART initiation, it is crucial that children remain in care. Early 
retention in paediatric sub-Saharan African cohorts is significantly affected by mortality. Advanced 
HIV disease at presentation, often accompanied with severe malnutrition, systemic bacterial 
infections and opportunistic infections as tuberculosis or Pneumocystis jirovecii pneumonia, is 
associated with early mortality after enrolment (Eley et al., 2006; Bolton-Moore et al., 2007; Bong 
et al., 2007; Reddi et al., 2007; Anaky et al., 2010; Leyenaar et al., 2010; McConnell et al., 2010; 
Koller et al., 2015). In our cohort, in 2013 - 2014, mortality ascertainment six months after 
enrolment was 15.7%. All deaths occurred among children diagnosed through provided-initiated 
HIV testing and counselling, after they presented at the hospital seeking for health care and 
almost all were malnourished. Analogous findings have been reported from Malawi, where 12-
months mortality after diagnosis through provider-initiated HIV testing was 20% (McCollum et al., 
2011), and Zambia, where mortality among malnourished children was 46%, with HIV-infected 
children being 80% more likely to die (Munthali et al., 2015). This high mortality is the 
consequence of a series of barriers and missed opportunities that impeded, in first place, the 
prevention of vertical infection and, later, the provision of early diagnosis and life-saving 
treatment.  
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Uncovering and analysing the problem of virological failure and drug resistance 
mutations among children 
After the establishment of the One Stop Clinic, a reduced team of clinicians, nurse and counsellor 
started to take care of all children and adolescents of KIULARCO as well as their HIV-infected 
relatives. We organized a child and family-friendly unit, implement flexible age-based clinic days, 
and arrange activities to deliver tailored health education messages as group disclosing sessions 
and teen clubs. Moreover, a patient-health provider relationship could be established with a 
consequent closer follow-up and better understanding of the patients’ family and social 
circumstances. This child and family-centred approach drew attention to some problems that were 
previously unnoticed.  
The most relevant of these uncovered issues was the impression that children presented 
treatment failure more often than adults and that failure was recognized late. To explore this 
perceived problem, we first described a well-characterised series of children and adolescents 
presenting treatment failure and acquired HIV drug resistance-associated mutations (Study 4). 
Later on, we designed Study 5, a longitudinal study to assess the prevalence and predictors of 
virological failure and drug resistance mutations among children. 
The case series (Study 4) raised concerns about a scarcely reported emerging public health 
concern in sub-Saharan Africa. By the time of publication, only one study from Kenya had 
described the pattern of acquired drug resistance mutations in children failing to ART in Africa 
(Wamalwa et al., 2013). Factors known to be related to virological failure, such as suboptimal 
adherence, non-parental caregiver, and ART regimen switches (Sigaloff et al., 2011; Zoufaly et al., 
2013; Mutwa et al., 2014) were common among our patients in Ifakara. Furthermore, we 
identified a frequently overlooked factor: the prescription of inadequate doses of antiretrovirals. 
This last factor indicates that awareness needs to be raised among health workers and tools to 
facilitate the prescription of paediatric drugs need to be widely disseminated and routinely used 
(ICAP, 2006). Another relevant finding was the confirmation that the WHO’s clinical and 
immunological criteria failed to identify most children presenting treatment failure and already 
multi-class resistance mutations, thus emphasising the urgent need for routine viral load 
monitoring. 
Study 5 is one of the first studies to comprehensively assess virological failure and the acquisition 
of drug resistance-associated mutations among a large paediatric population in sub-Saharan 
 113 
 
Africa. Key findings are a high rate of both virological failure and acquired HIV drug resistance 
mutations after a median of over four years on ART and an increased risk of both among 
participants receiving NNRTI-based regimens, those with younger age at treatment initiation and 
female patients.  
The virological failure rate of 25.4% found in our study is comparable to previous reports from 
Eastern and Western Africa (Kamya et al., 2007; Emmett et al., 2010; Sigaloff et al., 2011; Kebe et 
al., 2013; Wamalwa et al., 2013; Mutwa et al., 2014; Salou et al., 2016), but exceeded by far the 
9.1% failure rate observed among adults in the same cohort (Erb et al., 2017). The only Tanzanian 
data available for comparison are the unpublished results of a study presented by the Tanzanian 
CDC at a national conference. They reported an average virological failure rate of 38.8% among 
children (Ward, J et al., 2014). Our lower virological failure prevalence can be partially attributed 
to the specialised counselling and clinical team of the One Stop Clinic, but it is still alarmingly high 
when compared with the observed failure rates among adults. 
Similarly, the 90.4% prevalence of drug-resistance mutations among failing children and 
adolescents is comparable with other African settings (Sigaloff et al., 2011; Kebe et al., 2013; Salou 
et al., 2016) and the adult population from KIULARCO (Ntamatungiro et al., 2017). Almost 80% of 
all patients with drug resistance-associated mutations present multi-class resistances, limiting 
future treatment options and representing an important public health concern. The absence of 
major PI mutations is reassuring and indicates that PI-based second-line regimens potently 
suppress HIV in children and adolescents. However, new drug classes such as integrase inhibitors 
and new paediatric drug combinations are strongly needed in sub-Saharan African settings to treat 
individuals with multi-class resistant virus. Even children with an active second-line regimen will 
eventually depend on new drug classes as they rely on ART for decades, and with time they may 
fail to the second line.  
Our findings suggest that at least in 86.4% of patients with drug resistance mutations, the resistant 
virus variants emerged after ART initiation; mutations were acquired while on treatment, not 
transmitted from the mothers. We acknowledge that since we used population sequencing for 
genotyping, our assessment for acquisition of mutations may have allowed some transmitted 
mutations to remain unnoticed by sequencing pre-ART samples. However, our analysis renders 
this explanation unlikely for most of the observed cases: no recorded failure of the mother, initial 
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period of treatment success in the child, and paediatric regimen different from the mother’s 
therapy.  
Adherence to treatment and availability of paediatric drugs 
Optimal treatment outcomes can be predominantly ensured if children adhere to available, 
effective, correctly dosed, simple and child-friendly drugs. However, such drugs are not widely 
available in sub-Saharan Africa and treatment compliance among children and adolescents can be 
complex. In our study, poor adherence predicted virological failure and showed a trend to predict 
the acquisition of drug resistance mutations. Further analysis of our data revealed that the 
number of treatment switches significantly increased the odds for poor adherence and for 
prescription of low-dose of antiretrovirals. Adherence among children depends on drug, social, 
family, health system and health workers factors (Sutcliffe et al., 2008; Nachega et al., 2009; 
Fetzer et al., 2011; Bernays et al., 2014). Interventions to support children and families, a 
functioning procurement and distribution system, and tools to facilitate the prescription of 
paediatric drugs are much needed (Luyirika et al., 2013; Lowenthal et al., 2014). Furthermore, 
more efforts have to be put to develop new child-friendly formulations, with fixed-dosed 
combinations that allow weight-band dosing, minimize the number of drugs needed and, in turn, 
improve procurement and availability (Penazzato et al., 2015).  
Predictors of virological failure and acquisition of drug resistance mutations 
Younger age at ART start, NNRTI-based regimens and female sex were identified as risk factors for 
virological failure and the acquisition of HIV drug resistance-associated mutations. Sub-therapeutic 
drug levels in younger children due to difficulties to administer the drugs, faster metabolism, 
differences in pharmacokinetics and dose-prescribing errors could partly explain these findings 
(van Rossum, Fraaij and de Groot, 2002; Menson et al., 2006; Ellis et al., 2007; Fillekes et al., 2011; 
Wamalwa et al., 2013). Prescribing correct doses of drugs to young infants and children when 
paediatric formulations are not available is challenging and in many cases halves of adult tablets 
are administered, leading to inaccurate dosing. As mentioned before, an additional sub-group 
analysis revealed that 35% of participants with virological failure had been prescribed low doses of 
antiretrovirals at least once. Of note, after the One Stop Clinic was established in Ifakara, such 
dosing errors did not occur again. Moreover, the younger they are, the more children rely on a 
diligent caregiver to adhere to ART.  
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Compared to PI-based regimens, children and adolescents on NNRTI-based regimens had much 
higher odds to experience virological failure and acquire drug resistance mutations. This difference 
between groups suggests good performance of PI regimens in suppressing HIV and preventing the 
development of resistance mutations. However, the additional counselling that patients switched 
to second line receive may have biased these results.  
Girls were more vulnerable to virological failure and the development of mutations for reasons 
that we could not explain in the framework of this study, but indeed sex inequalities were also 
found in other recent studies from East Africa (Lazzerini et al., 2016). 
Our results confirmed the already described very low sensitivity of the WHO immunological and 
clinical criteria to detect treatment failure (Mutwa et al., 2014). Not having routine viral load 
monitoring leads to an unacceptable delay in the diagnosis of failure and accumulation of 
mutations, and limits treatment options (Sutcliffe et al., 2008; Sigaloff et al., 2011, 2012). 
After a decade of successful ART rollout in Africa, children and adolescents still represent an 
underprivileged population.  ART coverage is lower and failure rates are higher than in adults. The 
management of treatment failure is still suboptimal in resource-limited settings due to limited 
availability of drug choices, limited access to viral load, and a general lack of guidance in national 
treatment guidelines, with consequent delays in switching from failing regimens (Davies et al., 
2011). Awareness needs to be raised in order to advocate for the strengthening of adherence 
strategies tailored to this vulnerable population, the development and widespread availability of 
new paediatric ART formulations and the universal roll-out of routine viral load monitoring for the 
millions of children and adolescents living with HIV. 
10.3. The way forward: implications for policy and practice 
The findings of this thesis have implications for policy and practice to ensure a better care for HIV-
infected pregnant women, mothers and children. These implications are relevant for Ifakara and 
similar rural settings across sub-Saharan Africa.  
Some of the results can and should be translated into immediate actions at a public health and 
service delivery levels. 
 Integration of antenatal, postpartum and PMTCT/HIV services. Offering HIV testing, ART and 
clinical follow-up at the reproductive and child health clinics is key to identify HIV-infected 
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mothers, facilitate their linkage and retention in care and provide the necessary care to HIV-
exposed infants. 
 Continuous counselling throughout pregnancy and breastfeeding periods. Women diagnosed 
to be HIV-infected during pregnancy must receive continuous counselling. Post-test 
counselling does improve linkage to HIV care but is not sufficient. Education and counselling 
of women and, ideally, their male partners have to be incorporated as part of the routine care 
delivered during clinic visits to enhance retention and adherence to ART.     
 Early Infant Diagnosis strengthening. In order to ensure effective EID circuits in the priority 
Global Plan countries, decentralised laboratory capacity to perform pro-viral HIV DNA PCR is 
necessary at a distrital, or at least regional level. Laboratory capacity has to be coupled with 
effective modes to deliver results to the health facilities and strategies to track mother-infant 
pairs. 
 Provider-initiated HIV testing and counselling. Opt-out HIV testing has to be effectively 
incorporated as routine practice in all health facility settings. Offering also an HIV test to 
partners and children of index cases will further increase the benefits of provider-initiated HIV 
testing. This approach needs to be well articulated to ensure that patients’ rights are 
respected and HIV testing is not coercive. 
 Family and child-centred units. Family and child-friendly units or clinic days can be easily 
organized within functioning HIV clinics. They have the potential to improve the care and 
retention of children and families. HIV clinics in sub-Saharan Africa should incorporate such 
approach and adapt it to the size of the paediatric population they attend. 
 Expansion of routine viral load monitoring. The findings of this thesis contribute to the already 
significant evidence to advocate for the implementation of viral load monitoring in all 
settings, and specifically for the treatment monitoring of children. Timely detection of 
treatment failure is crucial to improve clinical outcomes, preserve treatment options and 
prevent transmission of HIV infection. 
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Priority research questions have emerged from this PhD work. Despite the changes introduced on 
the service delivery model for HIV-affected families in Ifakara, some gaps persist. Further research 
is needed to tackle these questions and adapt PMTCT and paediatric HIV programs in rural African 
settings.  
 Strengthening of HIV re-screening in late pregnancy and HIV testing in the labour ward. To 
maximise the coverage of PMTCT it is crucial to identify women who have seroconverted 
during pregnancy and test those who reach the labour with an unknown serostatus.  
Continuous education of the attending staff and a reliable supply chain of tests are essential 
to bridge these gaps. 
 “Test and start” or better “test, ensure readiness and start”? Early disengagement from care 
of HIV-infected pregnant women is the main downside of Option B+. This has been partially 
attributed to the immediate ART initiation policy. Despite it is clear that an accelerated ART 
initiation should be recommended, different timings in the context of Option B+ need to be 
studied to ensure the optimal treatment coverage, adherence and retention in care. 
 HIV testing outside health facilities. Approaches to expand HIV testing outside health facilities 
are not yet fully explored. Interventions involving the community, schools and religious and 
spiritual congregations can contribute to overcome HIV testing barriers related to stigma and 
health access. 
 Development of paediatric drugs. The development of new antiretroviral drugs and 
appropriate formulations for children continues to be far too slow. Few paediatric 
antiretroviral formulations and fixed-dose combinations are available. This represents an 
important limitation for paediatric ART programs and undermines children’s adherence. 
Health agencies, pharmaceutical companies and donors must joint efforts to ensure that 
treatment is available for all children in need. 
In conclusion, ART scaling-up for pregnant women and children in sub-Saharan Africa should be 
based on integrated service delivery models; the expansion of case-finding strategies to identify 
HIV-infected children; the widespread implementation of routine viral load monitoring; the use of 
point-of-care, or at least locally-based, EID tests; and the adoption of tailored interventions to 
enhance adherence and retention among pregnant women, children and adolescents.  
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11. Conclusions 
Study 1 
1. Several gaps were identified through the PMTCT care pathway in Ifakara. The most important 
ones were: a) no re-testing of seronegative pregnant women in late pregnancy; b) poor 
linkage of newly-diagnosed HIV-infected pregnant women into HIV care; and c) lack of a 
standardized follow-up of HIV-exposed infants. 
2. The prior complexity of the guidelines, with different recommendations and antiretroviral 
regimens based on the immunological and clinical stage of pregnant women, and the infant’s 
feeding method, prevented a broad and efficient PMTCT coverage. 
3. The lack of integration and comprehensiveness of the different health services that HIV-
affected pregnant women and mother-infant pairs require further aggravated the low uptake 
of PMTCT recommendations. 
Study 2 
4. The implementation of the One Stop Clinic of Ifakara combined with the improved efficiency 
of a paperless clinic and the rollout of provider initiated HIV testing and counselling and EID 
resulted in: a) an increased number of pregnant women and children diagnosed and linked 
into care; b) an increased detection of children with AIDS; c) universal ART coverage; d) lower 
loss to follow-up and better ascertainment of mortality; and e) a proof that elimination of 
MTCT can be achieved in rural Tanzania. 
5. Children enrolled after 2012 presented with more advance disease and immunosuppression, 
reflecting the high yield of infants and children enrolled from the in-patient wards. Measures 
to identify HIV-infected children must be implemented in parallel to the efforts to achieve 
universal PMTCT and the elimination of MTCT.  
6. The One Stop Clinic model may provide a feasible and scalable model for delivering high-
quality family-centred HIV care in Tanzania and other sub-Saharan African countries. 
Study 3 
7. The implementation of Option B+ through an integrated service delivery model resulted in: a) 
universal HIV testing in the antenatal care clinic; b) high rates of linkage into care and ART 
prescription; and c) a MTCT rate below the elimination threshold.  
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8. HIV re-screening in late pregnancy and HIV testing during labour were still poorly 
implemented, preventing mother-infant pairs with high risk of MTCT from receiving an 
appropriate PMTCT intervention. 
9. Losses along the PMTCT cascade were concentrated among newly-diagnosed HIV-infected 
pregnant women and during the first months after diagnosis. Intensified counselling after 
diagnosis and specific interventions for tracking women lost during the first months should be 
implemented.  
Study 4 
10. The absence of routine viral load monitoring lead to a late recognition of children with 
treatment failure and development of multi-class HIV drug resistance-associated mutations 
that threatened the efficacy of the second line drugs available in Tanzania.  
Study 5 
11. A high rate of virological failure (25.4%) was observed among 213 HIV-infected children and 
adolescents after a median of 4.5 years on ART. This rate exceeded by far the 9.1% observed 
for the adult population in the same cohort. The prevalence of drug resistance mutations in 
children and adolescents with virological failure was 90.4% and 79% of these patients had 
multi-class resistances. 
12. Both virological failure and the emergence of drug resistance-associated mutations were 
associated with NNRTI use, younger age at ART initiation, poor adherence, and female 
gender.  
13. The implementation and scale-up of viral load monitoring is essential to maintain treatment 
options and optimize health outcomes in resource-limited setting with restricted treatment 
possibilities. New drug classes and new paediatric formulations are urgently needed in sub-
Saharan Africa to be able to treat individuals with multi-class resistant virus. 
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